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GENERAL INTRODUCTION 
Dissertation Organization 
This dissertation contains three separate manuscripts. Each individual manuscript 
is complete in itself and includes an Abstract, Introduction, Materials and Methods, 
Results, Discussion, and Reference section. The Ph.D. candidate, Eric Martin Vaughn, 
is the senior author and principal investigator for each manuscript. The first manuscript 
describes tiie isolation and preliminary characterization of new porcine respiratory 
coronavirus (PRCV) isolates and has been submitted for publication in the Jourml of 
Clinical Microbiology. The second manuscript, which has yet to be submitted for 
publication, describes the molecular characterization of new PRCV isolates and the 
potential role of coronavirus genes in pathogenesis and virulence. The third manuscript 
describes the use of nonradioactive cDNA probes in a nucleic acid hybridization for the 
differentiation of PRCV isolates from transmissible gastroenteritis virus (TGEV) isolates, 
and has yet to be submitted for publication. Patrick Halbur is listed as a secondary 
author on the manuscripts for providing clinical samples from which some of the PRCV 
isolates were obtained, and for providing his expert opinion as a pathologist in the 
determination of the pathogenicity of the PRCV isolates AR310, LEPP, and IA1894. An 
appendbc describing the cloning of the TGEV S gene and expression of the S 
glycoprotein of TGEV in insect cells is also included and follows the Acknowledgments 
section of this work. In addition, a current review of the literature relevant to this 
dissertation is included as well as a General Conclusions section. Literature citations 
contained within the General Introduction, Literature Review, and Appendix are listed in 
the Literature Cited section. 
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Introduction 
Porcine respiratory coronavirus (PRCV), a member of the family Coronaviridae, 
is antigenically related to transmissible gastroenteritis virus (TGEV) of swine. 
Coronaviruses are pleomorphic enveloped viruses with a positive-sense single stranded 
RNA genome (Spaan et al., 1988). Transmissible gastroenteritis virus causes severe 
diarrhea with a high mortality in neonatal swine as TGEV replicates in and destroys the 
enterocytes of the villus epithelium in the small intestine which causes the subsequent 
malabsorption and dehydration characteristic of transmissible gastroenteritis (TOE) (Saif 
and Bohl, 1986). Transmissible gastroenteritis virus has also been shown to replicate in 
respiratory tissue of infected swine (Laude et al., 1984; Underdahl et al., 1975). Porcine 
respiratory coronavirus is thought to be a mutant of TGEV as it is closely related to 
TGEV yet replicates to high titers in respiratory tissue with little or no clinical disease 
evident (Laude al., 1993; Pensaert et al., 1986). Porcine respiratory coronavirus appears 
to replicate very little, if at all, in intestinal tissue of infected swine (Cox et al., 1990a; 
Pensaert et al., 1986). Porcine respiratory coronavirus was first isolated in 1984 
(Pensaert et al., 1986) from pigs in Belgium that were seropositive for TGEV but did not 
have a history of clinical TGE. Since the initial isolation of PRCV, infections of swine in 
Europe with PRCV are widespread (Cox et al., 1990a; Laude et al., 1993; Pensaert et 
al., 1986, Pensaert et al, 1993). Porcine respiratory coronavirus also has been found in 
the United States, but its prevalence in the United States is not known (Hill et al, 1990; 
Paul et al, 1992; Wesley et al, 1990b). Because TGEV and PRCV are closely related 
and yet display differences in tissue tropism and pathogenicity, they can serve as useful 
models for the study of coronavirus genes involved in tropism and virulence. 
Porcine respiratory coronavirus is antigenically similar to TGEV in that 
polyclonal sera which neutralize TGEV also neutralize PRCV (Callebaut et al, 1989; Hill 
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et al., 1990; Pensaert et al., 1986; Wesley et al., 1990b). Anti-TGEV neutralizing 
monoclonal antibodies (MAbs) directed against the S glycoprotein readily neutralize 
PRCV; however, there are some non-neutralizing anti-TGEV MAbs directed against the 
S glycoprotein that can be used to distinguish between PRCV and TGEV isolates in a 
competitive binding assay (Callebaut et al., 1989; Garwes et al., 1988; Simkins et al, 
1993; Van Nieuwstadt and Boonstra, 1992). 
There are several similarities between PRCV and TGEV. Both viruses have three 
major structural proteins: the surface spike (S) glycoprotein, the integral membrane (M) 
glycoprotein, and an internal nucleoprotein (N). Nucleotide sequence of PRCV isolates 
thus far studied show that they are closely related to TGEV (Britton et al., 1991; 
Jackwood et al., 1992; Rasschaert et al., 1990; Wesley et al., 1991b). Previous studies 
of the genetic structure of PRCV have shown that all of the isolates have two unique 
characteristics. First, the S gene of PRCV contains a large inframe deletion ranging from 
672- to 681-nucleotides in length (Britton et al., 1991; Jackwood et al., 1992; Rasschaert 
et al., 1990; Wesley et al., 1991b). This deletion in the S gene results in a smaller S 
glycoprotein. Second, all of the PRCVs analyzed thus far have had the CTAAAC 
consensus leader RNA binding site preceding the 3a gene altered or partially deleted 
(Page et al., 1991; Rasschaert et al., 1990; Wesley et al., 1991b). Thus, the subgenomic 
mRNA 3 is not detected in PRCV infected ceils (Page et al., 1991; Wesley et al., 1991b). 
Also, the 3 gene of the European PRCVs contains several small deletions that render the 
3 gene to a psuedogene (Page et al., 1991; Rasschaert et al., 1990). One PRCV isolate 
from the United States, Ind/89, was found to have an nearly intact 3 gene but the 
CTAAAC consensus leader RNA binding site had been altered to CTAAAT, thus making 
the subgenomic mRNA 3 of Ind/89 undetectable in infected cells (Wesley et al., 1991b). 
The presence of a large deletion in the 5' end of the S gene is thought to play a role in 
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determining the tissue tropism of PRCV (Parker et al., 1989; Sanchez et al., 1992). In 
the case of TGEV, the genes 3 and 3-1 (formerly designated as ORF A and ORF B, 
respectively) have been hypothesized to be important in the virulence and pathogenesis of 
TGEV infection (Wesley et al., 1991b). It is interesting to note that all previously 
described PRCV isolates have been demonstrated to have an altered or deleted 3 gene and 
that these PRCVs all cause minimal to no apparent clinical disease in swine. 
My colleagues and I have been interested in obtaining isolates of PRCV to 
determine how prevalent this virus is in the swine population, to identify its role in 
pneumonia in swine, to better understand the mechanism of the origin of PRCV from 
TGEV, and to clarify the role of genes 3 and 3-1 in determining the pathogenicity of 
PRCV isolates. In the first study, my colleagues and I report on the isolation of three 
new PRCV isolates in the United States and present evidence that these isolates have 
deletions in the S gene that appear to be of varying sizes. Also, Halbur et al. (1994) 
recently have shown that three of the PRCV isolates analyzed in the study vary in 
pathogenicity. The PRCV isolates AR310 and LEPP caused moderate bronchointerstitial 
pneumonia in specific pathogen free (SPF) pigs, whereas the PRCV isolate IA1894 
caused only a very mild bronchointerstitial pneumonia in five-week-old SPF pigs. This 
presented a unique opportunity to determine whether the S gene deletions and the 3 and 
3-1 genes of these new PRCV isolates are different fi'om previously studied isolates. If 
the 3 gene does play a role in the determination of pathogenicity, then the PRCV isolates 
AR310 and LEPP should have an intact 3 gene. Therefore, in the second study, my 
colleagues and I have analyzed the 5' end of the S gene and the 3 and 3-1 genes of four 
PRCV isolates. The size and location of the S gene deletion of the PRCV isolates was 
determined as my colleagues and I had previously shown that two of the PRCV isolates 
in this study, AR310 and LEPP, had smaller deletions in the 5' end of the S gene when 
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compared with another United States PRCV isolate designated ISU-1. Because the 3 and 
3-1 genes have been hypothesized to determine the virulence of TGEV, my colleagues 
and I wished to examine the 3 and 3-1 genes of the two pathogenic and the one 
nonpathogenic PRCV isolates to determine if the 3 and 3-1 genes of these PRCV isolates 
could be related to the differences in virulence exhibited by the PRCV isolates. In the 
third study, my colleagues and I have used two cDNA probes from the S gene of TGEV 
that were developed in the first study to differentiate between PRCV and TGEV isolates. 
In this study, my colleagues and I used a nucleic acid hybridization assay that uses a 
immunochemiluminescent detection method to differentiate between TGEV and PRCV 
isolates, thus avoiding the use of radioactive materials usually used in a nucleic acid 
hybridization assay. 
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LITERATURE REVIEW 
The History of Coronaviruses 
The coronaviruses are large, enveloped, plus (+) stranded RNA viruses that 
belong to the Coronavitidae family of viruses and have been implicated in respiratory, 
cardiovascular, neurological, and enteric diseases of both humans and domestic animals 
(Holmes, 1990; Lai, 1990; Saif and Bohl, 1986). The coronaviruses are so named 
because of the petal-shaped glycoproteins projecting from the envelopes of virions that 
reveal a "corona" or crown-like appearance when viewed by electron microscopy 
(Mcintosh, 1990). Schalk and Hawn are believed to be the first to describe a disease that 
was caused by a coronavirus when avian infectious bronchitis was differentiated from 
other respiratory ailments of chickens in 1931 (Schalk and Hawn, 1931). Later, TOE of 
swine was described in 1946 by Doyle and Hutchings, and murine hepatitis virus was 
recognized in 1949 by Cheever et al. In 1965, Tyrrell and Bynoe described recovering 
an ether-labile virus recovered from a boy with a cold and its subsequent passage in 
human embryonic tracheal organ cultures. This virus had a morphology that was very 
similar to that of avian infectious bronchitis virus when viewed by electron microscopy. 
Mcintosh et al. (1967) had isolated other strains of human coronaviruses and showed 
that these human coronaviruses were related, both antigenically and morphologically, to 
murine hepatitis virus. At this point, a new genus was suggested for these viruses 
exhibiting a crown-like appearance (Tyrrell et al., 1968; Garwes et al., 1976). For many 
years, classification of coronaviruses was based solely on this characteristic morphology 
(Holmes 1990). However, coronaviruses can now be identified by properties of their 
structural proteins, genomic RNA and mRNAs, and by antigenic cross-reactivity and 
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nucleic acid homology with known coronaviruses, in addition to their morphology 
(Holmes, 1990). 
Coronaviruses are divided into four antigenic groups, and generally infect only 
one species or several closely related species (Holmes, 1990). Table 1 shows the host 
species infected by coronaviruses. 
TABLE 1. Coronaviruses: Antigenic groups, abbreviations, names, and hosts^ 
Antigenic • 
group Abbreviation Name Host 
I HCV-229E 
TGEV 
PRCV 
CCV 
FECV 
FIPV 
Human respiratory 
coronavirus 
Transmissible gastro­
enteritis virus 
Porcine respiratory 
coronavirus 
Canine coronavirus 
Feline enteric 
coronavirus 
Feline infectious 
peritonitis virus 
Human 
Pig 
Pig 
Dog 
Cat 
Cat 
II HCV-OC43 
MHV 
HEV 
BCV 
RbCV 
SDAV 
Human respiratory 
coronavirus 
Mouse hepatitis 
virus 
Hemagglutinating 
encephdomyelitis 
virus 
Bovine coronavirus 
Rabbit coronavirus 
Sialodacryadentis 
virus 
Human 
Mouse 
Pig 
Cow 
Rabbit 
Rat 
ni IBV Infectious bronchitis 
vkus 
Chicken 
IV TCV Turkey coronavirus Turkey 
^ Adapted from Holmes (1990). 
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Coronaviruses 
Examination of coronavirus particles by negative staining electron microscopy 
reveals that coronaviruses are generally spherical, yet pleomorphic, with a diameter 
ranging from 60 to 160 nanometers (nm) (Holmes, 1990; Saif and Bohl, 1986). The 
coronavirion is enveloped with a single layer of large, widely spaced club-shaped 
projections called peplomers (Holmes, 1990; Saif and Bohl, 1986). These peplomers 
evenly cover the virion surface and are 12 to 25 nm in length (Saif and Bohl, 1986). 
Coronavirus particles have a molecular mass of 6 to 9 x 10^ and a buoyant density of 
1.18 to 1.21 g/ml in sucrose and 1.14 to 1.23 g/ml in CsCl (Bohl, 1989; Brian et al., 
1980; Garwes and Pocock, 1975). 
Coronaviruses appear to use specific cellular receptors to infect specific host 
tissues via plasma membrane fusion. Blockage of the phagocytic or endosomal 
pathways by cytochalasin B or lysosomotropic bases did not affect coronavirus infection 
of susceptible cells (Kooi, et al., 1992; Payne et al., 1990). A receptor of 110 kDa has 
been found to be used by MHV to enter murine enterocytes and hepatic cells (Williams et 
al., 1990). This 110 kDa MHV receptor was found to be mmCGMl (murine 
carcinoembryonic antigen gene family member 1) which belongs to the carcinoembryonic 
antigen family of proteins (Williams et al., 1991). Recentiy, mmCGM2 (murine 
carcinoembryonic antigen gene family member 2), another member of the 
carcinoembryonic antigen family, was found to be an alternative receptor for MHV 
(Yokomori and Lai, 1992). The receptor for both HCV-229E and TGEV has been found 
to be aminopeptidase N, a protein that is abundant in respiratory tissue and the intestinal 
tract (Delmas et al., 1992; Yeager et al., 1992). 
The genomic RNA of coronaviruses is the largest among RNA viruses, 
approximately 27 to 32 kilobases (kb) in size (Spaan et al., 1988; Lai, 1990). When the 
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plus-strand genomic RNA of a coronavirus is extracted and introduced into a host cell, 
the genomic RNA is infectious and can serve directly as a mRNA template (Holmes, 
1990; Spaan et al., 1988). The genomic RNA of coronaviruses is capped at its 5' end 
and is polyadenylated at its 3' end (Spaan et al., 1988). The replication of coronaviruses 
occurs exclusively in the cytoplasm of infected cells. Once the virus has penetrated the 
host cell, the genomic RNA attaches to ribosomes and a virus-specific RNA-dependent 
RNA polymerase is synthesized (Holmes, 1990). The polymerase regions of IBV and 
MHV has shown that in both cases "two ORFs are translated via a -1 frame shifting-
pseudoknot" to produce the polymerase polyprotein. Several putative domains are found 
in the two polymerase ORFs. These domains include "membrane anchor, cysteine rich, 
and protease domains in ORF la" (Lee et al.; 1991, Olsen, 1993) and "polymerase, 
helicase, and zinc-finger domains and protease cleavage sites in ORF lb" (Denison et al., 
1991; Lee et al., 1991, Olsen, 1993). This RNA-dependent RNA polymerase activity 
transcribes the plus-strand genomic RNA into both full-length negative-strand RNA 
(Spaan et al., 1988) and subgenomic negative-strand RNAs (Lai, 1990). The negative-
strand RNAs then serve as templates for the transcription of genomic RNA and 
subgenomic mRNAs (Spaan et al., 1988). The synthesis of coronavirus mRNAs occurs 
by leader primed transcription "in which a leader RNA is transcribed from one end of the 
RNA template, dissociates from the template, and then rejoins the template RNA at 
downstream transcription initiation sites to serve as a primer for transcription. This 
model is unlike any of the discontinuous transcription mechanisms known to exist" (Lai, 
1990). Coronavirus "genomes contain approximately 220 to 500 nucleotides of 
untranslated sequence at the 5' end. The terminal 60 to 70 nucleotides are termed as the 
leader sequence and are transposed to the 5' ends of every mRNA species. This leader 
sequence is important in the regulation and transcription of coronavirus genomic RNA 
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and subgenomic mRNAs. At every intergenic region there is a small stretch of 
consensus sequence of approximately 8 to 10 nucleotides which is important for the 
downstream genes" (Lai, 1990). "The leader sequence of MHV is roughly 72 to 77 
nucleotides long while that of IBV is roughly 60 nucleotides. A stretch of 7 to 18 
nucleotides is homologous between the 3' end of the leader RNA and the intergenic 
regions. This homologous region is assumed to be the point of leader RNA binding and 
priming. Within this homologous region, seven nucleotides (UCUAAAC) are conserved 
among most coronaviruses. This conserved region is probably the consensus sequence 
recognized by RNA polymerases for mRNA transcription " (Lai, 1990). One nucleotide 
change in the consensus region "may account for the failure of a coronavirus to transcribe 
a mRNA. These results indicate the importance of both leader sequence and intergenic 
sequences in mRNA transcription " (Lai, 1990). At approximately 80 nucleotides from 
the 3' end of the genomic RNA, there is a stretch of sequences (CGAAGAGC) that is 
conserved in all the coronaviruses sequenced so far. This conserved sequence may be 
the recognition signal for the negative-stranded RNA synthesis" (Lai, 1990). 
Once a susceptible cell is infected with a coronavirus, five to eight subgenomic 
mRNAs are generated, with the actual number varying among coronaviruses (Holmes, 
1990; Spaan et al., 1988). The largest mRNA, designated number one, is identical in 
size to the virion genomic RNA (Lai, 1990). The subgenomic mRNAs form a coterminal 
3' nested set in which they all have common 3' ends; thus, each mRNA contains all the 
nucleotide sequence in the next smaller mRNA plus one additional gene at the 5' end 
(Spaan et al., 1988; Holmes, 1990). This 5' end contains the ORF that is translated into 
the designated protein. "However, in vitro translation studies showed that only the 5' 
portion of each mRNA that does not overlap with the next smaller mRNA is translatable. 
Thus, these mRNAs are functionally monocistronic. Whether, the untranslated 
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downstream sequence in each nriRNA serves any structural or functional role is not clear 
(Lai, 1990). However, some of the mRNAs of MHV, BCV, and IBV have recently 
been found to be bicistronic and tricistronic in nature (Boursnell et al., 1985; Liu et al., 
1991; Liebowitz et al., 1985; Budzilowicz and Weiss, 1987; Senanayake et al., 1992). 
The predicted products from these bi- and tricistronic mRNAs have been detected in 
infected cells by using serum from animals naturally infected with the respective virus. 
Thus, the standard rule that only the 5' portion of each mRNA that does not overlap with 
the next smaller mRNA is translatable does not necessarily hold true. "The mRNAs are 
then used for the synthesis of structural and non-structural proteins. The functions of the 
non-structural proteins are not yet clear, some of them probably participate in viral RNA 
synthesis and others may be involved in virus assembly, and still others may be 
responsible for the shut-off of host macromolecular synthesis" (Lai, 1990). 
Three major structural proteins are found in all coronaviruses, these are the 
nucleocapsid protein (N), the integral membrane glycoprotein (M), and the spike 
glycoprotein (S) (Spaan et al., 1988). 
The peplomers are composed of the 180 to 200 kDa S glycoprotein. Only a small 
portion of the S glycoprotein is anchored in the lipid bilayer via a C-terminal domain, 
with the majority of the glycoprotein projecting to the outside surface of the virion in a 
coiled-coil structure (DeGroot et al., 1987; Spaan et al., 1988). The S glycoprotein is 
also involved in the attachment of the virion to specific cell receptors on the host cell, 
induction of cell-to-cell fusion, elicitation of neutralizing antibodies, and cell-mediated 
immunity (Holmes, 1990; Lai, 1990; Hogue et al., 1989). Most, but not all, of the 
neutralizing domains tend to be located in the amino terminal half of the S glycoprotein. 
The S glycoprotein is also thought to be involved in determining the tissue tropism of 
coronaviruses (Sanchez et al., 1992). The S glycoprotein of MHV has been 
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demonstrated to have a Fc-receptor-like activity (Oleszak et al., 1992). Like the HA 
protein of influenza viruses, the coronavirus S glycoprotein undergoes a trimerization to 
form a functional S glycoprotein via disulfide linkages between cysteine residues 
(Opstelten et al., 1993). The S glycoprotein is cotranslationally inserted through the 
rough endoplasmic reticulum (RER) membrane via a N-terminal signal peptide and 
undergoes N-linked glycosylation as the polypeptide grows in length (Holmes, 1990; 
Spaan et al., 1988). Most of the S glycoprotein synthesized in infected cells is 
incorporated into budding virions at pre-Golgi membranes with a smaller portion being 
transported to the plasma membrane (Holmes, 1990; Opstelten et al., 1993). 
The N protein is a basic phosphoprotein with an apparent molecular mass 
ranging from 45 to 60 kDa that serves to bind the genomic RNA to form a helically 
symmetrical nucleocapsid (Holmes, 1990). The N protein appears to be an essential 
component in viral transcription as the level of N protein may act as the switch between 
transcription/mRNA synthesis and replication/genomic RNA synthesis (Lai, 1990, 
Olsen, 1993). 
The M protein is a glycosylated transmembrane protein of an apparent molecular 
mass of 25 to 30 kDa that spans the host cell derived lipid bilayer several times (Holmes, 
1990). The M protein of FIPV, FECV, and TGEV is N-linked; however, the M protein 
of MHV is O-linked (Spaan et al., 1988). Also the M protein serves as a base to which 
the nucleocapsid protein and its attached genomic RNA can anchor to the lumen of the 
lipid bilayer (Holmes, 1990). The M glycoprotein is also synthesized on membrane-
bound polysomes, but its insertion and processing differ from the other viral 
glycoproteins (Holmes, 1990). The M glycoprotein lacks a N-terminal signal sequence, 
and yet is still inserted into the RER membrane (Spaan et al., 1988). This membrane 
insertion is dependent on internal signal recognition sites in the first or third hydrophobic 
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domains of the M glycoprotein (Holmes, 1990; Spaan et al., 1988; Britton et al, 1988b). 
A putative N-terminal signal peptide of 17 residues has been identified for the 
transmissible gastroenteritis virus M glycoprotein (Laude et al., 1987), thus, the lack of 
the signal sequence for insertion of the M glycoprotein may not be universal among all 
coronaviruses (Spaan et al., 1988). The glycosylation of the M glycoprotein occurs well 
after the protein is synthesized, unlike the S and hemagglutination-esterase (HE) 
glycoproteins that are glycosylated as they are synthesized (Holmes, 1990). 
A small number of coronaviruses also possess the HE glycoprotein that is 
involved in hemagglutination (Holmes, 1990; Hogue et al., 1989; Spaan et al., 1988). 
Many coronaviruses, including the HCV-OC43 (human respiratory coronavirus), BCV 
(bovine coronavirus), HEV (hemagglutinating encephalomyelitis virus), TCV (turkey 
coronavirus), and several strains of MHV (mouse hepatitis virus) all contain the HE 
glycoprotein (Spaan et al., 1988; Holmes 1990). When present, the HE glycoprotein is 
also involved in virion attachment to the host cell, in addition to the S glycoprotein 
(Holmes, 1990). The many remaining coronaviruses that lack the HE glycoprotein 
neither hemagglutinate nor have esterase activity (Holmes, 1990). As with the S 
glycoprotein, the HE glycoprotein is cotranslationally inserted through the RER 
membrane via a N-terminal signal peptide and glycosylated as the polypeptide grows in 
length (Holmes, 1990; Spaan et al., 1988). 
The N protein and several non-structural proteins are apparently made on the 
polysomes in the cytoplasmic matrix (Holmes, 1990). In contrast, the synthesis and 
processing of the M, S and HE (if present) glycoproteins occurs on the polysomes 
attached to the RER (Holmes, 1990). 
The assembly of the virions occurs with budding at the membranes between the 
RER and the Golgi apparatus of the infected cell (Holmes, 1990). The N protein and 
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newly synthesized genomic RNA come together and form a helical nucleocapsid, and this 
nucleocapsid binds to the cytoplasmic surface of the RER and Golgi apparatus 
membranes. The mouse hepatitis virus does not package subgenomic mRNAs (Van der 
Most et al., 1991). In contrast, the subgenomic mRNAs of BCV and TGEV have been 
shown to be packaged into virions (Hofmann et al., 1990; Sethna et al., 1991). The 
packaging signal recognized by the N protein in MHV infected cells has been determined 
to be located in the 3' end of gene lb (Makino et al., 1990). The packaging signal 
recognized by the N protein in TGEV and BCV infected cells is thought to be located in 
either the leader sequence or the 3' end of the genome since these regions are contained in 
both genomic RNA and subgenomic mRNAs, thus allowing both genomic RNA and 
subgenomic mRNAs to be packaged into virions. 
It is believed that the cytoplasmic domain of the M glycoprotein inserted in the 
RER and Golgi apparatus membranes serves as an anchor for the binding of the 
nucleocapsid (Holmes, 1990). "This interaction could be the focal point for virus 
assembly because virus budding appears to occur at the site of the M accumulation" (Lai, 
1990). The S glycoprotein is transported through the Golgi apparatus and is inserted into 
its membrane, where it may or may not be cleaved into two 90 kDa fragments (Holmes, 
1990). Whether or not this cleavage of the S glycoprotein occurs depends on the 
particular coronavirus and the type of host cell infected. Excess S glycoprotein is 
transported to the plasma membrane of the host cell, and once at this location it will not 
be incorporated into any virions (Holmes, 1990). Opstelten et al. (1993) have observed 
that "the M protein associates with the S protein almost immediately after synthesis, 
forming large complexes which presumably accumulate at the site of budding and since 
budding occurs in the pre-Golgi membranes, this association is aimed at retaining the M 
protein and preventing it from escaping to the Golgi apparatus". Once a complete 
15 
nucleocapsid is bound to the M glycoprotein domain, a virion can then bud into the 
lumen of the RER and Golgi apparatus (Holmes, 1990). Virions containing a 
nucleocapsid, M, S, and HE (if present), are then released by cell lysis or by fusion of 
the Golgi apparatus derived, virion-containing, smooth-walled vesicles with the plasma 
membrane (Holmes, 1990). Since the M glycoprotein is restricted in its transport within 
the host cell (i.e., M can only be inserted in the cytoplasmic surface of the RER 
membrane), this accounts for the fact that coronaviruses can only bud from the RER and 
Golgi apparatus of the cell and not directly from the plasma membrane (Holmes, 1990). 
The ability of coronaviruses to bud from the RER or the Golgi apparatus, and 
replication of viral subgenomic and genomic RNAs via 3' coterminal nested sets, are two 
very unique features of coronaviruses that enable them to be differentiated from other 
virus families. 
The Transmissible Gastroenteritis Virus 
In 1946, Doyle and Hutchings described a filterable agent that caused TGE in 
pigs. Transmissible gastroenteritis is a common and economically important disease of 
neonatal swine (Hill, 1989; Saif and Bohl, 1986). In Iowa alone, it is estimated that 
TGE cost the pork industry about $10 million annually in 1987 and 1988 (HiU, 1989). 
The extent that TGE will affect a swine herd depends on the immune status and age of the 
swine in the herd (Hill, 1989). The virus that is the etiologic agent of TGE is TGEV, 
and it is classified as a member of the Coronaviridae family of viruses. 
Transmissible gastroenteritis is commonly divided into two major forms of the 
disease, these being the epizootic and enzootic forms (Saif and Bohl, 1986). The 
epizootic form of TGE occurs when the virus is introduced into a totally susceptible herd 
(Bohl, 1989), and is characterized by severe diarrhea, dehydration, vomiting, and high 
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mortality in young piglets (Saif and Bohl, 1986). The mortality in piglets under two 
weeks of age may reach 100%, but, in nursery age pigs, those of three to eight weeks of 
age, the mortality is usually less than 10 to 20% (Hill, 1989; Saif and Bohl, 1986). 
However, in these three- to eight-week-old piglets infected with TGE, the damage that 
has occurred to their small intestinal epithelium results in a slower and less efficient 
growth rate (Hill, 1989). In the older pigs in an affected herd, such as the growing and 
finishing pigs, sows, and boars, inappetence, vomiting, and diarrhea develops that lasts 
from two to four days (Hill, 1989; Saif and Bohl, 1986). Agalactia commonly occurs in 
lactating sows infected with TGEV, which in turn contributes to the severity of the 
disease in suckling pigs (Bohl, 1989). In the older age groups of pigs, the morbidity 
may reach 100% while the mortality is usually less than 5% (Hill, 1989). The epizootic 
form of TGE has traditionally been thought of as usually occurring in the winter months 
(Saif and Bohl, 1986), when the colder temperatures allow the labile TGEV to remain 
viable and be spread more readily. 
The enzootic form of TGE is attributed to a continuance of the infection and the 
disease within a herd (Bohl, 1989). Weaned pigs are very susceptible to enzootic TGE 
since they have had a sudden loss of any passive immunity to TGEV that may have been 
passed on to them by suckling the sow (Hill, 1989; Bohl, 1989). Mortality is usually 
low, around 10 to 20% (Hill, 1989; Bohl, 1989), but, if enzootic TGE remains in a herd 
for over a year, the economic loses may exceed those incurred from the original epizootic 
outbreak (Hill, 1989). Generally, these losses are from a reduced growth rate and an 
increased susceptibility to other diseases (Hill, 1989). 
There is an inverse relationship between the age of the animal infected with 
TGEV and the severity of the clinical signs, duration of the disease, and mortality (Bohl, 
1989; Saif and Bohl, 1986). Pigs under two weeks of age will often have a mortality 
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rate of 100%. In most pigs under two weeks of age, death will occur in two to seven 
days after the onset of symptoms (Bohl, 1989). Three-week old or older swine show 
much less mortality, but they will have a decreased growth rate (Saif and Bohl, 1986). 
Transient vomiting, watery yellowish diarrhea, rapid weight loss, and dehydration are 
the major clinical signs of TGE (Bohl, 1989; Saif and Bohl, 1986). The affected young 
pigs will have profuse, foul-smelling diarrhea which often contains small curds of 
undigested milk (Saif and Bohl, 1986). 
Growing, finishing, or adult swine have limited clinical signs associated with 
TGE. These signs include inappetence, a mild diarrhea of short duration, and occasional 
vomiting (Bohl, 1989; Saif and Bohl, 1986). Agalactia can also occur in lactadng sows. 
The site of vkus replication in the small intestine is in the jejunum, and, to a 
lesser extent the ileum, with very little evidence of viral replication in the duodenum 
(Hooper and Haelterman, 1966). In the small intestine, a marked shortening or atrophy 
of the villi occurs and the walls of the small intestine become very thin (Hill, 1989; 
Garwes, 1988). The villi are shortened due to the loss and death of the villus enterocytes 
that are infected with TGEV (Pensaert et al., 1970). The crypt enterocytes do not appear 
to be infected, and as immature cells migrate up from the crypts to the tips of the villi to 
replace the infected villus enterocytes, they are more resistant to TGEV infection 
(Pensaert et al., 1970). The rate at which villus enterocytes can be replaced depends on 
the age of the pig. In normal one-day-old pigs, villus enterocytes can be replaced in 
seven to ten days, and in normal three-week-old pigs the villus enterocytes can be 
replaced in as little as two to four days (Moon, 1978). This difference in the time 
necessary to replace villus enterocytes can account for the higher mortality of newborn 
piglets infected with TGEV as compared to pigs of three weeks of age or older (Bohl, 
1989). 
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There is evidence that TGEV can replicate in sites other than the gastrointestinal 
tract of swine. Transmissible gastroenteritis virus has been found in the milk of infected 
sows (Kemeny and Woods, 1977), in the respiratory tract of infected pigs (Underdahl et 
al., 1975). Also, TGEV also has been shown to replicate in alveolar macrophages (Laude 
et al., 1984). 
Being a coronavirus, TGEV is enveloped and pleomorphic with characteristic 
club-shaped surface projections or peplomers. The nucleic acid of TGEV is single 
stranded RNA of positive polarity (Holmes, 1990; Spaan et al., 1988), and can be 
directly infectious (Norman et al., 1968). Transmissible gastroenteritis virus has three 
structural viral proteins, these being M, S, and N. The M protein is glycosylated with an 
apparent molecular mass of 25 to 30 kDa and is associated with the viral envelope. The 
S protein, has an apparent molecular mass of 200 kDa and is also glycosylated (Garwes 
et al., 1976). The N protein is not glycosylated as it is a basic phosphoprotein, has an 
apparent molecular mass of 45 to 50 kDa, is also associated with the binding of viral 
RNA, and serves as a nucleocapsid (Britton et al., 1988a). Antibodies directed against 
the S protein are neutralizing(Garwes et al., 1978/79). Transmissible gastroenteritis 
virus lacks a HE glycoprotein that is present in many other coronaviruses (Holmes, 
1990). 
Being an enveloped virus, TGEV is inactivated by ether and chloroform. 
Transmissible gastroenteritis virus is relatively stable at pH 3 and is trypsin resistant, as 
are enteric viruses in general (Saif and Bohl, 1986). 
Transmissible gastroenteritis virus is routinely grown in the swine testicular cell 
line (McClurkin and Norman, 1966), in which TGEV shows a distinctive cytopathic 
effect (CPE). Through the years, several different cell lines were utilized in the attempt 
to propagate TGEV outside of the natural host. Only primary swine kidney cells (Harada 
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et al., 1963; Witte and Easterday, 1967), primary swine thyroid cells (Witte and 
Easterday, 1967; Dulac et al., 1977), and swine testicular cells (McClurldn and Norman, 
1966) show a distinct CPE (Bohl, 1989). 
Transmissible gastroenteritis vkus is antigenically related to the feline infectious 
peritonitis virus (FIPV) and canine coronavirus (CCV), as antisera produced against 
these viruses react with TGEV (Horzinek et al., 1982; Sanchez et al., 1990). Porcine 
respiratory coronavirus has been shown to be closely related antigenically to TGEV, as 
antisera produced against both viruses react strongly with each of the viruses (Pensaert et 
al., 1986). However, the PRCV has a tropism for the respiratory tract of pigs and does 
not cause enteric disease symptoms (Cox et al., 1990a). Transmissible gastroenteritis 
virus shows no antigenic cross reactivity to the other porcine coronaviruses, namely, 
hemagglutinating encephalomyelitis virus (HEV) and porcine epidemic diarrhea virus 
(PEDV or CV777) (Pensaert et al., 1981; Egerbrink et al., 1988). 
The replication of TGEV in a target cell line results in the synthesis of seven or 
eight mRNAs, depending on the TGEV strain. The full-length genomic mRNA 1 
(approximately 25 kb) probably encodes for a RNA-dependent RNA polymerase. The S 
protein is encoded by the 8.2 kb subgenomic mRNA 2 (Wesley et al., 1991b). In the 
case of the virulent Miller strain of TGEV, the two nonstructural proteins, 3a and 3-1, are 
encoded by the 3.8 kb subgenomic mRNA 3 and by the 3.5 kb subgenomic mRNA 3-1, 
respectively (Wesley et al., 1989). The 3a and 3-1 regions are encoded by a single 3.8 
kb subgenomic mRNA 3 in the virulent FS/72 British strain and the Purdue strain of 
TGEV (Britton et al., 1989; Kapke et al., 1988). The small integral membrane (sM) 
protein is associated with the viral envelope and is encoded by subgenomic mRNA 4 
(Godet et al., 1992). The M and N proteins are encoded by the 2.5 kb subgenomic 
mRNA 5 and by the 1.7 kb subgenomic mRNA 6, respectively (Wesley et al., 1991b). 
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The 0.5 kb subgenomic mRNA 7 is the smallest subgenomic mRNA and has been 
shown to encode for a possible DNA binding protein in TGEV infected cells (Garwes et 
al., 1989; Britton et al., 1990). Preceding each large potential ORF is the conserved 
hexameric sequence of CTAAAC, which is thought to serve as a consensus leader RNA 
binding site in the transcription of the subgenomic mRNAs from a full-length negative 
sense template. 
In the case of TGEV, the 3a and 3-1 genes (formerly designated as ORFs A and 
B, respectively) have been hypothesized to be important in the virulence and 
pathogenesis of TGEV infection (Wesley et al., 1990a). The small plaque (SP) mutant 
of TGEV was determined to have a S gene like that of TGEV, but that the entire 3a and 
3-1 regions were missing due to a 462-nucleotide deletion (Wesley et al., 1990a). When 
three-day-old piglets were infected with SP virus, no signs of TGE were observed 
(Woods 1978). The SP mutant was found to replicate in the cells of the lamina propria 
rather than the villus enterocytes of the small intestine (Wesley et al., 1990a; Woods et 
al., 1981, Woods, 1978). Wesley et al. (1990a) concluded that the 3a and 3-1 genes are 
not needed for virus replication and hypothesized that the 3a and 3-1 genes "appear to be 
the contributing entities for TGEV virulence, SP morphology, tissue tropism, and/or 
persistence in swine leukocytes". The extent of SP virus replication in the respiratory 
tissue of infected swine has not been reported. 
Until the polymerase region of the coronavirus genome from virulent and 
avirulent coronaviruses can be studied in depth, the area of the genome most likely to be 
involved in determining pathogenicity will be genes 3 and 3-1. No function has been 
assigned to the proteins encoded from the genes 3 and 3-1 as of yet. 
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The Porcine Respiratory Coronavirus Virus 
Porcine respiratory coronavirus has been shown to be closely related to TGEV 
and yet replicates to high titers in respiratory tissue with little or no clinical disease 
evident. Porcine respiratory coronavirus appears to replicate very little, if at all, in 
intestinal tissue of infected swine. Porcine respiratory coronavirus is widespread in 
Europe where it was first found. Porcine respiratory coronavirus has also been found in 
the United States, but not to the extent that has been found in Europe. 
Evidence for PRCV was first found in Belgium in 1984 when a routine 
serological survey of sows indicated that 68% of the sows had neutralizing antibodies to 
TGEV (Pensaert et al., 1986). This was a dramatic increase as the earlier surveys had 
shown that the percentage of sows with anti-TGEV antibodies to be 12 to 24%. (Pensaert 
et al., 1986). This dramatic increase in seropositive sows was even more confusing 
because the diarrhea typically associated with TGE was not evident in the seropositive 
herds. Further studies with sentinel pigs placed among these herds showed that the 
sentinel pigs seroconverted to TGEV but had not demonstrated any clinical signs typical 
of TGE. Eventually, a "TGE-like mutant" was isolated from nasal swabs and was 
designated TLM83. The isolate TLM83 was shown to be a coronavirus and cross 
reacted strongly with anti-TGEV serum. Later, the name TLM83 was changed to PRCV 
because of the almost exclusive respiratory tropism exhibited by this virus. 
By utilizing a classical virus neutralization test, antibodies directed towards 
TGEV or PRCV can not be differentiated. Thus, determining whether swine had been 
previously infected with PRCV or TGEV became an important issue among swine 
producers as "the wide prevalence of PRCV had created serious obstacles for export of 
pigs to TGE-free countries" (Laude et al., 1993). Several differential competitive 
inhibition ELISA tests have been developed that can discern whether antibodies were 
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produced in response to TGEV or PRCV (Garwes et al., 1988; Callebaut et al., 1989; 
Van Nieuwstadt and Boonstra, 1992; Simkins et al., 1993). All of these ELISA 
procedures are developed on the same concept of using "a non-neutralizing MAb directed 
against an epitope on the S protein of TGEV with no counterpart in PRCV, in order to 
permit the detection of TGEV-specific antibodies without interference of PRCV 
antibodies" (Laude et al., 1993). Thus, it is the "combination of a negative result in the 
competitive blocking ELISA and a positive result in the seroneutralization test that gives 
evidence of a PRCV infection" (Laude et al., 1993). 
The use of cDNA probes in a dot blot nucleic acid hybridization assay have also 
been employed to differentiate between TGEV and PRCV isolates grown in the 
laboratory (Bae et al., 1991; Jackwood et al., 1992; Wesley et al., 1991a). These assays 
utilize cDNA probes from the 5' end of the TGEV S gene of which there is no 
counterpart region found in known PRCV isolates. 
Porcine respiratory coronavirus is readily adapted to growth in cell culture. The 
CPE induced by PRCV in susceptible cell cultures is often apparent on the first passage, 
compared to the 3 or 4 blind passages in cell culture needed before TGEV field strains 
induce CPE. Porcine respiratory coronavirus is are readily grown in swine testicle (ST) 
cells, swine kidney (PK15) cells, primary swine kidney cells, and a continuous cell line 
of cat fetuses (FCWF) (Laude et al., 1993). The ST cell line developed by McClurkin 
and Norman (1966) has been determined to be the most susceptible to PRCV infection 
(Pensaert, 1989). 
The antigenic similarities between TGEV and PRCV, plus the fact the "wide 
distribution of PRCV in the European swine population, has been accompanied by a 
marked reduction in the number of TGEV outbreaks" (Laude et al., 1993), caused 
questions to arise about the possibility of using PRCV as a vaccine to induce lactogenic 
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immunity against TGE. As described previously, lactogenic immunity refers to the 
development of IgA anti-TGEV antibodies in sow's milk that can then be passed on to 
suckling piglets. After a natural PRCV infection, sows do secrete TGEV-neutralizing 
antibodies in their milk (Laude et al., 1993), though not always of the IgA class 
(Callebaut et al., 1990; Laude et al., 1993). Several researchers have used PRCV as a 
potential vaccine to induce lactogenic immunity against TGE and have obtained varying 
results. Paton and Brown (1990) found that following TGEV challenge, PRCV-
vaccinated sows provided no passive protection to nursing piglets. Bernard et al. (1989) 
and De Diego et al. (1992) showed that 47% and 56% of piglets nursing on PRCV-
vaccinated sows were protected from TGEV challenge, respectively. Recently, Wesley 
and Woods (1993) showed that 70% of piglets nursing on PRCV-vaccinated gilts were 
protected against TGEV challenge as compared with a 16% survival rate for TGEV-
challenged piglets nursing on nonimmunized gilts. Wesley and Woods (1993) 
speculated that the higher level of protection achieved in their study was probably due to 
the fact that one of the immunizations was an intramuscular injection of PRCV emulsified 
in adjuvant, which resulted in higher virus neutralization titers in the vaccinated gilts 
serum. As for an explanation of the sharp reduction of TGEV outbreaks in Europe, 
Laude et al. (1993) propose that "regular PRCV-infection waves on breeding farms most 
probably favor and maintain the presence of anti-TGEV IgA in sow milk". Laude et al. 
(1993) further propose that "in PRCV-immune breeding herds, TGEV outbreaks are of a 
milder course which may be due to the presence of lactogenic IgA in sow milk, but they 
are also of a shorter duration". "When PRCV-primed sows subsequently become 
infected with TGEV, an amnestic response will quickly develop" and "a rapid increase of 
IgA antibodies in milk will occur and piglets born a few days after the start of the 
[TGEV] outbreak already receive a solid lactogenic immunity" (Laude et al., 1993). 
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The ability of PRCV-vaccinated swine to develop an intestinal immunity to TGEV 
is also unclear. Van Nieuwstatdt et al. (1989) could not demonstrate a reduction of 
TGEV antigen in the feces of PRCV-immune specific pathogen free (SPF) pigs. 
However, Cox et al. (1993) found that although "PRCV-immune pigs showed 
serological evidence of TGEV replication" the "PRCV-immune pigs eliminated TGEV 
infection more rapidly, or that they produced lower quantities of infectious virus than the 
seronegative pigs". Van Nieuwstatdt et al. (1989) utilized an ELIS A that detected both 
infectious virus and inactivated virus, whereas Cox et al. (1993) used a competitive 
inhibition ELIS A for the differentiation of serum antibodies directed against TGEV or 
PRCV and attempted to isolate infectious TGEV from experimentally challenged pigs. 
However, both of the studies by Van Nieuwstatdt et al. (1989) and Cox et al. (1993) 
indicated that when PRCV-immune pigs were challenged with TGEV a rapid secondary 
humoral immune response occurred. 
The extent of clinical disease signs caused by natural PRCV infection are 
debatable. Originally, PRCV was thought to be non-pathogenic since the first described 
isolate TLM83 was isolated from clinically normal swine (Pensaert et al., 1986). The 
role of PRCV in respiratory disease is most likely affected by "multiple environmental 
factors such as climate, housing, and concomitant infections" (Laude et al., 1993). As 
an example, two separate experiments gave conflicting information as to the 
pathogenicity of PRCV when combined with swine influenza in experimentally infected 
swine. Lanza et al. (1992) showed that dual infection with PRCV and swine influenza 
did not appear to affect clinical signs and lung lesions. However, Laude et al. (1993) 
described unpublished data that indicated that "clinical signs and lung lesions were more 
severe in dual infected animals than in those infected with either of the respiratory agents 
alone". 
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The occurrence of clinical disease and lung lesion development in swine 
experimentally infected with PRCV also varies. O'Toole et al. (1989) described one-
week-old SPF pigs oronasally infected with a British PRCV isolate designated as 
Stopps, to be clinically healthy, have no clinical disease, but had mild bronchointerstitial 
pneumonia upon histological examination. Cox et al. (1990a) infected one-week-old 
SPF pigs by aerosol with TLM83 and reported a "diffuse interstitial pneumonia" but that 
the pigs also experienced no respiratory distress. Five-week-old SPF pigs inoculated 
oronasally with a PRCV isolate from the Netherlands showed no clinical signs of 
respiratory disease but did display a catarrhal bronchopneumonia at necropsy (Van 
Nieuwstatdt and Pol, 1989). Vannier (1990) utilized intratracheal inoculation to infect 90 
day-old SPF pigs and produced mild clinical signs of dyspnea, polypnea, and a short 
lasting fever. The United States PRCV isolate Ind/89 was inoculated into conventional 
and hysterectomy-derived colostrum-deprived (HDCD) neonatal piglets and no clinical 
disease was observed (Wesley et al., 1990b). Another United States PRCV isolate 
designated ISU-1 failed to induce clinical disease in experimentally infected HDCD swine 
(Hill et al., 1989). Laude et al. (1993) described unpublished data from experiments 
using "fattening pigs" that were inoculated by aerosol with 7 Belgian PRCV isolates. In 
this experiment, Laude et al. (1993) described the development of "mild respiratory signs 
such as nasal discharge and sneezing", and that "variation in virulence between the 
isolates was not detected". Halbur et al. (1993) intranasally inoculated three-day-old 
gnotobiotic pigs with a new United States PRCV isolate designated AR310, and 
microscopic examination of lung tissue revealed a "necrotizing and proliferative 
bronchointerstitial pneumonia characterized by necrosis, squamous metaplasia, 
dysplasia, proliferation of airway epithelium, mononuclear cell infiltration of alveolar 
septa, mild type II pneumocyte proliferation, and lymphohistiocytic exudation". The 
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lesions described by Halbur et al. (1993) were "mild by 3 days post inoculation (DPI), 
moderate by 5 DPI, severe by 10 DPI, and mostly resolved by 15 DPI" with no clinical 
disease observed among the infected gnotobiotic pigs. Halbur et al. (1993) speculated 
that lack of clinical disease in the PRCV AR310 infected gnotobiotic pigs was due to the 
gnotobiotic environment, and hypothesized that if PRCV AR310 " causes similar lesions 
in conventional pigs, it might predispose them to secondary bacterial infections". Halbur 
et al. (1994) has shown that when PRCV AR310 was intranasally inoculated into five-
week-old SPF pigs the results showed that PRCV AR310 caused moderate 
bronchointerstitial pneumonia. In contrast, when another PRCV isolate designated 
IA1894 was inoculated into five-week-old SPF pigs in the same experiment the results 
showed that PRCV IA1894 caused only mild bronchointerstitial pneumonia. Laude et al. 
(1993) proposed that the diversity in presentation of clinical disease signs among 
experimentally PRCV infected swine "may be influenced by the age of pigs and/or the 
inoculation technique". However, the recent findings by Halbur et al. (1994) indicate 
that the pathogenicity of some PRCV isolates in five-week-old SPF pigs may vary based 
on clinical disease signs and lung lesion development. More study into the role of 
coronavirus genes involved in tissue tropism, pathogenesis, and virulence should help 
clarify why some recent PRCV isolates vary in clinical disease signs and lung lesion 
development. 
Porcine respiratory coronavirus has been found to replicate in a variety of 
anatomical sites in swine. In experimentally infected swine, PRCV has been easily 
isolated from lung, trachea, nasal mucosa, tonsils, stomach, and small intestine and its 
contents (OToole et al., 1989; Cox et al., 1990a). Porcine respiratory coronavirus has 
been occasionally isolated from lymph nodes, thymus, spleen, liver, kidney, and 
leukocytes (Cox et al., 1990a). The replication of PRCV in the gastrointestinal tract is 
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limited and does not destroy villus enterocytes as does TGEV. By using 
immunofluorescent detection, the cells in the intestinal tract from PRCV infected swine 
containing viral antigen were villus enterocytes, crypt cells, and unidentifiable cells under 
the villus enterocytes and crypts (Cox et al., 1990a). Viremia and/or ingestion of PRCV 
produced in the respiratory tissue were proposed mechanisms for the ability of PRCV to 
get to the intestinal tract and undergo limited replication (Cox et al., 1990a). The limited 
ability of PRCV to replicate in the intestine was quantified by Cox et al. (1990b) as it 
took over 10^ TCID50 of PRCV directly inoculated into the intestines of swine to start 
intestinal infection. Although European researchers have routinely isolated PRCV from 
the intestines of experimentally infected swine (OToole et al., 1989; Cox et al., 1990a; 
Cox et al., 1990b), researchers in the United States have not isolated PRCV from 
intestinal homogenates from experimentally infected swine (Halbur et al, 1993; Hill et 
al., 1989; Wesley et al., 1990). United States researchers have isolated PRCV from 
rectal swabs collected from experimentally infected pigs which may reflect the ingestion 
of PRCV produced in respiratory tissue (Halbur et al., 1993; Wesley et al., 1990b). 
The sudden occurrence of PRCV was in itself puzzling, but an even more 
intriguing puzzle was determining the origin of PRCV. It was suggested that PRCV 
might actually be a TGEV vaccine that had developed an extreme tropism for respiratory 
tissue. Other hypothesis considered the possibility that PRCV was a result of "laboratory 
manipulation" or the "spontaneous genome recombination between TGEV and another 
heterologous coronavirus" (Laude et al, 1993). But information provided by the 
nucleotide sequence analysis of PRCV isolates shows that PRCV most likely arose from 
TGEV itself. Nucleotide sequence analysis thus far has shown that PRCV isolates have 
no sequences unique to themselves when compared to the genome of TGEV, however, 
PRCV isolates do demonstrate some consistent nucleotide deletions. 
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There are several similarities between PRCV and TGEV. Both viruses have three 
major structural proteins: the surface S glycoprotein, the M glycoprotein, and an internal 
N protein. Previous studies of the genetic structure of PRCV have shown that the 
isolates all have had two unique characteristics. First, the S gene of PRCV contains a 
large inframe deletion ranging from 672- to 681-nucleotides in length (Rasschaert et al., 
1990; Britton et al., 1991; Wesley et al., 1991b; Jackwood et al., 1992). This deletion in 
the S gene results in a smaller S glycoprotein. Second, all of the PRCVs analyzed thus 
far have had the CTAAAC consensus leader RNA binding site preceding the 3a gene 
altered or partially deleted (Rasschaert et al, 1990; Britton et al., 1991). Also, the 3a 
gene of the European PRCVs contains several small deletions that render the 3a gene to a 
psuedogene. One PRCV isolate from the United States, Ind/89, was found to have an 
intact 3a gene but the CTAAAC consensus leader RNA binding site had been altered to 
CTAAAT, thus making the subgenomic mRNA 3 of Ind/89 undetectable in infected cells 
(Wesley et al., 1991b). 
The presence of a large deletion in the 5' end of the S gene is thought to play a 
role in determining the tissue tropism of PRCV. Sanchez et al. (1992) have proposed 
that four amino acid residues (92,94,218, and 219) in the S protein of TGEV are 
important in the binding of virus to enterocytes and that the tropism of certain strains of 
TGEV may be shifted from the intestinal tract to the respiratory tract. The amino acid 
residues 92,94,218, and 219 are within the region of the S gene that is characteristically 
deleted in PRCV isolates. Studies with the MHV coronavirus have shown that small 
deletions or point mutations within the 5' end of the S gene results in reduced 
neurovirulence (Dalziel et al., 1986; Fleming et al., 1986) However, it should be pointed 
out that these MHV studies have looked exclusively at the S gene of MHV mutants and 
29 
have not taken into consideration any other possible changes in the genome of the 
attenuated MHV mutants. 
A protein that is expressed on the brush border membrane of small intestinal villi, 
designated aminopepddase N (APN), has been shown to serve as a receptor for TGEV 
(Delmas et al., 1992). Aminopeptidase N also is "most likely to be expressed on 
respiratory epithelial cells and alveolar macrophages" (Laude et al., 1993) and PRCV 
may also use APN as a receptor to gain entry into cells. The mmCGMl (murine 
carcinoembryonic antigen gene family member 1) was the first protein to be shown to 
serve as a receptor for MHV, however, an alternate receptor mmCGM2 (murine 
carcinoembryonic antigen gene family member 2) has been shown to be used by MHV to 
gain entry into cells (Williams et al., 1991; Yokomori and Lai, 1992). Thus, there is a 
possibility that PRCV may use an alternative receptor other than APN to gain entry into 
cells. 
Laude et al. (1993) presents two possible explanations on why PRCV replicates 
very little if at all in the intestinal tissue of pigs. First, Laude et al. (1993) proposes that 
the "N-terminal domain of the PRCV S protein contributes in some way to the stability" 
of the whole S protein. Thus the "physiochemical environment of the digestive tract 
could result in a decreased attachment or fusogenic capacity of the PRCV S protein" if 
indeed it was destabilized due to alteration of the N-terminal domain" (Laude et al, 
1993). Second, Laude et al. (1993) also consider the possibility that "PRCV restriction 
may take place after penetration into the enterocyte" and that this focuses "attention 
towards the second alteration of the PRCV genome, i.e. the conversion of the 3 gene to a 
pseudogene". 
In the case of TGEV, the 3 and 3-1 genes (formerly designated as ORFs A and 
B, respectively) have been hypothesized to be important in the virulence and 
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pathogenicity of TGEV (Wesley et al., 1990a). It is interesting to note that all previously 
described PRCV isolates have been demonstrated to have an altered or deleted 3 gene and 
that these PRCVs all cause no apparent disease in swine. Wesley et al. (1990a) have 
hypothesized that the role of the 3 and 3-1 regions of TGEV are involved in pathogenesis 
and virulence. This hypothesis can be extended to PRCV. 
In this study, my colleagues and I have analyzed the 5' end of the S gene and the 
3 and 3-1 genes of four PRCV isolates. My colleagues and I wished to determine the 
size and location of the S gene deletion of each of the PRCV isolates. Also, Halbur et al. 
(1994) has recently shown that three of the PRCV isolates analyzed in this study vary in 
pathogenicity. The PRCV isolates AR310 and LEPP caused moderate bronchointerstitial 
pneumonia in SPF pigs, whereas the PRCV isolate lA 1894 caused only a very mild 
bronchointerstitial pneumonia in SPF pigs. Since the 3 and 3-1 genes have been 
hypothesized to determine the virulence of TGEV, my colleagues and I wished to 
examine the 3 and 3-1 genes of the two pathogenic and the one nonpathogenic PRCV 
isolates to determine if the 3 and 3-1 genes of these PRCV isolates could be related to the 
differences in virulence exhibited by the PRCV isolates. 
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THREE NEW ISOLATES OF PORCINE RESPIRATORY CORONA VIRUS 
WITH VARYING PATHOGENICITY AND S GENE DELETIONS 
A paper submitted to the Journal of Clinical Microbiology 
Eric M. Vaughn, Patrick G. Halbur, and Prem S. Paul 
Abstract 
Three new isolates of porcine respiratory coronavirus (PRCV) were isolated and 
partially characterized. These PRCV isolates showed a selective tropism for respiratory 
tissue and were antigenically related to transmissible gastroenteritis virus (TGEV). 
Polymerase chain reaction (PCR) amplification of the 5'-half of the spike (S) genes of the 
three PRCV isolates indicated that a large deletion, characteristic of PRCV, was present. 
Using cDNA probes specific for the TGEV S gene, the PCR products were shown to be 
specific in a Southern blot. The three new PRCV isolates were shown to vary in S gene 
deletion size. In a separate study, these isolates have also been shown to vary in 
pathogenicity. These new PRCV isolates should serve as important tools in gaining a 
better understanding of the pathogenesis of coronavirus infections. 
Note 
Porcine respiratory coronavirus (PRCV), a member of the family Coronaviridae, 
is antigenically related to transmissible gastroenteritis virus (TGEV) of swine. Porcine 
respiratory coronavirus was first isolated in 1984 (14) from pigs in Belgium that were 
seropositive for TGEV but did not have a history of clinical transmissible gastroenteritis 
(TGE). Since the initial isolation of PRCV, infections of swine in Europe with PRCV 
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are widespread (13,19). Porcine respiratory coronavirus has also been isolated from 
three herds in the United States (7,12,23). The prevalence of PRCV infections in United 
States swine is currently not known, as several investigators in the United States have 
been attempting to isolate PRCV without much success. 
There are several similarities between PRCV and TGEV. Both viruses have three 
major structural proteins: the surface spike (S) glycoprotein, the integral membrane (M) 
glycoprotein, and an internal nucleoprotein (N). Nucleotide sequence of PRCV isolates 
thus far studied show that they are closely related to TGEV (1,8,15,21). However, there 
are some striking differences in that PRCV isolates have a deletion in the 5' end of the S 
gene (Figure 1); also, there are deletions in the nonstructural region coded by mRNA 3, 
when compared to TGEV (1,15). Porcine respiratory coronavirus has a different tissue 
tropism than TGEV. TGEV replicates in both the respiratory and intestinal tissues and 
causes gastroenteritis, whereas PRCV replicates to high titers in lung tissue of swine and 
with little or no replication in the intestinal tissues and no evidence of villus atrophy and 
gastroenteritis (3,4,10). Currently, the presence of the deletion in the S gene is thought 
to contribute to the differences in tissue tropism shown by these viruses (9,11,17). The 
nonstructural genes encoded by mRNA 3 and 3-1 are hypothesized to be involved in the 
pathogenesis of TGEV (9,21,22). 
Porcine respiratory coronavirus is antigenically similar to TGEV in that 
polyclonal sera which neutralizes TGEV also neutralizes PRCV (2,7,23). Anti-TGEV 
neutralizing monoclonal antibodies (MAbs) directed against the S glycoprotein readily 
neutralize PRCV, however, there are some non-neutralizing anti-TGEV MAbs directed 
against the S glycoprotein that can be used to distinguish between PRCV and TGEV 
isolates in a competitive binding assay (2,5,18,19). 
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Of the European PRCV isolates that have had their nucleotide sequences 
published all have a 672-nucleotide deletion in the 5' end of the S gene (1,15,17). The 
U.S. PRCV isolates Ind/89 and ISU-1 had a 681-nucleotide deletion present in the 5' 
end of the S gene (8,21). This deletion in the 5' end of the PRCV S gene yields a 
smaller S glycoprotein. 
My colleagues and I have been interested in obtaining additional isolates of PRCV 
in order to determine how prevalent this virus is in the swine population, to identify its 
role in pneumonia in swine, and to better understand the mechanism of the origin of 
PRCV from TGEV. Here, my colleagues and I report on the isolation of three new 
PRCV isolates in the United States and present evidence that these isolates have deletions 
in the S gene that appear to be of varying sizes. 
The PRCV isolate AR310 was isolated from the small intestine of a pig from an 
Arkansas swine herd which suffered from endemic TGE. Approximately 10 percent 
suspensions of the intestinal sample were prepared in 0.05 M phosphate buffered saline 
(pH 7.4) and clarified by centrifugation at 1000 x g for 10 minutes. The supernatants 
were harvested, passed through a 0.45 |Lim filter (Costar, Cambridge, MA) and stored at 
-70°C until viral isolation was attempted. The swine testicular (ST) cell line was used to 
isolate and propagate the viruses in this study and were maintained as previously 
described (23). Four-day-old ST cells in 25 cm^ flasks (Costar, Cambridge, MA) were 
treated with minimum essential medium (MEM) containing DEAE-dextran (50 |ig/ml) 
(Sigma, St. Louis, MO) at 37°C for 30 minutes before the intestinal tissue filtrate was 
added. Prior to inoculation onto ST cell monolayers, 0.2 ml of the intestinal filtrate was 
mixed with 0.8 ml of a 1:10 dilution of porcine anti-enterovirus (Group 8C) 
hyperimmune serum (virus neutralization titer of 1:1600) in MEM with 2 percent fetal 
bovine serum (FBS) and antibiotics (penicillin 20,000 U/ml, streptomycin 20,000 |J.g/ml, 
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and amphotericin B 50 p,g/ml) (GIBCO BRL, Grand Island, NY), and were incubated at 
37°C for one hour. The ST cell monolayers were inoculated with the entire 1 ml of vkus 
and anti-enterovirus hyperimmune serum mixture, and the inoculum was adsorbed onto 
the ST cells for 60 minutes at 37°C, after which additional MEM with 2 percent FES plus 
antibiotics was added. The cultures were incubated at 37°C for 48 hours and observed 
daily for cytopathic effect (CPE). After 48 hours, whether or not CPE was evident, all 
cultures were frozen and thawed three times, clarified by centrifugation at 1000 x g for 
10 minutes, and used as inoculum for the next passage. Cytopathic effect was evident at 
the third passage of AR310 in ST cells. 
Two of the PRCV isolates in this study, IA1894 and LEPP, were isolated from 
nasal swabs from swine fi-om herds that had antibodies to TGEV but had not presented 
evidence of diarrhea, and thus were suspected of having a PRCV infection. Nasal swabs 
were collected and placed into one ml of MEM with 2 percent FBS and antibiotics and 
mixed on a vortex mixer for 20 seconds. Two hundred |xl of the MEM was inoculated 
onto ST cells. Cytopathic effect was present on the first passage in ST cells for both 
IA1894 and LEPP. All three isolates were plaque purified a total of three times and stock 
virus was stored at -70°C. 
The gut-passaged virulent Miller strain of TGEV (National Veterinary Services 
Laboratory, Ames, lA), also referred to as CHV TGEV, was used as a standard TGEV 
strain in this study. The PRCV isolate ISU-1 was received as a plaque-purified 
preparation and was kindly provided by Dr. Howard Hill (Iowa State University 
Veterinary Diagnostic Laboratory) (7). 
The PRCV isolates produced a CPE in ST cells similar to that of TGEV however 
syncytia formation was detected in the PRCV-infected ST cells that was not present in 
TGEV-infected ST cells. Both swine polyclonal anti-TGEV serum and the neutralizing 
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anti-TGEV S monoclonal antibody (MAb) MHl 1 (24) recognized the PRCV isolates 
AR310, LEPP, and IA1894 in an indirect immunofluorescence assay (Figure 2) 
performed as previously described (24). 
Polymerase chain reaction (PGR) amplification of the 5'-half of the S genes of the 
three PRCV isolates was performed to determine if a large deletion, characteristic of 
PRCV, was present. ST cells were infected at a multiplicity of infection of 
approximately 0.1 PFU/cell with CHV TGEV, AR310, ISU-1, IA1894, or LEPP. At 19 
hours post infection, the medium was removed and the total RNA was isolated from the 
infected ST cell monolayers by a rapid guanidinium thiocyanate method (Stratagene, La 
Jolla, CA). The RNA was washed with 70% ethanol and dissolved in DEPC-treated 
distilled water and stored at -70°C. First strand cDNA was made by avian 
myeloblastosis virus reverse transcriptase by using random oligonucleotide primers 
(Invitrogen, San Diego, CA). The cDNA-RNA hybrids were amplified by PGR using 
Tag DNA polymerase (Boehringer Mannheim, Indianapolis, IN) by using specific 
primers (Table 1). The 5'-half of the S genes of TGEV and the PRCV isolates were 
amplified with the primers 21209 and 060704 under the following parameters: 1 cycle of 
1 minute at 94°C, 1 minute at 48°C, and 5 minutes at 72°C; 30 cycles of 1 minute at 
94°C, 1 minute at 48°C, and 3 minutes at 72°C; followed by 1 cycle of 1 minute at 94°C, 
1 minute at 48°C, and 5 minutes at 72°C in a DNA thermal cycler (Coy Corporation, 
Grass Lake, MI). 
The TGEV and PRCV S gene PGR products were separated on a 2% NuSieve 
GTG (FMC Bioproducts, Rockland, ME) agarose gel and then purified from the agarose 
gel by the Magic PGR prep method (Promega, Madison, WI). The purified PGR 
products were then separated on a 1.5% SeaKem ME (FMC Bioproducts, Rockland, 
ME) agarose gel (Figure 3). The PGR products of the PRCV isolates showed that there 
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was a deletion in the S gene in comparison to TGEV. The PGR products from the 
isolates AR310 and LEPP appeared to migrate at the same rate, whereas the PGR 
products from the isolates IA1894 and ISU-1 migrated more slowly. To confirm that the 
amplified PGR products were specific for the S gene, a Southern blot was performed 
(16). The PGR products were separated on a 1.5% SeaKem ME agarose gel, 
depurinated with 0.25 N HGl, denatured with 0.5 N NaOH and 1.5 M NaGl, neutralized 
with 0.1 M Tris-HGl (pH 7.5) and 1.5 M NaGl and then transferred by using a Posiblot 
pressure blotter (Stratagene, La Jolla, GA) with lOx SSG (Ix SSG is 0.15 M NaGl plus 
15 mM sodium citrate) to nylon membranes (Magna NT, Micron Separations Inc., 
Westboro, MA). After the transfer was complete, the membranes were baked at 80°G for 
2 hours to fix the DNA. The membranes were prehybridized for 2 hours in a solution 
containing 50% formamide, 5x SSPE (Ix SSPE is 0.18 M NaGl, 10 mM sodium 
phosphate, and 1 mM EOTA), 4x Denhardt's solution, 0.3% sodium dodecyl sulfate 
(SDS), and sonicated salmon sperm DNA (30 |Xg/ml) at 42°G. The cDNA probes used 
in the hybridization procedure were designated FP2 and FPl (Figure 1). FP2 is a 2.2 
kb PGR product that was amplified by the primers 101004 and 060704 and cut with the 
BamHl restriction enzyme and cloned in the phagemid vector pKS+ (Stratagene, La 
Jolla, GA). FPl is a 0.6 kb PGR product that was amplified by the primers 101004 and 
100907 and cut with BamHl and EcoRl restriction enzymes and cloned in the phagemid 
vector pKS+. FP2 encompasses the 5 -half of the TGEV S gene and thus will hybridize 
to both TGEV and PRGV S genes. However, FPl encompasses the region of the TGEV 
S gene that is deleted from all PRGV isolates known thus far and will only hybridize with 
the S gene of TGEV. Twenty-five ng each of FPl and FP2 were labeled with [a 
32p]dGTP (IGN Biochemicals, Gosta Mesa, GA) in the presence of random hexamer 
primers and Klenow fragment of DNA polymerase I (Amersham Gorporation, Arlington 
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Heights, IL). Unincorporated [a 32p]dCTP was removed by passing the labeled DNA 
through a Sephadex G-50 column (Boehringer Mannheim, Indianapolis, IN). The 
labeled FPl and FP2 probes were then heated to 100°C, cooled on ice, and then added to 
the appropriate prehybridization reaction and allowed to hybridize overnight. The 
membranes were washed once in 2xSSC-0.3% SDS at room temperature, twice in 
2xSSC-0.3% SDS at 65°C, and once with 0.2x SSC at room temperature. 
Autoradiographs were made by exposing X-ray film (RX film, Fuji Photo Film Co., 
Japan) to the membranes (Figure 4). As expected, the probe FP2 detected the PGR 
products of all the PRGV isolates and TGEV, whereas the probe FPl detected only the 
TGEV PGR product. Thus the Southern blot reveals that the amplified PGR products 
from TGEV and the PRGV isolates were specific and that these new PRGV isolates have 
deletions in their S genes typical of PRGV yet the differences in the migration rate of the 
PRGV PGR products in an agarose gel indicates that the S genes of these PRGV isolates 
have deletions of varying sizes. 
The PRGV isolate AR310 has been shown to cause interstitial pneumonia in 
gnotobiotic pigs (6). By using five-week-old SPF pigs, PRGV isolates AR310, LEPP, 
and IA1894 were shown to exhibit a tropism for respiratory tissue with no detectable 
replication in intestinal tissue (Halbur et al., 1994). Also, the pathogenicity of the PRGV 
isolates AR310, LEPP, and IA1894 was shown to vary. The PRGV isolates AR310 and 
LEPP induced moderate bronchointerstitial pneumonia in five-week-old SPF pigs, 
whereas the PRGV isolate IA1894 induced very mild bronchointerstitial pneumonia 
(Halbur et al., 1994). This information is summarized in Table 2. 
Porcine respiratory coronavirus is believed to have originated from TGEV. 
Although the mechanism of the deletion occurring in the S gene of PRGV is not known, 
RNA recombination with polymerase jumping is a possible mechanism (9,17). Whether 
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immune pressure plays a role in the deletion of the S gene in PRCV is not known. The 
PRCV isolate AR310 is the first PRCV strain to be isolated from intestinal tissue. The 
herd in which AR310 was isolated had been vaccinated with a commercial TGEV vaccine 
and immune pressure may have played a role in the development of the S gene deletion of 
AR310. However, it should be noted that TGEV was also isolated from other pigs in the 
same herd from which AR310 was isolated. Whether the original AR310 intestinal 
homogenate contained a mixture of TGEV variants, or the S gene deletion of AR310 
occurred during cell culture adaptation is under study at this time. Porcine respiratory 
coronavirus can cause a viremia (3) and a possible explanation for the isolation of PRCV 
AR310 from intestinal tissue homogenates may have been due to a PRCV viremia at the 
time tissue collection. 
The RM4, 86/137004, TLM83, Ind/89 and ISU-1 PRCV isolates were isolated 
from clinically normal swine herds that had serum titers to TGEV yet had not presented 
signs of enteric disease associated with TGEV infection (1,7,13,15,23). One of the 
PRCV isolates in this study, AR310, was isolated from intestinal tissue of a piglet with 
TGE and is the first to be isolated from such conditions. The other PRCV isolates LEPP 
and LA 1894 originated from pigs with pneumonia. 
The size of the S gene from these PRCV isolates also varies. The deletion in the 
PCR product of AR310 is smaller than that of ISU-1 and has been determined to be 621-
nucleotides (12). The size of the deletion present in the LEPP S gene appears to be 
similar to that of AR310. The size of the deletion of LA 1894 appears to be similar to the 
681-nucleotide deletion of ISU-1. Studies involving the cloning and sequencing of the S 
gene of these isolates are underway to determine the precise location and size of the 
deletion. The nonstructural regions of the PRCV isolates AR310, LEPP, and LAI 894 are 
currently under study as it has been proposed that the genes 3 and 3-1 are important in 
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the pathogenesis of TGEV and may play a similar role in the pathogenicity of PRCV 
(9,21,22). The analysis of these nonstructural regions of these PRCV isolates should be 
of interest since these isolates do vary in pneumopathogenicity. 
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TABLE 1. TGEV S gene specific oligonucleotide primers used in PGR to amplify regions of the S gene of PRCV and TGEV 
Primer 
Name Sequence Nucleotide localization 
021209 5 ' gggaattcgGGGTAAGTTGCTCATTAGAAA 3' 56-76 a 
060704 5 ' ggggatccGCAGTGCCACGAGTCCTATCAT 3 ' 2462-2483 a 
101004 5' ggggggat COAGAACTATAGGTAACCATTGG 3' 1678-1698b 
100907 5 ' gggÇrgaaTTCTAATGTAGTCGCACGCAT 3 ' 2230-2250 b 
^ From the sequence of D. Rasschaert and H. Laude. J. Gen. Virol. (1987) 68:1883-1890. 
b From the sequence of P. Britton and K.W. Page. Virus Res. (1990) 18:71-80. 
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TABLE 2. Tissue tropism and pathogenicity of PRCV isolates AR310, 
LEPP, and IA1894 
Virus Replication ^ Lesions 
Isolate Lung Intestine Lung Intestine 
AR310 + + 
LEPP 
IA1894 ± 
Control - -
Presence (+), or absence (-) of CPE after ST cells were infected with 
twenty percent lung or intestinal homogenates from five-week-old SPF 
pigs inoculated intranasally with 10^ pfu of the appropriate virus. 
Lung lesions were determined by the presence of moderate (+), mild (±), 
or ab^sence (-) of bronchointerstitial pneumonia. Intestinal lesions were 
determined by the presence (+), or absence (-) of villus atrophy. 
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Figure 1. Schematic diagram of the S gene of TGEV with the characteristic 
deletion of PRCV shown, a) PGR product of the 5'-half of the S gene of 
TGEV and PRCV amplified by primers 021209 and 060704. b) Probe 
FP2 used to detect the S gene of both TGEV and PRCV in Southern 
blot. FP2 was amplified by the primers 101004 and 060704 and cloned 
in pKS+. c) Probe FPl used to detect the S gene of TGEV in Southern 
blot. FPl was amplified by the primers 101004 and 100907 and cloned 
in pKS+. Dashed line represents the area that is deleted in PRCV. 
Figure 2. Immunofluorescent staining of PRCV AR310 infected (A), or uninfected 
(B), methanol/acetone fixed ST cells with the anti-TGEV S glycoprotein 
MAb MHl 1. The Miller strain of TGEV and the PRCV isolates LEPP, 
IA1894, and ISU-1 all reacted with the MAb MHl 1 in a similar pattern. 

Figure 3. PGR amplification of the 5'-half of the S gene of TGEV and PRCV 
isolates. cDNA was amplified by PGR as with primers 021209 and 
060704 as described in text and separated on 1.5% agarose gel. 
Molecular weight markers (M), CHV TGEV (lane 1), ISU-1 (lane 2), 
AR310 (lane 3), IA1894 (lane 4), LEPP (lane 5). Note that the PGR 
products from AR310 and LEPP migrate at the same rate, whereas the 
PGR products from ISU-1 and IA1894 migrate more slowly. 
M 1 2 3 4 5 M 
3.0 Kb 
2.0 Kb 
1.6 Kb 
Figure 4. Southern blot of the PGR product from the 5-half of the S gene of TGEV 
and PRCV isolates with the cDNA probes FP2 and FPl. a) The cDNA 
probe FP2 was labeled with [a 32p]clCTP and was hybridized with the 
PGR products from GHV TGEV (lane 1), ISU-1 (lane 2), AR310 (lane 
3), IA1894 (lane 4), LEPP (lane 5). Note that the cDNA probe FP2 
hybridized with the PGR products from both TGEV and PRGV. b) The 
cDNA probe FPl was labeled with [a 32p]dGTP and was hybridized 
with the PGR products from GHV TGEV (lane 1), ISU-1 (lane 2), 
AR310 (lane 3), IA1894 (lane 4), LEPP (lane 5). Note that the cDNA 
probe FPl hybridized only with the PGR products from TGEV, the 
PRCV PGR products were not detected with the cDNA probe FPl. 
A 
1 2 3 4 5 
B 
1 2 3 4 5 
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SEQUENCE COMPARISON OF THE SPIKE, 3, AND 3-1 GENES OF PORCINE 
RESPIRATORY CORONA VIRUS ISOLATES WITH VARYING PATHOGENICITY 
A paper to be submitted to the Journal of Virology 
Eric M. Vaughn, Patrick G. Halbur, and Prem S. Paul 
Abstract 
Four porcine respiratory coronavirus (PRCV) isolates with varying pathogenicity 
were characterized. Subgenomic mRNA patterns and the nucleotide sequence of the 5' 
end of the S genes, the 3/3a genes, and the 3-l/3b genes of these PRCV isolates were 
determined and compared to other PRCV and transmissible gastroenteritis virus (TGEV) 
isolates. Two of the PRCV isolates, AR310 and LEPP, were shown to be more 
pathogenic than another PRCV isolate IA1894 in a five-week-old specific pathogen free 
model. Northern blot analysis of the subgenomic mRNAs produced in infected-ST cells 
revealed that the mRNA 2 (S) of the PRCV isolates migrated faster than the homologous 
species of mRNA from TGEV. Also, the number of subgenomic mRNAs produced in 
infected ST cells was found to vary. The PRCV isolates AR3I0 and LEPP produced 
eight subgenomic mRNA species, the same number as that produced by the Miller strain 
of TGEV. However, the PRCV isolates IA1894 and ISU-1 produced only seven 
subgenomic mRNA species. All four of the PRCV isolates were found to have a large 
inframe deletion in the 5' end of the S gene. The PRCV isolates AR310 and LEPP both 
had identical S gene deletions of 621-nucleotides starting 47 nucleotides after the S gene 
start site. The PRCV isolate IA1894 had a 678-nucleotide deletion 44 nucleotides after 
the S gene start site, whereas the PRCV isolate ISU-1 had a 681-nucleotide deletion 62 
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nucleotides after the S gene start site. Analysis of the 3/3a gene nucleotide sequence 
from the four PRCV isolates showed a high degree of variability. The 3 gene of the 
PRCV isolates AR310 and LEPP was preceded by a CTAAAC leader RNA binding site 
and the 3 gene was predicted to yield a protein of 72 amino acids, the same size as that of 
the virulent Miller strain of TGEV. The 3a gene of the PRCV isolate IA1894 was 
preceded by a CTAAAC leader RNA binding site and the 3a gene was predicted to yield a 
truncated protein of 53 amino acids due to a 23-nucleotide deletion in the 3a gene. The 
CTAAAC leader RNA binding site and ATG start codon of the 3 gene of the PRCV 
isolate ISU-1 was removed due to a 168-nucleotide deletion. Analysis of the 3-l/3b gene 
nucleotide sequence from the four PRCV nucleotides isolates also showed a rather high 
degree of variability. The 3-1 gene of the PRCV isolates AR310 and LEPP was 
preceded by a CTAAAC leader RNA binding site but was found to have a one-nucleotide 
deletion that was predicted to yield a truncated (63 amino acids versus 244 amino acids) 
3-1 protein. The last two nucleotides of the CTAAAC leader RNA binding site preceding 
the 3-1 gene of the PRCV isolate IA1894 were removed by a five-nucleotide deletion but 
the 3-1 gene was predicted to encode for a protein of 244 amino acids. The 3-1 gene of 
the PRCV isolate ISU-1 was preceded by a CTAAAC leader RNA binding site but was 
found to have a 117-nucleotide inframe deletion that was predicted to yield a truncated 
(205 amino acids versus 244 amino acids) 3-1 protein. The PRCV isolates AR310 and 
LEPP have been shown to be more pathogenic than the PRCV isolate IA1894, which 
suggests that the presence of an intact 3 gene may be an important virulence determinant 
in PRCV. 
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Introduction 
Porcine respiratory coronavirus (PRCV) and transmissible gastroenteritis virus 
(TGEV) are members of the Coronaviridae family of viruses (18,21). Coronaviruses are 
pleomorphic enveloped viruses with a positive-sense single stranded RNA genome (21). 
Transmissible gastroenteritis virus causes severe diarrhea with a high mortality in 
neonatal swine (18). Transmissible gastroenteritis virus replicates in and destroys the 
villus enterocytes of the small intestinal epithelium which causes the subsequent 
malabsorption and dehydration characteristic of transmissible gastroenteritis (TGE) (18). 
Transmissible gastroenteritis virus has also been shown to replicate in respiratory tissue 
of infected swine. Porcine respiratory coronavirus is believed to be a mutant of TGEV as 
it has been shown to be antigenically and genetically related to TGEV but has a selective 
tropism for respiratory tissue with very little to no replication in intestinal tissue of 
infected swine (10,15). Porcine respiratory coronavirus is widespread in Europe where 
it was first detected (15). Porcine respiratory coronavirus has also been found in the 
United States, but the extent of its prevalence is not known (7,14,26). Because TGEV 
and PRCV are closely related and yet display differences in tissue tropism and 
pathogenicity, they can serve as useful models for the study of coronavirus genes 
involved in tropism and virulence. 
The replication scheme of coronaviruses is characterized by the development of a 
3'-terminal nested set of subgenomic mRNAs in infected cells (21). The subgenomic 
mRNAs, with the exception of the smallest, are polycistronic in nature yet only unique 5' 
ORF is translated (21). Seven or eight subgenomic mRNAs are synthesized during 
TGEV replication in infected cells (21,25). The full-length genomic mRNA 1 encodes 
for a RNA-dependent RNA polymerase (21). The spike (S) protein is encoded by 
subgenomic mRNA 2 (21). Two nonstructural proteins, 3 and 3-1, are encoded by the 
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subgenomic mRNAs 3 and 3-1 respectively, for the Miller strain of TGEV (21,24,27). 
The homologous genes found in the Purdue and FS772/70 strains of TGEV are encoded 
by a single mRNA species and are designated genes 3a and 3b (2,9). The small integral 
membrane (sM) protein is associated with the viral envelope and is encoded by 
subgenomic mRNA 4 (5). The integral membrane protein (M) and nucleocapsid (N) 
proteins are encoded by subgenomic mRNAs 5 and 6, respectively (21). The 
subgenomic mRNA 7, the smallest subgenomic mRNA, is the only monocistronic 
subgenomic mRNA and has been shown to encode for a possible DNA binding protein 
in infected cells (2,4). Preceding each large potential ORF is the conserved hexameric 
sequence of CTAAAC, which is thought to serve as a consensus leader RNA binding site 
in the transcription of the subgenomic mRNAs from a full-length negative sense template 
(21). 
Previous studies of the genetic structure of PRCV have shown that all of the 
isolates have two unique characteristics. First, the S gene of PRCV contains a large 
inframe deletion ranging from 672- to 681-nucleotides in length (1,8,10,17,24), This 
deletion in the S gene results in a smaller S glycoprotein. Second, all of the PRCVs 
analyzed thus far have had the CTAAAC consensus leader RNA binding site preceding 
the 3 gene altered or partially deleted (10,12,17,24). Thus the subgenomic mRNA 3 is 
not detected in PRCV infected cells (10). Also, the 3 gene of the European PRCVs 
contains several small deletions that render the 3 gene to a psuedogene (12,17). One 
PRCV isolate from the United States, Ind/89, was found to have an intact 3 gene but the 
CTAAAC consensus leader RNA binding site had been altered to CTAAAT, thus making 
the subgenomic mRNA 3 of Ind/89 undetectable in infected cells (24), The presence of a 
large deletion in the 5' end of the S gene is thought to play a role in determining the tissue 
tropism of PRCV (13,20). In the case of TGEV, the genes 3 and 3-1 (formerly 
57 
designated as ORF A and ORF B respectively) have been hypothesized to be important in 
the virulence and pathogenesis of TGEV infection (25). It is interesting to note that all 
previously described PRCV isolates have been demonstrated to have an altered or deleted 
3 gene and that these PRCVs all cause minimal to no apparent clinical disease in swine. 
In this study, my colleagues and I have analyzed the viral mRNAs from four 
PRCV isolates by Northern blot analysis and nucleotide sequencing of the 5' end of the S 
gene and the 3 and 3-1 genes. The size and location of the S gene deletion of the PRCV 
isolates was also determined as my colleagues and I had previously shown that two of 
the PRCV isolates in this study, AR310 and LEPP, had smaller deletions in the 5' end of 
the S gene when compared to another United States PRCV isolate designated ISU-1. 
Also, Halbur et al. (1994) have recently shown that three of the PRCV isolates analyzed 
in this study vary in pathogenicity. The PRCV isolates AR310 and LEPP caused 
moderate bronchointerstitial pneumonia in five-week-old specific pathogen free (SPF) 
pigs whereas the PRCV isolate LA 1894 caused only a very mild bronchointerstitial 
pneumonia in SPF pigs. Since the 3 and 3-1 genes have been hypothesized to determine 
the virulence of TGEV, my colleagues and I examined the 3 and 3-1 genes of the two 
pathogenic and the one nonpathogenic PRCV isolates to determine if the 3 and 3-1 genes 
of these PRCV isolates could be related to the differences in virulence exhibited by the 
PRCV isolates. 
Materials and Methods 
Virus isolation 
The PRCV isolate AR310 was isolated from the small intestines of a pig from a 
swine herd in Arkansas with endemic TOE as previously described (22). Briefly, 
approximately 10 percent suspensions of the intestinal sample was prepared in 0.05 M 
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phosphate buffered saline (pH 7.4) and clarified by centrifugation at 1000 x g for 10 
minutes. The supernatants were harvested, passed through a 0.45 fxm filter (Costar, 
Cambridge, MA) and stored at -70°C until viral isolation was attempted. The swine 
testicular (ST) cell line was used to isolate and propagate the viruses in this study and 
were maintained as previously described (23). Four-day-old ST cells in 25 cm^ flasks 
(Costar, Cambridge, MA) were treated with minimum essential medium (MEM) 
containing DEAE-dextran (50 |Xg/ml) (Sigma, St. Louis, MO) at 37°C for 30 minutes 
before the intestinal tissue filtrate was added. Prior to inoculation onto ST cell 
monolayers, 0.2 ml of the intestinal filtrate was mixed with 0.8 ml of a 1:10 dilution of 
porcine anti-enterovirus (Group 8C) hyperimmune serum (virus neutralization titer of 
1:1600) in MEM with 2 percent fetal bovine serum (PBS) and antibiotics (penicillin 
20,000 U/ml, streptomycin 20,000 |Xg/ml, and amphotericin B 50 |Lig/ml) (GIBCO BRL, 
Grand Island, NY), and were incubated at 37°C for one hour. The ST cell monolayers 
were inoculated with the entire 1 ml of virus and anti-enterovirus hyperimmune serum 
mixture and the inoculum was adsorbed onto the ST cells for one hour at 37°C, after 
which additional MEM with 2 percent PBS plus antibiotics was added. The cultures 
were incubated at 37°C for 48 hours and observed daily for cytopathic effect (CPE). 
After 48 hours, whether or not CPE was evident, all cultures were frozen and thawed 
three times, clarified by centrifugation at 1000 x g for 10 minutes, and used as inoculum 
for the next passage. CPE was evident at the third passage in ST cells for AR310. 
The other two PRCV isolates in this study, IA1894 and LEPP, were isolated 
from nasal swabs from swine from herds that had antibodies to TGEV but had not 
presented evidence of diarrhea, and thus were suspected of having a PRCV infection 
(22). Nasal swabs were collected and placed into one ml of MEM with 2 percent PBS 
and antibiotics and mixed for 20 seconds. Two hundred |J,1 of the nasal swab MEM was 
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inoculated onto ST cells. CPE was present on the first passage in ST cells for both 
IA1894 and LEPP. All three isolates were plaque purified a total of three times and stock 
virus was stored at -70°C. 
The gut-passaged virulent Miller strain of TGEV (National Veterinary Services 
Laboratory, Ames, lA), also referred to as CHV TGEV, was used as a standard TGEV 
strain in this study. The PRCV isolate ISU-1 was received as a plaque-purified 
preparation and was kindly provided by Dr. Howard Hill (Iowa State University 
Veterinary Diagnostic Laboratory)(7). 
RNA isolation 
ST cells were infected at a multiplicity of infection of approximately 0.1 PFU/cell 
with CHV TGEV, and the PRCV isolates AR310, ISU-1, IA1894, or LEPP. At 19 
hours post infection, the medium was removed and the total RNA was isolated from the 
infected ST cell monolayers by a rapid guanidinium thiocyanate method (Stratagene, La 
Jolla, CA). The RNA was washed with 70% ethanol and dissolved in 
diethylpyrocarbonate (DEPC) -treated distilled water and stored at -70°C. 
cDNA synthesis and PGR amplification 
First strand cDNA was made from total RNA from infected ST cells by avian 
myeloblastosis virus reverse transcriptase by using random oligonucleotide primers 
(Invitrogen, San Diego, CA). The cDNA-RNA hybrids were amplified by PCR using 
Taq DNA polymerase (Boehringer Mannheim, Indianapolis, IN) using the following 
primers (Table 1) and cycles. 
The S genes of TGEV and the PRCV isolates were amplified by using the 
primers 21209 and 060704 (Figure 2) under the following parameters: 1 cycle of 1 
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minute at 94°C, 1 minute at 48°C, and 5 minutes at 72°C; 30 cycles of 1 minute at 94°C, 
1 minute at 48°C, and 3 minutes at 72°C; followed by 1 cycle of 1 minute at 94°C, 1 
minute at 48°C, and 5 minutes at 72°C in a DNA thermal cycler (Coy Corporation, Grass 
Lake, MI). 
The 3 and 3-1 gene regions of TGEV and PRCV were amplified by using the 
primers 538 and 622 (Figure 2) under the following parameters: 1 cycle of 1 minute at 
94°C, 1 minute at 48°C, and 3 minutes at 72°C; 30 cycles of 1 minute at 94°C, 1 minute 
at 48°C, and 2 minutes at 72°C; followed by 1 cycle of 1 minute at 94°C, 1 minute at 
48°C, and 3 minutes at 72°C in a DNA thermal cycler. 
A 462 bp PGR product from the 3' end of the TGEV genome was amplified by 
using the primers 068 and 069 under the following parameters: 1 cycle of 1 minute at 
94°C, 1 minute at 48°C, and 3 minutes at 72°C; 30 cycles of 1 minute at 94°C, 1 minute 
at 48°C, and 1 minutes at 72°C; followed by 1 cycle of 1 minute at 94°C, 1 minute at 
48°C, and 3 minutes at 72°C in a DNA thermal cycler. 
The 5' end of mRNA 3 was amplified by using the primers 119 and 118, and the 
5' end of mRNA 3-1 was amplified by using the primers 119 and 048. Both reactions 
were amplified under the following parameters: 1 cycle of 1 minute at 94°C, 1 minute at 
48°C, and 3 minutes at 72°C; 30 cycles of 1 minute at 94°C, 1 minute at 48°C, and 1 
minutes at 72°C; followed by 1 cycle of 1 minute at 94°C, 1 minute at 48°C, and 3 
minutes at 72°C in a DNA thermal cycler. 
Cloning and sequencing 
The PCR products of the 5'-half of the S gene and 3 and 3-1 genes from TGEV 
and PRCV were separated on a 2% NuSieve GTG (FMC Bioproducts, Rockland, ME) 
agarose gel and then purified from the agarose gel by the Magic PCR prep method 
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(Promega, Madison, WI). The purified PGR products were then digested with EcoRI 
and BamWl and cloned in the phagemid vector pKS+. Five clones of the 5'-half of the S 
gene and the 3 and 3-1 gene regions from each virus were sequenced. The 3 and 3-1 
gene PGR products were also sequenced directly with specific oligonucleotide primers. 
Northern blot hybridization analysis 
Forty |Xg of total RNA was denatured with formaldehyde and formamide (19) and 
separated by electrophoresis in a 1.5% SeaKem (FMG Bioproducts, Rockland, ME) 
agarose gel. After electrophoresis, the agarose gel was treated with 0.05 N NaOH and 
1.5 M NaCl, neutralized with 0.1 M Tris-HGl (pH 7.5) and 1.5 M NaGl, washed twice 
in lOx SSG (Ix SSC is 0.15 M NaGl plus 15 mM sodium citrate), and then the RNA 
was transferred by using a Posiblot pressure blotter (Stratagene, La Jolla, GA) with lOx 
SSG to nylon membranes (Magna NT, Micron Separations Inc., Westboro, MA). After 
the transfer was complete, the membranes were baked at 80°G for 2 hours to fix the 
RNA. The membranes were prehybridized for 2 hours in a solution containing 50% 
formamide, 5x SSPE (Ix SSPE is 0.18 M NaGl, 10 mM sodium phosphate, and 1 mM 
EDTA) 4x Denhardt's solution, 0.3% sodium dodecyl sulfate (SDS), and sonicated 
salmon sperm DNA (30 |ig/ml) at 42°C. The probe used in the hybridization procedure 
was a 462 bp PGR product amplified with the primers 068 and 069 (Table 1). This PGR 
product was amplified from TGEV cDNA, gave a probe specific for the 3' end of TGEV, 
and was thus suitable for use as a probe in a Northern blot to detect TGEV and PRGV 
subgenomic mRNAs. One hundred twenty-five ng of the 3' end PGR product was 
labeled with [a ^^PjdGTP (IGN Biochemicals, Gosta Mesa, GA) in the presence of 
random hexamer primers and Klenow fragment of DNA polymerase I (Amersham 
Corporation, Arlington Heights, IL). Unincorporated [a ^ ^PjdGTP was removed by 
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passing the labeled DNA through a Sephadex G-50 column (Boehringer Mannheim, 
Indianapolis, IN). The labeled 3' end probe was then heated to 100°C, cooled on ice, 
and then added to the prehybridization reaction and allowed to hybridize overnight. The 
membranes were washed once in 2xSSC-0.3% SDS at room temperature, twice in 
2xSSC-0.3% SDS at 65°C, and once with 0.2x SSC at room temperature. 
Autoradiographs were made by exposing X-ray film (RX film, Fuji Photo Film Co., 
Japan) to the membranes. 
Analysis of the 5' end of mRNA 3 and mRNA 3-1 
PGR products from the 5' end of mRNA and mRNA 3-1 were generated using a 
method similar to that used by Page et al. (1991). Utilizing a primer (119) 
complementary to the TGEV and PRCV leader RNA sequence as determined by Page et 
al. (1990), and primers from either the 5' end of the 3/3a gene (118) or the 5' end of the 
3-l/3b gene(048), PGR products would be generated if the leader sequence had bound to 
the GTAAAG consensus leader binding site preceding the respective gene (Figure 10). 
Using the primers 119 and 118, a PGR product would be generated if the leader RNA 
was joined upstream of the 3/3a gene. Alternatively, using the primers 119 and 048, two 
PGR products would be generated if the leader RNA was joined upstream of both the 
3/3a and 3-l/3b genes, whereas only one PGR product would be generated if the leader 
RNA was joined upstream of either 3 gene or 3-1 gene (Figure 11). Amplified PGR 
products were then separated by electrophoresis in a 1.5% SeaKem (FMG Bioproducts, 
Rockland, ME) agarose gel and stained with ethidium bromide. 
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Results 
Analysis of sub^enomic mRNAs 
Coronaviral subgenomic mRNAs in ST cells infected with CHV TGEV or the 
PRCV strains were examined by Northern blot analysis using a probe specific for the 3' 
end of TGEV (Figure 1). The virulent Miller CHV TGEV had 8 mRNA species present 
as has been previously reported (27). The PRCV isolates AR310 and LEPP also had 8 
mRNA species present, whereas the PRCV isolates LA 1894 and ISU-1 only had 7 
mRNA species. The migration pattern of the mRNA species 4 through 7 of all four 
PRCV isolates were similar to that of the virulent TGEV. The mRNA 2 species of the 
PRCV isolates examined migrated faster than the TGEV equivalent, indicating that a large 
deletion was present. The PRCV isolates AR310 and LEPP and the virulent CHV TGEV 
all had the mRNA species 3 and 3-1 present. However, the PRCV isolates IA1894 and 
ISU-1 had only one mRNA species present in the area in which the mRNAs 3 and 3-1 
were detected for AR310, LEPP, and CHV TGEV. The PRCV isolate IA1894 had a 
mRNA species of approximately 3.61 kb that migrated at a slightly faster rate than the 
mRNA 3 of AR310, LEPP, and CHV TGEV. The PRCV isolate ISU-1 had a mRNA 
species of approximately 3.35 kb that migrated at a slightly faster rate than the mRNA 3-
1 of AR310, LEPP, and CHV TGEV. The mRNA 1 appeared to migrate at the same rate 
for all of the isolates. 
Analvsis of the 5'-half of the S gene PCR products 
To determine the size and location of the deletion present in the 5' end of the S 
gene of the PRCV isolates, the genome region from the 3' end of the polymerase gene 
(primer 021209) to the middle of the S gene (primer 060704) was amplified by PCR 
(Figure 2). Following amplification, a PCR product of the expected 2.4 kb size was 
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present for CHV TGEV. However, all the PRCV isolates had PCR products that 
migrated faster than the PCR product of TGEV indicating that deletions in the range of 
approximately 600- to 700-nucleotides were present. The deletions in the 5' end of the S 
genes varied in size as previously reported (22). The PCR products of the 5'-haIf of the 
S gene from the PRCV isolates were cloned and sequenced to map the size and location 
of the deletions present in the 5' end of the S gene. Alignment of the nucleotide sequence 
from the different isolates is shown in Figure 3. The PRCV isolates ARB 10 and LEPP 
had identical deletions of 621-nucleotides beginning 47 nucleotides after the ATG start of 
the S gene. The PRCV isolate IA1894 had a 678-nucleotide deletion 44 nucleotides after 
the S gene ATG. The 681-nucleotide deletion in the 5' end of the S gene of PRCV ISU-
1 was found to occur 62 nucleotides after the S gene ATG start. The S gene deletion 
found in PRCV ISU-1 is the same size and in the same location as had been previously 
determined by other researchers (8) and of that of another U.S. PRCV isolate Ind/89 
(24). A schematic diagram showing the various S gene deletions of the PRCV isolates is 
shown in Figure 4. 
Figure 5 shows the alignment of the predicted amino acid residues of the S gene 
from the PRCV isolates. The predicted S protein signal peptide cleavage site of lA 1894 
differs from that of TGEV or the other PRCV isolates. However, the signal peptide 
region of the PRCV isolate IA1894 still retains a core of hydrophobic amino acid 
residues that are essential for recognition by signal peptidase. 
Analvsis of the 3/3a gene and 3-1/3b pene regions 
The PCR products (primers 538 and 622) of the 3 and 3-1 gene regions of the 
PRCV isolates AR310 and LEPP, and of CHV TGEV were the expected size of 1.2 kb 
(Figure 6). The PCR product from the PRCV isolate IA1894 migrated slightly faster 
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indicating that a small deletion of approximately 20-nucleotides was present. However, 
the PGR product from the PRCV isolate ISU-1 migrated much faster, indicating that 
approximately 290-nucleotides were deleted. The alignment of the nucleotide sequence 
from the 3/3a and 3-l/3b gene regions of CHV TGEV, and the PRCV isolates AR310, 
LEPP, IA1894, and ISU-1 is shown in Figure 7. The nucleotide sequences of the 
TGEV isolates PP3 (Miller) (27), FS772/70 (2), and Purdue (9) and of the PRCV 
isolates 86/137004 (12) and RM4 (17) are included in Figure 7 for comparison. Also, 
the predicted amino acid residues for the 3/3a and 3-1/3b gene regions are shown in 
Figures 8 and 9 respectively. Cloning and sequencing of the PGR products from the 3 
and 3-1 gene region revealed that the PRCV isolates AR310, LEPP, IA1894, and ISU-1 
all had a three-nucleotide deletion beginning at position 42 which was identical to that 
detected in the British PRCV isolate 86/137004. The 3 gene from the isolates PRCV 
AR310, PRCV LEPP, and CHV TGEV was preceded by a consensus CTAAAC leader 
RNA-binding site. The 3-1 gene for PRCV AR310, PRCV LEPP, and CHV TGEV also 
was preceded by a consensus CTAAAC leader RNA-binding site. Analysis of the 3-1 
gene of PRCV AR310 and PRCV LEPP revealed that a one-nucleodde deletion was 
present at position 580. This one-nucleotide deletion causes a frameshift resulting in 
early termination of the 3-1 protein. The predicted 3-1 protein for PRCV AR310 and 
LEPP is 64 amino acids in length, 180 amino acid residues shorter than the predicted 3-1 
protein for CHV TGEV and the other PRCV isolates. (Figure 9). Analysis of PRCV 
lAl 894 revealed that there was a consensus CTAAAC leader RNA-binding site 
preceding the 3a gene. Of note, the PRCV IA1894 3a gene contained a 23-nucleotide 
deletion beginning at position 287 that would yield an early stop codon that would give 
rise to a truncated 3a protein (Figure 7). The truncated 3a protein of PRCV IA1894 
would consist of 53 amino acids as compared to the 72 amino acids present for PRCV 
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AR310, PRCV LEPP, and CHV TGEV 3 protein (Figure 8). The consensus CTAAAC 
leader RNA-binding site preceding the 3b gene of PRCV IA1894 was altered due to a 
five-nucleotide deletion that removed the last two nucleotides of the consensus sequence, 
thus making RNA 3-1 undetectable in PRCV LA 1894 infected cells by Northern blot. 
However, the 3-1 gene of PRCV IA1894 had a ATG start codon present and the encoded 
3b protein was predicted to be intact. Thus the PRCV isolate lA 1894 synthesizes a 
mRNA 3 similar to that of the Purdue and FS772/70 strains of TGEV in that the mRNA 
3 is thought to code for both 3a and 3b proteins. The PRCV isolate ISU-1 was found to 
have a 168-nucleotide deletion present at position 53 that removed both the consensus 
CTAAAC leader RNA-binding site and the ATG start codon of the 3 gene. Further 
downstream at position 118, a five-nucleotide deletion in the 3a gene of PRCV ISU-1 
was also detected. The CTAAAC leader RNA-binding site preceding the 3-1 gene of 
PRCV ISU-1 was present, however, the 3-1 gene had a 117-nucleotide inframe deletion 
beginning at position 329 that would remove 39 amino acids from the 244 amino acids 
found in the intact 3-1 protein of TGEV. 
Analvsis of the 5' end of mRNA 3 and mRNA 3-1 
PCR products from the 5' end of mRNA 3 were generated for CHV TGEV and 
the PRCV isolates AR310, LEPP, and IA1894 which confirms the joining of the leader 
RNA to the CTAAAC leader RNA binding site preceding the 3/3a gene (Figure 12). The 
PCR products from CHV TGEV, AR310 and LEPP were the expected size of 310 bp. 
The PCR product from IA1894 migrated slightly faster with a PCR product of 287 bp 
due to a 23-nucleotide deletion in the coding region of the 3a gene. As expected, no PCR 
product was evident from the PRCV isolate ISU-1 due to the CTAAAC leader RNA 
binding site preceding the 3 gene being removed by a 168-nucleotide deletion. 
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Two PGR products of 660 and 370 bp were amplified from CHV TGEV, AR310 
and LEPP indicating that the leader sequence had bound to the CTAAAC leader RNA 
binding site preceding the 3 gene and 3-1 gene (Figure 13). The PRCV isolate IA1894 
had only a single PGR product of 632 bp evident, which is consistent with the leader 
RNA joining the GTAAAG leader RNA binding site preceding the 3a gene and a 23-
nucleotide deletion in the 3a gene. The leader RNA did not bind to the GTAAAG leader 
RNA binding site preceding the 3b gene due to a five-nucleotide deletion removing the 
last two nucleotides of the GTAAAG sequence. The PRGV isolate ISU-1 had only a 
single PGR product of 253 bp evident, which is consistent with there being a GTAAAG 
leader RNA binding site preceding the 3-1 gene and a 117-nucleotide inframe deletion 
present in the coding region of the 3-1 gene, and the loss of the GTAAAG leader RNA 
binding site preceding the 3 gene due to the 168-nucleotide deletion present in the 3 gene 
region. 
Discussion 
Studies in this report show that three new PRGV isolates AR310, LEPP, and 
IA1894 are unique from previously reported PRGV isolates. The size and locations of 
the S gene deletions found in these PRGV isolates were shown to vary. Two of the 
PRGV isolates, AR310 and LEPP, have the smallest S gene deletions (621-nucleotides) 
found thus far among PRGV isolates. The size of the S gene deletions for other PRGV 
isolates from Europe is 672-nucleotides (1,17), and the size of the S gene deletion of 
other PRGV isolates from the United States is 681-nucleotides (8, 24). The PRGV 
isolates AR310 and LEPP had identical deletions of 621-nucleotides beginning 47 
nucleotides after the ATG start of the S gene. The PRGV isolate L\1894 had a 678-
nucleotide deletion 44 nucleotides after the S gene ATG. The 681-nucleotide deletion in 
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the 5' end of the S gene of PRCV ISU-1 was found to occur 62 nucleotides after the S 
gene ATG start. The S gene deletion found in PRCV ISU-1 is the same size and in the 
same location as had been previously determined by other researchers (8) and as that of 
another U.S. PRCV isolate Ind/89 (24). Even though the deletions in the 5' end of the S 
gene of PRCV AR310 and PRCV LEPP are smaller than that of other PRCV isolates, the 
area deleted encompasses the S protein amino acid residues of 92, 94, 218, and 219 that 
were predicted by Sanchez et al. (1992) to be important in predicting tissue tropism of 
PRCV and TGEV isolates. 
Also of significance, the PRCV isolates AR310 and LEPP are the first to have 
been found to have an intact and functional 3 gene. The sequence information from all 
other PRCV isolates previously sequenced have shown that the 3 gene has deletions or 
alterations that render the 3 gene nonfunctional. As the sequence information from the 
PRCV isolate IA1894 indicates, this particular isolate is more in keeping with the 
previously described PRCV isolates in that there is a 23-nucleotide deletion in the 3a gene 
that would result in a truncated 3a protein. The PRCV isolate lSU-1 also fits into the 
category of previously described PRCV isolates since PRCV ISU-1 had its 3 gene altered 
to a psuedogene due to a 168-nucleotide deletion in the 3 gene that removed both the 
CTAAAC leader RNA-binding site and the ATG start site of the 3 gene. 
Surprisingly, the 3-1 gene coding region of the PRCV isolates AR310 and LEPP 
contained a one-nucleotide deletion and is predicted to cause a frameshift in the 3-1 gene 
resulting in a truncated 3-1 protein of 64 amino acids. Whether this truncated 3-1 protein 
would still be functional is not known, but it may be possible that this truncated 3-1 
protein may still have the necessary domains to be functional. However, the 3-1 gene of 
all other PRCV isolates shows that the 3-1 gene is preceded by a CTAAAC leader RNA 
binding site and the following ORE was intact. However, the 3b gene of the PRCV 
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isolate IA1894 was preceded by an altered CTAAAC leader RNA-binding site but the 3b 
protein was found to be intact and nearly identical to that of TGEV. This would mean, 
with the exception of the 23-nucleotide deletion present in 3a gene, that the PRCV 
lAl 894 mRNA 3 is like that of Purdue and FS772/70 strains of TGEV in that the mRNA 
3 is thought to code for both the 3a and 3b proteins (2,9). Additionally, the 3-1 gene of 
PRCV ISU-1 was found to have a 117-nucleotide inframe deletion at amino acid residue 
32, that would effectively remove 39 out of a possible 244 amino acid residues found in 
the intact 3-1 protein. Whether this 117-nucleotide inframe deletion in the 3-1 gene of 
PRCV ISU-1 would still yield a functional protein is not known. 
Since both the 3 and 3-1 genes of the PRCV isolate ISU-1 are altered, it exhibits 
the same genetic characteristics as the SP mutant of TGEV which is lacking the entire 3 
gene and part of the 3-1 gene (previously described as regions A and B, respectively) due 
to a 462-nucleotide deletion (25). By using SI nuclease analysis, Wesley et al. (1990) 
demonstrated that the SP TGEV S gene was similar to that of virulent TGEV and 
contained no large deletions in the SP S gene characteristic of PRCV. The SP TGEV 
was not able to replicate in the villus epithelium of the gut of neonatal pigs and thus did 
not cause enteric disease. However, using IFA the SP TGEV was shown to replicate in 
the cells of the lamina propria of neonatal pigs infected with SP TGEV. It is not known 
if the SP TGEV was able to replicate in the lungs and other respiratory tissue of SP 
TGEV infected pigs. The SP TGEV was able to replicate in ST cells, but exhibited a SP 
morphology. The lack of intact 3 and 3-1 genes in PRCV ISU-1 does not affect its 
ability to replicate in ST cells or its plaque morphology, as PRCV ISU-1 can reach titers 
exceeding 10^ pfu/ml and the plaque size is approximately 5 mm (data not shown). The 
lack of an intact 3a gene does not affect the ability of PRCV IA1894 to replicate in ST 
cells as it can reach titers exceeding 10^ pfu/ml and the plaque size is approximately 5 
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mm (data not shown). In a similar manner, the same can be said for the PRCV isolates 
AR310 and LEPP as these isolates readily grow to titers exceeding 10^ pfu/ml and the 
plaque size is approximately 5 mm (data not shown). Wesley et al. (1990) proposed that 
one of the functions of the 3 and 3-1 genes was determination of plaque size in cell 
culture. Since the PRCV isolate ISU-1 is missing the 3 gene just like all other PRCV 
isolates (except ARB 10 and LEPP), but has a truncated 3-1 protein and can still form 
large plaques in cell culture, the ability of the PRCV isolate ISU-1 to form large plaques 
may indicate that its smaller 3-1 protein is still functional. The 3-1 gene may be 
responsible for determining plaque size in cell culture as the SP TGEV mutant was 
lacking this region, and was not able to produce large plaques in cell culture. 
Studies in our laboratory (Halbur et al., 1994) have shown that the PRCV 
isolates AR310 and LEPP are more virulent in five-week-old SPF pig model than the 
PRCV isolate IA1894. Wesley et al. (1990) have hypothesized that the role of the 3 and 
3-1 genes of TGEV are involved in pathogenesis and virulence. This hypothesis can be 
extended to PRCV. The fact that the PRCV isolates AR310 and LEPP both have an 
intact 3 gene, and the fact that these two isolates have been shown to cause more 
extensive lung lesion development and are more pathogenic than the typical PRCV isolate 
IA1894, supports the hypothesis that the 3 gene is important in the virulence of both 
TGEV and PRCV. A schematic diagram of the comparison of gene deletions, tissue 
tropism, and pathogenicity of TGEV and PRCV isolates is shown in Figure 14. 
The PRCV isolate IA1894, except for a 23-nucleotide deletion in the coding 
region of the 3a gene, has a mRNA 3 that was revealed to be very similar to that of the 
virulent TGEV isolates FS772/70 and Purdue. These two TGEV isolates have genes 3a 
and 3b present on single mRNA species, and the 3b protein is assumed to be expressed 
from the functionally bicistronic mRNA 3. Since the PRCV isolate IA1894 has been 
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determined to be less pathogenic than the PRCV isolates AR310 and LEPP, and yet the 
mRNA 3 of PRCV IA1894 is very similar (with the exception of the 23-nucleotide 
deletion) to that of two virulent TGEV isolates, this suggests that the 3 gene is important 
in determining the virulence of PRCV and TGEV isolates. Specifically, the region of the 
3/3a protein that is deleted from IA1894 and yet is still conserved in the PRCV isolates 
AR310 and LEPP and the virulent TGEV isolates CHV, PP3, FS772/70, and Purdue is a 
region of four amino acid residues in length designated KLGL. These four amino acid 
residues may comprise an important motif or domain in the 3/3a protein that is essential 
for virulence in the animal host. The function of the 3/3a protein and its role in virulence 
needs to be clarified with further study. 
Future studies to clarify the role of the 3/3a gene in virulence of PRCV and 
TGEV isolates would best be addressed by the correction of 3/3a gene defects by RNA 
recombination. Also, the use of RNA recombination to introduce a TGEV-like S gene to 
repair the deleted S gene regions of PRCV isolates would also be useful to further clarify 
the role of the S gene and its smaller S protein product in the change of tissue tropism of 
PRCV from the enteropathogenic TGEV. The PRCV isolates, AR310, LEPP, and 
IA1894, would be excellent candidates for future experiments to correct its 3a and S gene 
deletions. For example, if the S gene deletion of AR310 or LEPP was corrected to a 
TGEV-like S gene, would the S gene-corrected AR310 or LEPP become 
enteropathogenic? Additionally, if the PRCV isolate IA1894 had the 23-nucleotide 
deletion present in the 3a gene corrected, would the 3a gene-corrected L\1894 cause as 
severe lung lesions as AR310 or LEPP in the five-week-old SPF pig model? 
Furthermore, if the S gene deletion of the 3a gene-corrected IA1894 was corrected by 
RNA recombination would the S gene-corrected-3a gene-corrected L\1894 become an 
enteropathogenic TGEV isolate? 
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From the present study, my colleagues and I can confirm, as have others, that the 
3/3a genes of both TGEV and PRCV isolates are highly variable. In addition, the 3-l/3b 
genes of at least PRCV isolates appears to be variable also. The extent of deletions 
present in the PRCV isolates AR310, LEPP, IA1894, and ISU-1 allows for some 
intriguing speculation as to the relationship of the S, 3/3a, and 3-l/3b genes in PRCV 
isolates. All previously analyzed PRCV isolates have been found to have large deletion 
in the 5' end of the S gene accompanied by an altered or deleted 3/3a gene, while the 3-
l/3b gene has remained intact. In this study, my colleagues and I have reported on 
additional PRCV isolates that do have large S gene deletions. However, the 3/3a and 3-
l/3b genes were more variable in that two of the PRCV isolates (AR310 and LEPP) are 
predicted to have intact 3 proteins of 72 amino acids combined with truncated 3-1 
proteins of 64 amino acid residues. Another PRCV isolate (IA1894) is predicted to have 
a truncated 3a protein of 55 amino acids combined with an intact 3-1 protein of 244 
amino acids. Also, the PRCV isolate (ISU-1) has the entire 3 protein is missing 
combined with a smaller 3-1 protein of 205 amino acid residues. It has been suggested 
by Laude et al. (1993) that there is a possibility of a functional link between the 3/3a gene 
and S gene alterations of PRCV isolates that may be complementing each other. With the 
information presented here, the complementation of an altered 3-l/3b gene with an altered 
S gene may be necessary also. This mean that in order to be a PRCV isolate, there must 
be a deletion in the S gene (to alter tissue tropism), accompanied by an altered 3/3a gene, 
an altered 3-l/3b gene, or both the 3/3a and 3-l/3b genes altered. In order to exhibit the 
characteristic tropism of PRCV, it may be that a large S gene deletion has to be 
accompanied by alterations in the 3/3a, the 3- l/3b genes, or both. A large deletion in the 
S gene may not be compatible without these alterations. Until the polymerase region of 
the coronavirus genome from virulent and avirulent coronaviruses can be studied in 
73 
depth, the area of the genome most likely to be involved in determining pathogenicity will 
be the 3 and 3-1 genes. No function has been assigned to these proteins as of yet. 
Thus, the PRCV isolates previously described have displayed two certain 
characteristics typical of PRCV. First, previously described PRCV isolates displayed the 
characteristic of a large deletion in the 5' end of the S gene ranging from 672- to 681-
nucleotides. Second, these previously described PRCV isolates all have altered or 
deleted CTAAAC leader RNA-binding sites that result in the 3 gene being nonfunctional. 
Additionally, previously studied PRCV isolates all have various size deletions ranging 
from five- to 36-nucIeotides present in the putative 3 gene (12,17). The PRCV isolates 
AR310 and LEPP can thus be described as "uncharacteristic" PRCV isolates in that they 
have a smaller S gene deletion (621-nucleotides) and the 3 gene is predicted to be intact 
and functional and yet these isolates exhibit a tropism for respiratory tissue. It is believed 
that PRCV evolved from TGEV. The PRCV isolates AR310 and LEPP will be useful in 
understanding the origins of PRCV as they may represent intermediate isolates in the 
evolution of PRCV from TGEV. 
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TABLE 1. TGEV specific oligonucleotide primers used in PCR to amplify regions of PRCV and TGEV 
Primer 
Name Sequence Nucleotide localization 
021209 5' gggaa11 cgGGGTAAGTTGCTCATTAGAAA 3' 56-76 a 
060704 5' ggggatccGCAGTGCCACGAGTCCTATCAT 3' 2462-2483 a 
538 5 ' gggggaattcCTATTGAAAAAGTGCACGTC 3' 30-49 b 
622 5 ' ggggggatCcAATGATGCTAATGACCATTC 3' 1199-1218b 
068 5' CGAGATGCTC6TCTTCCTCCATGC 3 ' 3403-3426 c 
069 5 ' CTAGATCCAGACGTTAGCTCTTCC 3 ' 3841-3864 c 
119 5' GCTATATCTCTTCTTTTACTT 3 ' 29-49 d 
118 5' TTTGTGTGTTTACTTCTTCA 3 ' 314-333 e 
048 5 ' GCATAGGTCCTAAAAGTGTCATT6 3 ' 662-685 e 
^ From the sequence of Rasschaert and Laude (1987). 
^ From the sequence of Wesley et al., (1989). 
c From the sequence of Rasschaert et al., (1987). 
From the sequence of Page et al., (1990). 
® From CHV TGEV nucleotide sequence, this study. 
Figure 1. Northern blot analysis of TGEV and PRCV subgenomic mRNAs. Total 
RNA from TGEV or PRCV infected ST cells was separated in a 1.5% 
agarose and transferred to a nylon membrane. A PCR product from the 
3' end of the TGEV genome was amplified with primers 068 and 069 and 
was labeled with [a 32p]dCTP and was used to detect TGEV and PRCV 
subgenomic mRNAs in a Northern blot. PRCV AR310 (lane A), CHV 
TGEV (lane B), PRCV LEPP (lane C), PRCV IA1894 (lane D), and 
PRCV ISU-1 (lane E). Note that mRNA 2 of all the PRCV isolates 
migrated faster than the mRNA 2 of CHV TGEV. Also, note that PRCV 
AR310, PRCV LEPP, and CHV TGEV all have mRNA 3 and 3-1 
present. The PRCV isolate IA1894 had only one mRNA species of 3.61 
kb corresponding to mRNA 3 present. The PRCV isolate ISU-1 had only 
one mRNA species of 3.35 kb corresponding to mRNA 3 present. 
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Figure 2. Schematic diagram of the regions of TGEV and PRCV isolates amplified by PGR for 
nucleotide sequence analysis in this study. The gray shaded area in the S gene 
represents the area that is deleted in PRCV isolates, a) The 5'-half of the S gene of 
TGEV and PRCV isolates were amplified with the primers 021209 and 060704 using 
conditions described in the text b) The 3/3a and 3-l/3b gene regions of TGEV and 
PRCV isolates were amplified with the primers 538 and 622 using conditions 
described in the text. 
s start 
+!-> 
CHV S ATGAAAAAAT TATTTGTGGT TTTGGTTGTA ATGCCATTGA TTTATGGAGA CAATTTTCCT 60 
AR310 S ATGAAAACAT TATTTGTGGT TTTGGTTATA ATGCCATTGA TTTATGG 47 
LEPP S ATGAAAACAT TATTTGTGGT TTTGGTTATA ATGCCATTGA TTTATGG 47 
IA1894 S ATGAAAACAT TATTTGTGGT TTTGGTTATA ATGCCATTGA TTTA 44 
ISU-1 S ATGAAAACAT TATTTGTGGT TTTGGTTATA ATGCCATTGA TTTATGGAGA TAATTTTCCT 60 
Ind/89 S ATGAAAACAT TATTTGTGGT TTTGGTTATA ATGCCATTGA TTTATGGAGA TAATTTTCCT 60 
86/137004 S ATGAAAAAAT TATTTGTGGT CTTGGTTGTA ATGCCATTGA TTTATGGAGA CAAGTTTCC- 59 
RM4 S ATGAAAAAAT TATTTGTGGT CTTGGTTGTA ATGCCATTGA TTTATGGAGA CAAGTTTCC- 59 
00 
w 
Figure 3. Alignment of the nucleotide sequence from the 5' end of the S gene of CHV TGEV and the PRCV isolates 
AR310, IA1894, ISU-1, Ind/89,86/137004, and RM4. The PRCV isolates AR310 and LEPP had identical S 
gene deletions of 621 nucleotides present The PRCV isolate IA1894 had a S gene deletion of 678 nucleotides 
present The PRCV isolates ISU-1 and Ind/89 both had identical deletions of 681nucleotides present The 
PRCV isolates 86/137004 and RM4 both had identical deletions of 672 nucleotides present The start codon 
of the S gene is marked with +1—>. The nucleotides comprising the predicted signal peptide region of the 
TGEV S gene as determined by Rasschaert and Laude (1987) are underlined. The nucleotide sequences of the 
TGEV isolate CHV and of the PRCV isolates AR310, LEPP, IA1894, and ISU-1 were determined in this 
study. The other nucleotide sequences presented in this table were previously reported (Ind/89, Wesley et al., 
1991; 86/137004 PRCV, Page et al., 1991; and RM4 PRCV, Rasschaert et al., 1990). 
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CHV S TGTTCTAAAT TGACTAATAG AACTATAGGT AACCATTGGA ATCTCATTGA AACCCTCCTT 
AR310 S 
LEPP S 
IA1894 S 
ISU-1 S TG 
Ind/89 S TG 
86/137004 S 
RM4 S 
CHV S ACGCTTGTAG ACCTTTGGTG GTTTAATCCT GTTTATGATG TCAGTTATTA TAGAGTTAAT 
ARB 10 S AG ACCTTTGGTG GTTTAATCCT GTTTATGATG TCAGTTATTA TAGAGTTAAT 
LEPP S AG ACCTTTGGTG GTTTAATCCT GTTTATGATG TCAGTTATTA TAGAGTTAAT 
IA1894 S 
ISU-1 S 
PInd/89 S 
86/137004 S 
RM4 S 
CHV S AATAAAAATG GTACTACCGT AGTTTCCAAT TGCACTGATC AATGTGCTAG TTATGTGGCT 
AR310 S AATAAAAATG GTACTACCGT AGTTTCCAAT TGCACTGATC AATGTGCTAG TTATGTGGCT 
LEPP S AGTAAAAATG GTACTACCGG AGTTTCCAAT TGCACTGATC AATGTGCTAG TTATGTGGCT 
IA1894 S —TAAAAATG GTACTACCGT AGTTTCCAAT TGCACTGATC AATGTGCTAG TTATGTGGCT 
ISU-1 S TTCCAAT TGCACTGATC AATGTGCTAG TTATGTGGAT 
lnd/89 S TTCCAAT TGCACTGATC AATGTGCTAG TTATGTGGCT 
86/137004 S -TACTTCCGT AGTTTCCAAT TGCACTGATC AATGTGCTAG TTATGTGGCT 
RM4 S -TACTTCCGT AGTTTCCAAT TGCACTGATC AATGTGCTAG TTATGTGGCT 
Figure 3. (continued). 
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Figure 4. Schematic diagram showing the size and location of the S gene deletions of PRCV isolates. 
The underlined region represents the signal peptide region of the TGEV S gene as 
determined by Rasschaert and Laude (1987). The nucleotide sequences of Sie TGEV isolate 
CHV and of the PRCV isolates AR310, LEPP, IA1894, and ISU-1 were determined in this 
study. The nucleotide sequences of the other PRCV isolates were previously reported 
(Ind/89, Wesley et al., 1991; 86/137004, Britton et al., 1990; and RM4, Rasschaert et al., 
1990). The nucleotide sequence located between positions 20 and 40 are not shown for 
clarity. 
CHV S MKKLFWLW MPLIYGDNFP CSKLTNRTIG NHWNLIETLL 40 
AR310 S MKTLFWLVI MPLIYG 16 
LEPP S MKTLFWLVI MPLIYG 16 
IA1894 S MKTLFWLVI MPLIYKN 17 
ISU-1 S MKTLFWLVI MPLIYGDNFP C 21 
Ind/89 S MKTLFWLVI MPLIYGDNFP C 21 
86/137004 S MKKLFWLW MPLIYGDKFP 20 
RM4 S MKKLFWLW MPLIYGDKFP 20 
^ ^ /V /V /V 
Figure 5. Alignment of the predicted amino acid residues from the 5' end of the S gene of 
the TGEV isolate CHV, and the PRCV isolates AR310, LEPP, IA1894, ISU-1, 
Ind/89,86/137004, and RM4. The underlined amino acid residues indicate the 
signal peptide region at the 5' end of the S gene as determined by Rasschaert and ^ 
Laude, 1987. Deleted amino acid residues are marked with (-) and identical amino 
acid residues are marked with (^). The PRCV isolates AR310 and LEPP had 207 
amino acid residues deleted. The PRCV isolate IA1894 had 226 amino acid 
residues deleted. The PRCV isolates ISU-1 and Ind/89 both had 227 amino acid 
residues deleted. The PRCV isolates 86/137004 and RM4 both had 224 amino 
acid residues deleted The predicted amino acid residues were derived from the 
nucleotide sequences of the TGEV isolate CHV and of the PRCV isolates AR310, 
LEPP, IA1894, and ISU-1 determined in this study. The other amino acid 
residues presented in this table were previously reported (Ind/89, Wesley et 
al., 1991; 86/137004 PRCV, Page et al., 1991; and RM4 PRCV, Rasschaert et 
al., 1990). 
i 
CHV S LNYSSRLSPN SDWLGDYFP TVQPWFNCIR NNSNDLYVTL 80 
AR310 S 16 
LEPP S 16 
IA1894 S 17 
ISU-1 S 21 
Ind/89 S 21 
86/137004 S 20 
RM4 S 20 
CHV S QWSGTVTLGD MRATTLEAAG TLVDLWWFNP VYDVSYYRVN 240 
AR310 S DLWWFNP VYDVSYYRVN 33 
LEPP S DLWWFNP VYDVSYYRVN 33 
IA1894 S 17 
ISU-1 S 21 
Ind/89 S 21 
86/137004 S 20 
RM4 S 20 
oc 
-j 
CHV S NKNGTTWSN CTDQCASYVA 260 
AR310 S NKNGTTWSN CTDQCASYVA 53 
LEPP S SKNGTTGVSN CTDQCASYVA 53 
IA1894 S GTTWSN CTDQCASYVA 34 
86/137004 S TSWSN CTDQCASYVA 36 
RM4 S TSWSN CTDQCASYVA 36 
Figure 5. (continued). 
Figure 6. PGR amplification of the 3/3a and 3- l/3b gene region of TGEV and 
PRCV isolates. cDNA was amplified by PGR with primers 538 and 
622 as described in text. Molecular weight markers (M), and PGR 
products from GHV TGEV (lane 1), ISU-1 (lane 2), AR310 (lane 3), 
LA 1894 (lane 4), LEPP (lane 5) were separated on 2.0% agarose gel. 
Note that the PGR products from TGEV, AR310 and LEPP migrate at the 
same rate. The PGR product from IA1894 migrated slightly faster 
whereas the PGR product from ISU-1 migrated much faster. 
M 1 2 3 4 5 
1200 bp 
bp 
Oligo 538 S 
=================== Stop 
CHV CTATTGAAAA AGTGCACGTC CATTAAATTT A AAATGTTAAT 41 
PP3 CTATTGAAAA AGTGCACCTC CATTAAATTT A AAATGTTAAT 41 
FS772/70 CTATTGAAAA AGTGCACATC CATTAAATTT CCAGGCTATA AAATGTTAAT 50 
Purdue CTATTGAAAA AGTGCACCTC CATTAAATTT A AAATGTTAAT 41 
AR310 CTATTGAAAA AGTGCACGTC CATTAAATTT A AAATGTTAAT 41 
LEPP CTATTGAAAA AGTGCACGTC CATTAAATTT A AAATGTTAAT 41 
IA1894 CTATTGAAAA AGTGCACGTC CATTAAATTT A AAATGTTAAT 41 
ISU-1 CTATTGAAAA AGTGCACGTC CATTAAATTT A AAATGTTAGT 41 
86/137004 CTATTGAAAA AGTGCACGTC CATTAAATTT A AAATGTTAAT 41 
RM4 CTATTGAAAA AGTGCACGTC CATTAAATTT A AAATGTTAAT 41 
g 
Figure 7. Comparison of the nucleotide sequence of the gene 3/3a and gene 3-l/3b regions of TGEV and 
PRCV isolates. Positions of the leader RNA binding site upstream of genes are marked with 
(*****). The positions of oligonucleotide primers 538, 118,048, and 622 are marked with 
( ). The start codons of the ORFs are marked with +1—and the stop codons are 
underlined. Positions having identical nucleotides are marked with (^), and positions of deleted 
nucleotides are marked with ( ). The nucleotide sequences of the TGEV isolate CHV and of the 
PRCV isolates AR310, LEPP, IA1894, and ISU-1 were determined in this study. The other 
nucleotide sequences presented in this table were previously reported (PP3 (Miller) TGEV, 
Wesley et al., 1988; FS772/70 TGEV, Britton et al., 1989; Purdue TGEV, Kapke et al., 1988; 
86/137004 PRCV, Page et al., 1991; and RM4 PRCV, Rasschaert et al., 1990). 
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53 
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74 
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134 
141 
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122 
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53 
99 
CHV 
PP3 
FS772/70 
Purdue 
AR310 
LEPP 
1A1894 
ISU-1 
86/137004 
RM4 
TTTATTATCT 
TTTATTATCT 
TTTATTATCT 
TCTATCATCT 
T TTATCT 
T TTATCT 
T TTATCT 
T TTATCC 
T TTATCT 
TTTATC-TCT 
GCTATAATAG CATTTGTT— GTTAAG 
GCTATAATAG CATTTGTT— GTTAAG 
GCTATAATAG CATTTGTT— GTTAAG 
GCTATAATAG CAGTTGTTTC TGCTAGAGAA TTTTGTTAAG 
GCTATAATAG CATTTGTT— ATTAAG 
GCTATAATAG CATTTGTT— ATTAAG 
GCTATAATAG CATTTGTT— ATTAAG 
GCTAT 
GCTATAATAT CATTTGTT— GTTAAG 
GCTATAATAT CATTTGTT— GTTAAG 
/V ^ 
CHV 
PP3 
FS772/70 
Purdue 
AR310 
LEPP 
IA1894 
ISU-1 
86/137004 
RM4 
GATGATGAAT 
GATGATGAAT 
GATGATGAAT 
GATGATGAAT 
GATGATGAAT 
GATGATGAAT 
GATGATGAAT 
AAAGTCCTTA 
AAAGTCCTTA 
AAAGTCCTTA 
AAAGTCTTTA 
AAAGTCCTTA 
AAAGTCCTTA 
AAAGTCCTTA 
****** 
AGAACTAAAC 
AGAACTAAAC 
AGAACTAAAC 
AGAACTAAAC 
AGAACTAAAC 
AGAACTAAAC 
AGAACTAAAC 
TTTCGAGTCA 
TTTCGAGTCA 
TTTCGAGTCA 
TTACGAGTCA 
TTTCAGGTCA 
TTTCTGGTCA 
TTTCAGGTCA 
TTACAGGTCC 
TTACAGGTCC 
TTACAGGTCC 
TTACAGGTCC 
TTACAGGTCC 
TTACAGGTCC 
TTACAGGTCC 
GATGATGAAT AAAG AAC TTTCAAGTCA 
GATGATGAAT AAAG AAC TT-CAAGTCA 
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175 
175 
184 
191 
172 
172 
172 
53 
137 
137 
225 
225 
234 
241 
222 
222 
222 
54 
187 
187 
ORF 3 
+1 —> 
CHV TGTATGGACA TTGTCAAATC CATTAATACA TCCGTAGATG CTGTACTTGA 
PP3 TGTATGGACA TTGTCAAATC CATTAATACA TCCGTAGATG CTGTACTTGA 
FS772/70 TGTATGGACA TTGTCAAATC CATTAATACA TCCGTAGATG CTGTACTTGA 
Purdue TGTATGGACA TTGTCAAATC CATTTACACA TCCGTAGATG CTGTACTTGA 
AR310 TGTATGGACA TTGTCAAATC TATTAATACA TCCGTGGATG CTGTACTTGA 
LEPP TGTATGGACA TTGTCAAATC TATTAATACA TCCGTGGATG CTGTACTTGA 
IA1894 TGTATGGACA TTGGCAAATC CATTATTACA TCCGTGGATG CTGTACTTGA 
ISU-1 
86/137004 —GTCAAATT TACTAATACA TCCGTGGACG TTGTACTTGA 
RM4 —G-CAAATT TACTAATACA TCCGTGGACG TTGTACTTGG 
CHV CGAACTTGAT TGTGCATACT TTGCTGTAAC TCTTAAAGTA GAATTTAAGA 
PP3 CGAACTTGAT TGTGCATACT TTGCTGTAAC TCTTAAAGTA GAATTTAAGA 
FS772/70 CGAACTTGAT TGTGCATACT TTGCTGTAAC TCTTAAAGTA GAATTTAAGA 
Purdue CGAACTTGAT TGTGCATACT TTGCTGTAAC TCTTAAAGTA GAATTTAAGA 
AR310 CGAACTTGAT TGTGCATACT TCGCTGTTAC TCTTAAAGTA GAATTTAAGA 
LEPP CGAACTTGAT TGTGCATACT TCGCTGTTAC TCTTAAAGTA GAATTTAAGA 
IA1894 CGAACTTGAT TGTGCATACT TCGCTGTAAC TCTTAAAGTA GAATTTAAGA 
ISU-1 A 
86/137004 CGAACTTGAT TGTGTATACT TTGCTGTAAC CCTTAAAGTA GAATTTAAGA 
RM4 CGAACTTGAT TGTGTATACT TTACTGTAAC CCTTAAAGTA GAATTTAAGA 
Figure 7. (continued). 
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275 
284 
291 
272 
272 
272 
104 
237 
237 
322 
322 
331 
341 
319 
319 
296 
146 
248 
248 
CHV CTGGTAAATT ACTTGTGTGT 
PP3 CTGGTAAATT ACTTGTGTGT 
FS772/70 CTGGTAAATT ACTTGTGTGT 
Purdue CTGGTAAATT ACTTGTGTGT 
AR310 CTGGTAAATT ACTTGTGTGT 
LEPP CTGGTAAATT ACTTGTGTGT 
IA1894 CTGGTAAATT ACTTGTGTGT 
ISU-1 CTGGTAAATT ACTTGTGTGT 
86/137004 CTTGTAAATT ACTTGTGTGC 
RM4 CTTGTAAATT ACTTGTGTGC 
ATAGGTTTTG GTGACACACT TCTTGCGGCT 
ATAGGTTTTG GTGACACACT TCTTGCGGCT 
ATAGGTTTTG GTGACACACT TCTTGCGGCT 
ATAGGTTTTG GTGACACACT TCTTGCTGCT 
ATAGGTTTTG GTGACACACT TCTTGCGGCT 
ATAGGTTTTG GTGACACACT TCTTGCGGCT 
ATAGGTTTTG GTGACACACT TCTTGCGGCT 
ATAGGTTTTG GTGACACACT TCTTGCGGCT 
ATAGGTTTTG GTGACATACT TCTTGCGGCT 
ATAGGTTTTG GTGACATACT TCTTGCGGCT 
Oligo 118 
CHV 
PP3 
FS772/70 
Purdue 
AR310 
LEPP 
IA1894 
ISU-1 
86/137004 
RM4 
AGGGATAAAG CATATGCTAA GCTTGGTCTC TCCATTATTG AAGAAGT 
AGGGATAAAG CATATGCTAA GCTTGGTCTC TCCATTATTG AAGAAGT 
AGGGATAAAG CATATGCTAA GCTTGGTCTC TCCACTATTT AAGAAGT 
AAGGATAAAG CATATGCTAA GCTTGGTCTC TCCATTATTG AAGAAGTCAA 
AGGGATAAAG CATATGCTAA GCTTGGTCTC GCCACTATTG AAGAAGT 
AGGGATAAAG CATATGCTAA GCTTGGTCTC GCCACTATTG AAGAAGT 
AGGGGTAAAG CATAT TG AAGAAGT 
AGGGATAAAG CATA A GCTTGGTCTC GCCACTATTG AAGAAGT 
A TTG AAGAAGT 
A TTG AAGAAGT 
Figure?, (continued). 
346 
346 
355 
391 
343 
343 
320 
170 
272 
272 
396 
396 
405 
441 
393 
393 
369 
220 
320 
320 
Oligo 118 
CHV AAAC ACACAAAATC CAAAGCATTA 
PP3 AAAC ACACAAAATC CAAAGCATTA 
FS772/70 AAAC ACACAAAATC CAAAGCATTA 
Purdue TAGTCATATA GTTGTTTAAT ATCATTAAAC ACACAAAACC CAAAGCATTA 
AR310 AAAC ACACAAAATC CAAAGCATTA 
LEPP AAAC ACACAAAATC CAAAGCATTA 
IA1894 AAAC ACACAAAATC CAAAGCATTA 
ISU-1 AAAC ACACAAAATC CAAAGCATTA 
86/137004 AAAC ACACAAAATC CAAAGCATTA 
RM4 AAAC ACACAAAATC CAAAGCATTA 
***** 
CHV AGTGTTACAA AACAATTAAA GAGAGATTAT AGAAAAACTG TCATTCTAAA 
PP3 AGTGTTACAA AACAATTAAA GAGAGATTAT AGAAAAACTG TCATTCTAAA 
FS772/70 AGTGTTACAA AACAATTAAA GAGAGATTAT AGAAAAACTG TCATTCTAAA 
Purdue AGTGTTACAA AACAATTAAA GAGAGATTAT AGAAAAACTG TCATTCTAAA 
AR310 AGTGTTACAA AACAATTAAA GAGAGATTAT AGAAAAACTG TCATTCTAAA 
LEPP AGTGTTACAA AACAATTAAA GAGAGATTAT AGAAAAACTG TCATTCTAAA 
IA1894 AGTGTTACAA AACAATTAAA GAGAGATTGT AGAAAAACTG TCATTCTAA-
ISU-1 AGTGTTACAA AACAATTAAA GAGAGATTAT AGAAAAACTG TCATTCTAAA 
86/137004 AGTGTTACAA AACAATTAAA GAGAGACTAT AGAAAAACT- -CGAACTAAA 
RM4 AGTGTTACAA AACAATTAAA GAGAGACTAT AGAAAAACT- -CGACCTAAA 
/V/V/V >\ >\ >\ A /V >\ >\/N/V /\ -A. /V 
Figure 7. (continued). 
446 
446 
455 
491 
443 
443 
415 
270 
368 
368 
496 
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505 
541 
493 
493 
465 
320 
418 
418 
CHV 
PP3 
FS772/70 
Purdue 
AR310 
LEPP 
IA1894 
ISU-1 
86/137004 
RM4 
* 
CTTCATGCGA 
CTTCATGCGA 
TTTCATGCGA 
TTCCATGCGA 
CTTTGTGTGA 
CTTTGTGTGA 
GTGTTA 
CTTTGTGTGA 
CTT—TGTGA 
CTT--TGTGA 
ORF 3-1 
+ 1—> 
AAATGATTGG 
AAATGATTGG 
AAATGATTGG 
AAATGATTGG 
AAATGATTGG 
AAATGATTGG 
AAATGATTGG 
AAATGATTGG 
AAATGATTGG 
AAATGATTGG 
TGGACTTTTT 
TGGACTTTTT 
TGGACTTTTT 
TGGACTTTTT 
TGGACTTTTT 
TGGACTTTTT 
TGGACTTTTT 
TGGACTTTTT 
TGGACTTTTT 
TGGACTTTTT 
CTTAATACTC 
CTTAATACTC 
CTTAATACTC 
CTTAGTACTC 
CTTAATACTC 
CTTAATACTC 
CTTAATACTC 
CTTAATACTC 
CTTAATACTC 
CTTAATACTC 
TGAGTTTTGT 
TGAGTTTTGT 
TGAGTTTTGT 
TGAGTTTTGT 
TGAGTTTGGT 
TGAGTTTGGT 
TGAGTTTTGT 
TGAGTTTTGT 
TGAGTTTTGT 
TGAGTTTTGT 
CHV" AATTGTTAGT AACCATTCTA 
PP3 AATTGTTAGT AACCATTCTA 
FS772/70 AATTGTTAGT AACCATTCTA 
Purdue AATTGTTAGT AACCATTCTA 
AR310 AATTGTTAGT AACCATTCTA 
LEPP AATTGTTAGT AACCATTCTA 
IA1894 AATTGTTAGT AACCATTCTA 
ISU-1 AATTGTTAGT AACCATTCTA 
86/137004 AATTGTTAGT AACCATCCTA 
RM4 AATTGTTAGT AACCATCCTA 
TTGTTAATAA CACAGCAAAT GTGCATCATA 
TTGTTAATAA CACAGCAAAT GTGCATCATA 
TTGTTAATAA CACAGCAAAT GTGCATCATA 
TTGTTAATAA CACAGCAAAT GTGCATCATA 
TTGTTAATAA CACAGCAAAT GTGCATCATA 
TTGTTAATAA CACAGCAAAT GTGCATCATA 
TTGTTAATAA TACAGCAAAT GTGCATCATA 
TTGTTAATAA CACAGCAAAT GTGCATCATA 
TCGTTAATAA CACAGCAAAT GTGCATCATA 
TCGTTAATAA CACAGCAAAT GTGCATCATA 
Figure?, (continued). 
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CHV 
PP3 
FS772/70 
Purdue 
AR310 
LEPP 
IA1894 
ISU-1 
86/137004 
RM4 
TAAAACAAGA 
TAAAACAAGA 
TACAACAAGA 
TACAACAAGA 
CACAACAAGA 
CACAACAAGA 
CACAACAAGA 
CACAACAAG-
TACAACAAGA 
TACAACAAGA 
ACGTGTTATA 
ACGTGTTATA 
ACGTGTTATA 
ACGTGTTATA 
CCGTGTTATA 
CCGTGTTATA 
CCGTGTTATA 
GTACAACAGC 
GTACAACAGC 
GTACAACAGC 
GTACAACAGC 
GTACAACAGC 
GTACAACAGC 
GTACAACATC 
ATCAGGTTGT 
ATCAGGTTGT 
ATCAGGTTGT 
ATCAGGTTGT 
ATCAGGTTGT 
ATCAGGTTGT 
ATCAGGTTAT 
TAGTGCTAGA 
TAGTGCTAGA 
TAGTGCTATA 
TAGTGCTAGA 
TAGTGCTAGA 
TAGTGCTAGA 
TAGTGCTAGA 
ACGTGTTATA GTACAACAGC 
ACGTGTTATA GTACAACAGC 
ACCATGTTGT TAGTGCTAGA 
ACCATGTTGT TAGTGCTAGA 
CHV 
PP3 
FS772/70 
Purdue 
AR310 
LEPP 
IA1894 
ISU-1 
86/137004 
RM4 
ACACAAAATT 
ACACAAAATT 
ACACAAAACT 
ACACAAAACT 
ACACAAAATT 
ACACAAAATT 
GCACAAAATT 
ATTACCCAGA 
ATTACCCAGA 
ATTACCCAGA 
ATTACCCAGA 
ATTACCCAGA 
ATTACCCAGA 
ATTATCCAGA 
GTTCAGCATC 
GTTCAGCATC 
GTTCAGCATT 
GTTCAGCATC 
GTTCAGCATC 
GTTCAGCATC 
GTTCAGCATC 
GCTGTACTTT 
GCTGTACTTT 
GCTGTACTTT 
GCTGTACCCT 
GCTGTAC-TT 
GCTGTAC-TT 
GCTGTACTTT 
TTGTATCTTT 
TTGTATCTTT 
TTGTATCTTT 
TTGTATCTTT 
TTGTATCTTT 
TTGTATCTTT 
TTGTATCTTT 
ACACAAAACT ATTACCCAGA GTTCAGCATC GCTGTACTTT TTGTATCTTT 
ACACAAAACT ATTACCCAGA GTTCAGCATC GCTGTACTTT TTGTATCTTT 
Figure 7. (continued). 
646 
646 
655 
691 
642 
642 
615 
353 
568 
568 
696 
696 
705 
741 
692 
692 
665 
403 
CHV TCTAGCTTTG TACCGTAGTA CAAACTTTAA GACGTGTGTC GGCATCTTAA 
PP3 TCTAGCTTTG TACCGTAGTA CAAACTTTAA GACGTGTGTC GGCATCTTAA 
FS772/70 TCTAGCTTTG TACCGCAGTA CAAACTTTAA GACGTGTGTC GGCATCTTAA 
Purdue TCTAGCTTTG TACCGTAGTA CAAACTTTAA GACGTGTGTC GGCATCTTAA 
AR310 CCTAGCTTTG TACCGTAGTA CAAACTTTAA GACGTGTGTC GGTATCTTAA 
LEPP CCTAGCTTTG TACCGTAGTA CAAACTTTAA GACGTGTGTC GGTATCTTAA 
IA1894 TCTAGCTTTG TACCGCAGTC CAAACTTTAA GACGTGTGTC GGTATCTTAA 
ISU-1 TTAA GACGTGTGTC GGTATCTTAA 
86/137004 TCTAGCTTTG TACCGTAGTA CAAACTTTAA GACGTGTGTC GGCATCTTAA 
RM4 TCTAGCTTTG TACCGTAGTA CAAACTTTAA GACGTGTGTC GGCATCTTAA 
Oligo 048 
CHV TGTTTAAGAT TTTATCAATG ACACTTTTAG GACCTATGCT TATAGCATAT 
PP3 TGTTTAAGAT TTTATCAATG ACACTTTTAG GACCTATGCT TATAGCATAT 
FS772/70 TGTTTAAGAT TTTATCAATG ACACTTTTAG GACCTATGCT TATAGCATAT 
Purdue TGTTTAAGAT TTTATCAATG ACACTTTTAG GACCTATGCT TATAGCATAT 
AR310 TGTTTAAGAT TTTATCAATG ACACTTTTAG GACCTATGCT TATAGTATAT 
LEPP TGTTTAAGAT TTTATCAATG ACACTTTTAG GACCTATGCT TATAGTATAT 
IA1894 TGTTTAAGAT TTTATCAATG ACACTTTTAG GACCTATGCT TATAGTATAT 
ISU-1 TGTTTAAGAT TTTATCAATG ACACTTTTAG GACCTATGCT TATAGTATAT 
86/137004 TGTTTAAGAT TTTATCAATG ACACTTTTAG GACCTATGCT TATAGCATAC 
RM4 TGTTTAAGAT TTTATCAATG ACACTTTTAG GACCTATGCT TATAGCATAC 
Figure 7. (continued). 
746 
746 
755 
791 
742 
742 
715 
453 
668 
668 
796 
796 
805 
841 
792 
792 
765 
503 
718 
718 
CHV GGTTACTACA TTGATGGCAT TGTTACAACA ACTGTCTTAT CTTTAAGATT 
PP3 GGTTACTACA TTGATGGCAT TGTTACAACA ACTGTCTTAT CTTTAAGATT 
FS772/70 GGTTACTATA TTGATGGCAT TGTTACAACA ACTGTCTTAT CTTTAAGATT 
Purdue GGTTACTACA TTGATGGCAT TGTTACAACA ACTGTCTTAT CTTTAAGATT 
AR310 GGTTACTACA TTGATGGCAT TGTTACAACA ACTGTCTTAT CTTTAAGATT 
LEPP GGTTACTACA TTGATGGCAT TGTTACAACA ACTGTCTTAT CTTTAAGATT 
IA1894 GGTTACTACA TTGATGGCAT TGTTACAACA ACTGTCTTAT CTTTAAGATT 
ISU-1 GGTTACTACA TTGATGGCAT TGTTACAACA ACTTTCTTAT CTTTAAGATT 
86/137004 GGTTACTACA TTGATGGCAT TGTTACAACA ACTGTCTTAT CTTTAAGATT 
RM4 GGTTACTACA TTGATGGCAT TGTTACAACA ACTGTCTTAT CTTTAAGATT 
CHV TGCCTACTTA GCATACTTTT GGTATGTTAA TAGTAGGTTT GAAGTTATTT 
PP3 TGCCTACTTA GCATACTTTT GGTATGTTAA TAGTAGGTTT GAATTTATTT 
FS772/70 CGCCTACTTA GCATACTTTT GGTATGTTAA TAGTAGGTTT GAATTTATTT 
Purdue TGTCTACTTA GCATACTTTT GGTATGTTAA TAGTAGGTTT GAATTTATTT 
AR310 CGCCTACTTA GCATACTTTT GGTATGTTAA TAGTAGGTTT GAATTTATTT 
LEPP CGCCTACTTA GCATACTTTT GGTATGTTAA TAGTAGGTTT GAATTTATTT 
IA1894 CGCCTACTTA GCATACTTTT GGTATGTTAA TAGTAGGTTT GAATTTATTT 
ISU-1 CGCCTACTTA GCATACTTTT GGTATGTTAA TAGTAGGTTT GAATTTATTT 
86/137004 CGCCTACTTA GCATACTTTT GGTATGTTAA TAGTAGGTTT GAATTTATTT 
RM4 CGCCTACTTA GCATACTTTT GGTATGTTAA TAGTAGGTTT GAATTTATTT 
A  A  A  A A A  A A  A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A  
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891 
842 
842 
815 
553 
768 
768 
896 
896 
905 
941 
892 
892 
865 
603 
818 
818 
CHV 
PP3 
FS772/70 
Purdue 
AR310 
LEPP 
IA1894 
ISU-1 
86/137004 
RM4 
TATACAATAC 
TATACAATAC 
TATATAATAC 
TATACAATAC 
TATACAACAC 
TATACAACAC 
TATACAACAC 
TATACAACAC 
TATACAATAC 
TATACAATAC 
AACGACACTC 
AACGACACTC 
AACGACACTC 
AACGACACTC 
AACGACACTC 
AACGACACTC 
AACGACACTC 
AACGACACTC 
AACGACACTC 
AACGACACTC 
ATGTTTGTAC 
ATGTTTGTAC 
ATGTTTGTAC 
ATGTTTGTAC 
ATGTTTGTAC 
ATGTTTGTAC 
ATGTTTGTAC 
ATGTTTGTAC 
ATGTTTGTAC 
ATGTTTGTAC 
ATGGCAGAGC 
ATGGCAGAGC 
ATGGCAGAGC 
ATGGCAGAGC 
ATGGCAGAGC 
ATGGCAGAGC 
ATGGCAGAGC 
ATGGCAGAGC 
ATGGCAGAGC 
ATGGCAGAGC 
TGCACCGTTT 
TGCACCGTTT 
TGCACCGTTT 
TGCACCGTTT 
TGCACCGTTT 
TGCACCGTTT 
TGCACCGTTT 
TGCACCGTTT 
TGCACCGTTT 
TGCACCGTTT 
CHV 
PP3 
FS772/70 
Purdue 
AR310 
LEPP 
IA1894 
ISU-1 
86/137004 
RM4 
AAGAGAAGTT 
AAGAGAAGTT 
AAGAGAAGTT 
ATGAGAAGTT 
AAGAGAAGTT 
AAGAGAAGTT 
AAGAGAAGTT 
AAGAGAAGTT 
AAGAGAAGTT 
AAGAGAAGTT 
CTCACAGCTC 
CTCACAGCTC 
CTCACAGCTC 
CTCACAGCTC 
CTCACAGCTC 
CTCACAGCTC 
CTCACAGCTC 
CTCACAGCTC 
CTCACAGCTC 
CTCACAGCTC 
TATTTATGTC 
TATTTATGTC 
TATTTATGTC 
TATTTATGTC 
TATTTATGTC 
TATTTATGTC 
TATTTATGTC 
TATTTATGTC 
TATTTATGTC 
TATTTATGTC 
ACATTGTATG 
ACATTGTATG 
ACATTGTATG 
ACATTGTATG 
ACATTATATG 
ACATTATATG 
ACATTGTATG 
ACATTATATG 
ACATTGTATG 
ACATTGTATG 
GTGGCATAAA 
GTGGCATAAA 
GTGGCATAAA 
GTGGCATAAA 
GTGGCATAAA 
GTGGCATAAA 
GTGGCATAAA 
GTGGCATAAA 
GTGGCATAAA 
GTGGCATAAA 
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946 
946 
955 
991 
942 
942 
915 
653 
868 
868 
996 
996 
1005 
1041 
992 
992 
965 
703 
CHV TTATATGTTT GTGAATGACC 
PP3 TTATATGTTT GTGAATGACC 
FS772/70 TTATATGTTT GTGAATGACC 
Purdue TTATATGTTT GTGAATGACC 
AR310 TTATATGTTT GTGAATGACC 
LEPP TTATATGTTT GTGAATGACC 
IA1894 TTATATGTTT GTGAATGACC 
ISU-1 TTATATGTTT GTGAATGACT 
86/137004 TTATATGTTT GTGAATGACC 
RM4 TTATATGTTT GTGAATGACC 
TCACGTTGCA TTTTGTAGAC CCTATGCTTG 
TCACGTTGCA TTTTGTAGAC CCTATGCTTG 
TCACGTTGCA TTTTGTAGAC CCTATGCTTG 
TCACGTTGCA TTTTGTAGAC CCTATGCTTG 
TCACGTTGCA TTTTGTAGAC CCTATGCTTG 
TCACGTTGCA TTTTGTAGAC CCTATGCTTG 
TCACGTTGCA TTTTGTAGAC CCTATGCTTG 
TCATGTTGCA TTTTGTAGAC CCTATGCTTG 
TCACGTTGCA TTTTGTAGAC CCTATGCTTG 
TCACGTTGCA TTTTGTAGAC CCTATGCTTG 
CHV 
PP3 
FS772/70 
Purdue 
AR310 
LEPP 
IA1894 
ISU-1 
86/137004 
RM4 
TAAGCATAGC 
TAAGCATAGC 
TAAGCATAGC 
TAAGCATAGC 
TAAGCATAGC 
TAAGCATAGC 
TAAGCATAGC 
TAAGCATAGC 
TAAGCATAGC 
TAAGCATAGC 
AATACGTGGC 
AATACGTGGC 
AATACGTGGC 
AATACGTGGC 
AATACGTGGC 
AATACGTGGC 
AATACGTGGC 
AATACGTGGC 
AATACGTGGC 
AATACGTGGC 
TTAGCTCATG 
TTAGCTCATG 
TTAGCTCATG 
TTAGCTCATG 
TTAACTCATG 
TTAACTCATG 
TTAGCTCATG 
TTAACTCATG 
TTAGCTCATG 
TTAGCTCATG 
CTGATCTAAC 
CTGATCTAAC 
CTGATCTAAC 
CTGATCTAAC 
CTGATCTAAC 
CTGATCTAAC 
CTGATCTAAC 
CTGATCTAAC 
CTGATCTAAC 
CTGATCTAAC 
TGTAGTTAGA 
TGTAGTTAGA 
TGTAGTTAGA 
TGTAGTTAGA 
TGTAGTTAGA 
TGTAGTTAGA 
TGTAGTTAGA 
TGTAGTTAGA 
TGTAGTTAGA 
TGTAGTTAGA 
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1046 
1046 
1055 
1091 
1042 
1042 
1015 
753 
968 
968 
1096 
1096 
1105 
1141 
1092 
1092 
1065 
803 
1018 
1018 
CHV GCAGTTGAAC TTCTCAATGG TGATTTTATT TATGTATTTT CACAGGAGCC 
PP3 GCAGTTGAAC TTCTCAATGG TGATTTTATT TATGTATTTT CACAGGAGCC 
FS772/70 GCAGTTGAAC TTCTCAATGG TGATTTTATT TATGTATTTT CACAGGAGCC 
Purdue GCAGTTGAAC TTCTCAATGG TGATTTTATT TATGTATTTT CACAGGAGCC 
AR310 GCAGTTGAAC TTCTCAATGG TGATTTTATT TATATATTTT CACAGGAGCC 
LEPP GCAGTTGAAC TTCTCAATGG TGATTTTATT TATATATTTT CACAGGAGCC 
IA1894 GCAGTTGAAC TTCTCAATGG TGATTTTATT TATATATTTT CACAGGATTC 
ISU-1 GCAGTTGAAC TTCTCAATGG TGATTTTATT TATATATTTT CACAGGAGCC 
86/137004 GCAGTTGAAC TTCTCAATGG TGATTTTATT TATGTATTTT CACAGGAGCC 
RM4 GCAGTTGAAC TTCTCAATGG TGATTTTATT TATGTATTTT CACAGGAGCC 
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TCAGGCGGTT 
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Figure?, (continued). 
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CHV 
PP3 
FS772/70 
Purdue 
AR310 
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IA1894 
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86/137004 
RM4 
TTGACTTAAA AGAAGAAGAA GAAGACCGTA CCTATGACGT TTCCTAGGGC 
TTGACTTAAA AGAAGAAGAA GAAGACCGTA CCTATGACGT TTCCTAGGGC 
TTGACTTAAA AGAAGAAGAG GGAGACCGTA CCTATGACGT TTCCTAGGGC 
TTGACTTAAA AGAAGAAGAA GAAGACCATA CCTATGACGT TTCCTAGGGC 
TTGACTTAAA AGAAGAAGAG GGAGACCGTA CCTATGACGT TTCCTAGGGC 
TTGACTTAAA AGAAGAAGAG GGAGACCGTA CCTATGACGT TTCCTAGGGC 
TTGACTTAAA AGAAGAAGAG GGAGACCGTA CCTATGACGT TTCCTAGGGC 
TTGACTTAAA AGAAGAAGAG GGAGACCGTA CCTATGACGT TTCCTAGGGC 
TTGACTTAAA AGAAGAAGAG GGAGACCGTA CCTATGACGT TTCCTAGGGC 
TTGACTTAAA AGAAGAAGAG GGAGACCGTA CCTATGACGT TTCCTAGGGC 
ATTGACTGTC ATAGATGACA ATGGAATGGT CATTAGCATC ATT 
ATTGACTGTC ATAGATGACA ATGGAATGGT CATTAGCATC ATT 
ATTGACTGTC ATAGATGACA ATGGACTGGT CATTAGCATC ATT 
ATTGACTGTC ATAGATGACA ATGGAATGGT CATTAACATC ATT 
ATTGACTGTC ATAGATGACA ATGGAATGGT CATTAGCATC ATT 
ATTGACTGTC ATAGATGACA ATGGAATGGT CATTAGCATC ATT 
ATTGACTGTC ATAGATGACA ATGGAATGGT CATTAGCATC ATT 
ATTGACTGTC ATAGATGATA ATGGAATGGT CATTAGCATC ATT 
ATTGACTGTC ATAGATGACA ACGGAATGGT CATTAGCATC ATT 
ATTGACTGTC ATAGATGACA ACGGAATGGT CATTAGCATC ATT 
Oligo 622 
Figure?, (continued). 
CHV 3 MDIVKSINTS VDAVLDELDC AYFAVTLKVE FKTGKLLVCI 40 
PP3 3 40 
FS772/70 3a 40 
Purdue 3a Y 40 
AR310 3 40 
LEPP 3 40 
IA1894 3a . 40 
CHV 3 GFGDTLLAAR DKAYAKLGLS IIEEVNTQNP KH 72 
PP3 3 72 
FS772/70 3a T. 62 
Purdue 3a K SHIV V 71 
AR310 3 AT 72 
LEPP 3 AT 72 
IA1894 3a G . . . Y  55 
Figure 8. Alignment of the predicted amino acid residues from the 3/3a gene of TGEV and PRCV 
isolates. Identical amino acid residues are marked with (.). The TGEV isolates CHV and 
PP3 have identical amino acid homology and are both 72 amino acid residues long. The 
TGEV isolate FS772/70 is 62 amino acid residues long. The Purdue TGEV isolate has an 
3a protein 71 amino acid residues in length and the last six amino acid residues are 
changed from that of CHV TGEV. The PRCV isolates AR310 and LEPP have identical 
3 proteins that are 72 amino acid residues in length and differ from that of CHV 
TGEV by two amino acid residues. The PRCV isolate IA1894 has a truncated 3a protein 
of 53 amino acid residues in length due to a 23 nucleotide deletion in the coding sequence 
of the 3a gene. 
CHV 3-1 MIGGLFLNTL SFVIVSNHSI VNNTANVHHI KQERVIVQQH QWSARTQNY 50 
PP3 3-1 50 
Purdue 3-lb S Q 50 
AR310 3-1 L T Q.D 50 
LEPP 3-1 L T Q.D 50 
FS772/70 3-lb Q I 50 
ISU-1 3-1 T Q. 32 
IA1894 3-lb T Q.D H. ..I...A... 50 
86/137004 3-1 P Q H 50 
RM4 3-1 P Q H 50 
Figure 9. Alignment of the predicted amino acid residues from the 3-l/3b genes of TGEV and PRCV 
isolates. Identical amino acid residues are marked with (.). The TGEV isolates CHV, PP3, 
Purdue, FS772/70, and the PRCV isolates IA1894,86/137004, and RM4 all have nearly 
identical 3-l/3b proteins of 244 amino acid residues in length. The PRCV isolates AR310 
and LEPP both have truncated 3-1 proteins of 64 amino acid residues in length due to an 
one nucleotide deletion that results in a frameshift in the coding region of the 3-1 gene. The 
PRCV isolate ISU-1 has a truncated 3-1 protein of 205 amino acid residues due to a 117 
nucleotide inframe deletion in the coding region of the 3-1 gene. 
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CHV 3-1 YPEFSIAVLF VSFLALYRST NFKTCVGILM FKILSMTLLG PMLIAYGYYI 
PP3 3-1 
Purdue 3-lb P 
AR310 3-1 L YLSS 
LEPP 3-1 L YLSS 
FS772/70 3-lb 
ISU-1 3-1 -V V 
IA1894 3-lb P V 
86/137004 3-1 
RM4 3-1 
CHV 3-1 DGIVTTTVLS LRFAYLAYFW YVNSRFEVIL YNTTTLMFVH GRAAPFKRSS 
PP3 3-1 F 
Purdue 3-lb V F M... 
AR310 3-1 
LEPP 3-1 
FS772/70 3-lb F 
ISU-1 3-1 F F 
IA1894 3-lb F 
86/137004 3-1 F 
RM4 3-1 F 
Figure 9. (continued). 
CHV 3-1 HSSIYVTLYG GINYMFVNDL TLHFVDPMLV SIAIRGLAHA DLTWRAVEL 200 
PP3 3-1 200 
Purdue 3-lb 200 
AR310 3-1 64 
LEPP 3-1 64 
FS772/70 3-lb 200 
ISU-1 3-1 FM T 161 
IA1894 3-lb 200 
86/137004 3-1 200 
RM4 3-1 200 
CHV 3-1 LNGDFIYVFS QEPWGVYNA AFSQAVLNEI DLKEEEEDRT YDVS 244 ® 
PP3 3-1 244 
Purdue 3-lb H 244 
AR310 3-1 64 
LEPP 3-1 64 
FS772/70 3-lb G 244 
ISU-1 3-1 1 G 205 
IA1894 3-lb I.. .DS G 244 
86/137004 3-1 G 244 
RM4 3-1 G 244 
Figure 9. (continued). 
Leader 
RNA gene 3/3a 
mRNA1^ 
ÏÏ9^ "*118 
310 bp PGR product expected from 
CHV TGEV, AR310, and LEPP 
287 bp PGR product expected from IA1894 
No PGR product expected from ISU-1 
Figure 10. Schematic diagram of the PGR products expected from amplification of mRNA 3 with the 
primers 119 and 118 using conditions described in the text The TGEV isolate CHV and the 
PRGV isolates AR310 and LEPP would be expected to yield a PGR product of 310 bp since 
these isolates have a GTAAAG leader RNA binding site preceding gene 3. The PRGV isolate 
IA1894 would be expected to yield a smaller PGR product of 287 bp since this isolate has a 
GTAAAG leader RNA binding site preceding gene 3a and also has a 23 nucleotide deletion 
present in the coding region of gene 3a. The PRGV isolate ISU-1 would be expected to have 
no PGR product since the GTAAAG leader RNA binding site preceding gene 3 is removed due 
to a 168 nucleotide deletion. 
Leader 
RNA gene 3/3a gene 3-l/3b 
mRNA 3 MiPiH ^ ^ 
mRNA 3-1 
048 
660 bp PGR product expected from 
CHV TGEV, AR310, and LEPP 
632 bp PGR product expected from IA1894 
Leader 
RNA gene 3-1 
048 
370 bp PGR product expected from 
CHV TGEV, AR310, and LEPP 
253 bp PGR product expected from ISU-1 
Figure 11. Schematic diagram of the PGR products expected from amplification of mRNA 3 and/or mRNA 3-1 with the 
primers 119 and 048 using conditions described in the text The TGEV isolate GHV and the PRGV isolates 
AR310 and LEPP would be expected to yield two PGR products of 660 bp and 370 bp because these isolates all 
produce mRNA 3 and mRNA 3-1 since fliere is a GTAAAG leader RNA binding site preceding both the 3 and 
3-1 genes. The PRGV isolate IA1894 would be expected to yield a single PGR product of 632 bp since this 
isolate has a GTAAAG leader RNA binding site preceding the 3a gene but not preceding the 3b gene. The PGR 
product from the PRGV isolate IA1894 is smaller because of a 23 nucleotide deletion present in the coding 
region of gene 3a. The PRGV isolate ISU-1 would be expected to have a single PGR product of 253 bp since 
there is a GTAAAG leader RNA binding site only preceding the 3-1 gene as Ae GTAAAG leader RNA binding 
site preceding gene 3 is removed due to a 168 nucleotide deletion. The PGR product from the PRGV isolate 
ISU-1 is smaîler because of a 117 nucleotide inframe deletion within the coding region of the 3-1 gene. 
Figure 12. PGR amplification of the 5' end of the 3/3a gene of TGEV and PRCV 
isolates. cDNA was amplified by PGR with primers 119 and 118 as 
described in text. Molecular weight markers (M), and PGR products 
from GHV TGEV (lane 1), ISU-1 (lane 2), AR310 (lane 3), IA1894 
(lane 4), LEPP (lane 5) were separated on 1.5% agarose gel. PGR 
products were generated for GHV TGEV and the PRGV isolates AR310, 
LEPP, and IA1894 which confirms the joining of the leader RNA to the 
GTAAAG leader RNA binding site preceding the 3/3a gene. Note that the 
PGR products of 310 bp migrated at the same rate for GHV TGEV, 
AR310 and LEPP. The PGR product of 287 bp fi-om IA1894 migrated 
slightly faster due to a 23 nucleotide deletion in the coding region of gene 
3a. No PGR product was evident from the PRGV isolate ISU-1 due to 
the GTAAAG leader RNA binding site preceding the 3 gene being 
removed by a 168 nucleotide deletion. 
400 bp 
300 bp 
200 bp 
Figure 13. PGR amplification of the 5' end of the 3- l/3b gene of TGEV and PRCV 
isolates. cDNA was amplified by PGR with primers 119 and 048 as 
described in text. Molecular weight markers (M), and PGR products 
fi-om GHV TGEV (lane 1), ISU-1 (lane 2), AR310 (lane 3), IA1894 
(lane 4), LEPP (lane 5) were separated on 1.5% agarose gel. Note that 
two PGR products of 660 and 370 bp were amplified from GHV TGEV, 
AR310 and LEPP indicating that the leader sequence had bound to the 
GTAAAG leader RNA binding site preceding the 3 and 3-1 genes. The 
PRCV isolate LA 1894 had only a single PGR product of 632 bp evident, 
which is consistent with the 23 nucleotide deletion in the 3a gene and with 
the leader sequence not binding to the GTAAAG leader RNA binding site 
preceding the 3b gene due to a 5 nucleotide deletion removing the last two 
nucleotides of the GTAAAG sequence. The PRGV isolate ISU-1 had 
only a single PGR product of 253 bp evident, which is consistent with 
there being a GTAAAG leader RNA binding site preceding the 3-1 gene 
and a 117 nucleotide inframe deletion present in the coding region of gene 
3-1, and the loss of the GTAAAG leader RNA binding site preceding the 
3 gene due to the 168 nucleotide deletion present in the 3 gene region. 
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Figure 14. Schematic diagram showing the comparison of gene deletions, tissue tropism, and pathogenicity of 
TGEV and PRCV isolates. Heavy black lines indicate no deletions are present Thin black lines 
indicate that deletions are present. Deletions are indicated as nucleotides (nt) deleted (A). The 
nucleotide sequences of the TGEV isolate CHV and of the PRCV isolates 10, LEPP, IA1894, 
and ISU-1 were determined in this study. The nucleotide sequences of the other PRCV isolates were 
previously determined (Ind/89, Wesley et al., 1991; 86/137004, Britton et al., 1990; and RM4, 
Rasschaert et al., 1990). *The tissue tropism of the SP TGEV isolate is unknown as SP TGEV does 
not replicate in villus enterocytes but rallier in cells found in the lamina propria, and that the extent of 
SP TGEV replication in respiratory tissue is not known. 
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THE USE OF NONRADIOACTIVE cDNA PROBES TO DIFFERENTIATE PORCINE 
RESPIRATORY CORONA VIRUS AND TRANSMISSIBLE GASTROENTERITIS 
VIRUS ISOLATES 
A paper to be submitted to the Journal of Veterinary Diagnostic Investigations 
Eric M. Vaughn, Patrick G. Halbur, and Prem S. Paul 
Abstract 
My colleagues and I have developed two cDNA probes from the S gene of TGEV 
that can be used to differentiate between PRCV and TGEV isolates. The probe FP2 
hybridizes with RNA from both PRCV and TGEV, whereas the probe FPl hybridizes 
only with RNA from TGEV. Both FPl and FP2 were amplified by PCR and labeled 
with digoxigenin-labeled dUTP. The digoxigenin-labeled FPl and FP2 probes were 
used in a dot blot hybridization assay to differentiate between PRCV and TGEV isolates 
grown in cell culture, and specific hybridization was detected using an 
immunochemiluminescent detection method. The probes FP 1 and FP 2 were found to 
be specific for TGEV and/or PRCV RNA as they did not react with nucleic acid from two 
group A rotaviruses (OSU and Gottfried), porcine parvovirus, and three enteroviruses 
(groups 1,2, 8c). My colleagues and I found that TGEV or PRCV RNA can be obtained 
from virus-containing lysates from infected cell cultures, or total RNA could be obtained 
from infected ST cell cultures that are displaying TGEV or PRCV CPE. When using 
TGEV genomic RNA from virus-containing cell culture lysates, my colleagues and I 
found that at least 10^ pfu of TGEV could be detected. The immunochemiluminescent 
dot blot hybridization assay described in this study should be useful in laboratories that 
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are attempting to isolate PRCV and need a rapid, specific, and nonradioactive detection 
system to differentiate PRCV from TGEV. Also, this procedure should be useful in field 
studies to determine the prevalence of PRCV in swine herds. 
Introduction 
Porcine respiratory coronavirus (PRCV), a member of the family Coronaviridae, 
is antigenically related to transmissible gastroenteritis virus (TGEV) of swine (3,4,6,9, 
12, 16,18,19,23). Porcine respiratory coronavirus is now thought to be a mutant of 
TGEV (3, 9, 13, 22). Porcine respiratory coronavirus was first isolated in 1984 (12) 
from pigs in Belgium that were seropositive for TGEV but did not have a history of 
clinical transmissible gastroenteritis (TGE). Since the initial isolation of PRCV, 
infections of swine in Europe with PRCV are widespread (4,9, 8). Porcine respiratory 
coronavirus has also been isolated from swine in the United States (7,11,19, 23). 
However, the prevalence of PRCV in swine herds within the United States is not known. 
There are several similarities between PRCV and TGEV. Both viruses have three 
major structural proteins: tiie surface spike (S) glycoprotein, the integral membrane (M) 
glycoprotein, and an internal nucleoprotein (N) (3, 9,13, 23). Nucleotide sequence of 
PRCV isolates tiius far studied show that they are closely related to TGEV (3,13,22). 
However, tiiere are some striking differences in that PRCV isolates have a characteristic 
deletion in the 5' end of the S gene when compared to TGEV (3, 8, 13, 19, 22). Porcine 
respiratory coronavirus has a different tissue tropism than TGEV. Transmissible 
gastroenteritis virus replicates in both the respiratory and intestinal tissues and causes 
gastroenteritis (14), whereas PRCV replicates to high titers in lung tissue of swine and 
with little or no replication in Uie intestinal tissues and no evidence of gastroenteritis and 
villus ati-ophy (5, 7, 23). 
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Porcine respiratory coronavirus is antigenically related to TGEV in that polyclonal 
sera which neutralize TGEV also neutralize PRCV (4,6,12,16, 23). Thus, 
conventional serological methods are not useful in determining if a swine herd with anti-
TGEV antibodies has been infected with PRCV or TGEV. Anti-TGEV neutralizing 
monoclonal antibodies (MAbs) directed against the S glycoprotein readily neutralize 
PRCV, however, there are some non-neutralizing anti-TGEV MAbs directed against the 
S glycoprotein that can be used to distinguish between PRCV and TGEV isolates in a 
competitive binding assay (4,6, 16, 18). 
Of the European PRCV isolates that have had their nucleotide sequences 
published all have a 672-nucleotide deletion in the 5' end of the S gene (3,13). The 
U.S. PRCV isolates Ind/89 and ISU-1 had a 681-nucleotide deletion present in the 5' 
end of the S gene (8, 19, 22). Recently, the PRCV isolate AR310 was shown to have a 
smaller S gene deletion of 621-nucleotides present (19). Hence, a cDNA probe that 
encompasses the region of the TGEV S gene that is characteristically deleted from PRCV 
isolates can be used in a nucleic acid hybridization to differentiate between PRCV and 
TGEV isolates. My colleagues and I have developed two cDNA probes on the basis of 
the nucleotide sequence of the S gene of TGEV that can be used to differentiate between 
PRCV and TGEV isolates (19). Other researchers have reported on the use of TGEV 
cDNA probes in a nucleic acid hybridization to differentiate between TGEV and PRCV 
isolates, however, these previously reported hybridization methods relied on using 
cDNA probes labeled with the radionuclide 32p (l, 8, 17,21). My colleagues and I 
report here a nucleic acid hybridization assay that uses a immunochemiluminescent 
detection method in order to differentiate between TGEV and PRCV isolates, thus 
avoiding the use of radioactive materials. 
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Materials and Methods 
Virus isolation 
The isolation of the PRCV isolates AR310, LEPP, and LA 1894 has been 
previously described (19). The PRCV isolates PON, IA725, and IA588 were isolated 
from nasal swabs from swine from herds that had antibodies to TGEV but had not 
presented evidence of diarrhea, and thus were suspected of having a PRCV infection. 
Nasal swabs were collected and placed into one ml of MEM with 2 percent FBS and 
antibiotics and mixed for 20 seconds. Two hundred fil of the nasal swab MEM was 
inoculated onto ST cells. CPE was present on the first passage in ST cells for the PRCV 
isolates PON, IA725, and IA588. The PRCV isolates AR310, LEPP, and IA1894 were 
plaque purified a total of three times and stock virus was stored at -70°C. The PRCV 
isolates PON, IA725, and IA588 were not plaque purified for this study. 
The Miller strain of TGEV was used as a standard TGEV strain in this study. 
The PRCV isolate ISU-1 was received as a plaque-purified preparation and was kindly 
provided by Dr. Howard Hill (Iowa State University Veterinary Diagnostic Laboratory) 
(7). 
Total RNA isolation 
ST cells were infected at a multiplicity of infection (moi) of approximately 0.1 
PFU/cell with CHV TGEV, and the PRCV isolates AR310, ISU-1, IA1894, or LEPP. 
At 19 hours post infection, the medium was removed and the total RNA was isolated 
from the infected ST cell monolayers by a rapid guanidinium thiocyanate method 
(Stratagene, La Jolla, CA). The moi used for the PRCV isolates PON, IA725, and 
IA588 was unknown as these isolates were not plaque purified and not titered. Total 
RNA from the ST cell monolayers infected with the PRCV isolates PON, IA725, and 
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IA588 was isolated when the infected ST cell monolayers started showing approximately 
25% CPE. Total RNA from uninfected ST cell monolayers was also isolated and used as 
a negative control. The RNA was washed with 70% ethanol and dissolved in DEPC-
treated distilled water and stored at -70°C. 
Dot blot hvbridization assay 
Ten |Xg of total RNA from the PRCV infected and uninfected ST cell monolayers 
was denatured with formaldehyde and formamide (15) and blotted to nylon membranes 
(Magna NT, Micron Separations Inc., Westboro, MA) using a 96-well hybridot manifold 
apparatus (Schleicher and Schull, Keene, NH). The membranes were washed in lOx 
SSC (Ix SSC is 0.15 M NaCl plus 15 mM sodium citrate), allowed to air dry, and then 
baked at 80°C for 2 hours to fix the RNA. The membranes were prehybridized for 2 
hours in a solution containing 50% formamide, 5x SSPE (Ix SSPE is 0.18 M NaCl, 10 
mM sodium phosphate, and 1 mM EDTA), 4x Denhardt's solution, 1.0% sodium 
dodecyl sulfate (SDS), and sonicated salmon sperm DNA (30 |Xg/ml) at 42°C. The 
cDNA probes used in the hybridization procedure were designated FP2 and FPl (Figure 
1). FP2 is a 2.28 kb PCR product that was amplified by the primers 101004 and 060704 
(Table 1 ) and cut with the BamYil restriction enzyme and cloned in the phagemid vector 
pKS+ (Stratagene, La Jolla, CA). FPl is a 0.58 kb PCR product that was amplified by 
the primers 101004 and 100907 (Table 1) and cut with BamHl and EcoKl restriction 
enzymes and cloned in the phagemid vector pKS+. FP2 encompasses the 5'-half of the 
TGEV S gene and thus will hybridize to both TGEV and PRCV S genes. However, FPl 
encompasses the region of the TGEV S gene that is deleted from all PRCV isolates 
known thus far and will only hybridize with the S gene of TGEV. The FPl and FP2 
PCR products were originally amplified from a plasmid containing the Miller TGEV S 
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gene using the appropriate primers under the following parameters: 1 cycle of 1 minute 
at 94°C, 1 minute at 48°C, and 5 minutes at 72°C; 30 cycles of 1 minute at 94°C, 1 
minute at 48 °C, and 3 minutes at 72°C; followed by 1 cycle of 1 minute at 94°C, 1 
minute at 48°C, and 5 minutes at 72°C in a DNA thermal cycler (Coy Corporation, Grass 
Lake, MI). To make cDNA probes the FPl and FP2 PCR products were reamplified 
from their respective plasmids using the conditions described above. The FPl and FP2 
PCR products were then separated on a 2% NuSieve GTG (PMC Bioproducts, 
Rockland, ME) agarose gel and then purified from the agarose gel by the Magic PCR 
prep method (Promega, Madison, WI). Twenty-five ng each of FPl and FP2 PCR 
products were labeled with digoxigenin-labeled dUTP in the presence of random 
hexamer primers and Klenow fragment of DNA polymerase I (Genius 1 Kit, Boehringer 
Mannheim, Indianapolis, IN). Unincorporated digoxigenin-labeled dUTP was removed 
by ethanol precipitation. The digoxigenin-labeled FPl and FP2 probes were then heated 
to lOO'C, cooled on ice, and then added to the appropriate prehybridization reaction and 
allowed to hybridize overnight. The membranes were washed once in 2xSSC-0.3% 
SDS at room temperature, twice in 2xSSC-0.3% SDS at 65°C, and once with 0.2x SSC 
at 65°C. The membranes were washed in buffer 1 (buffer 1 is 100 mM maleic acid and 
150 mM NaCl, pH 7.5) for 1 minute, followed by a 30 minute incubation in buffer 2 
(buffer 2 is 1% blocking agent). The membranes were then incubated for 30 minutes in 
buffer 2 containing 150 mU/ml of alkaline phosphatase labeled anti-digoxigenin 
conjugate. Unbound antibody conjugate was removed by washing the membranes twice 
in buffer 1 for 15 minutes. The membranes were equilibrated in buffer 3 (buffer 3 is 100 
mM Tris-HCl, 100 mM NaCl, and 50 mM MgCl2, pH 9.5) for 2 minutes. For 
immunochemiluminescent detection, the membranes were repeatedly passed through 
Lumi-Phos 530 (Boehringer Mannheim, Indianapolis, EN) and enclosed in plastic wrap. 
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Chemiluminescent signals were detected by exposing X-ray film (RX film, Fuji Photo 
Film Co., Japan) to the membranes. 
Sensitivity of the nonradioactive probes 
The titers of PRCV AR310 and Miller TGEV were determined by plaque assay as 
previously described (20). The PRCV isolate AR310, and the Miller strain of TGEV, 
were diluted in MEM to adjust to a virus concentration of 10^, 10^, lOt 10^, 10^, or 
10' pfu per 100 |Lll. SDS and proteinase K were added to each dilution of PRCV or 
TGEV to a final concentration of 0.1% and 500 fig respectively, mixed, and incubated at 
37°C for 30 minutes. The extracted viral RNA was then heated to 100°C for five minutes 
and then cooled on ice and blotted to nylon membranes as previously described (10) and 
then used in a dot blot hybridization assay as described above. 
Specificity of the nonradioactive probes 
To determine the specificity of the nonradioactive probes, cell culture lysates from 
two group A rotaviruses (OSU and Gottfried), three enterovirus isolates (groups 1, 2, 
and 8c), porcine parvovirus (NADL-2) were treated with SDS and proteinase K, boiled, 
and blotted to nylon membranes as previously described (10). The membranes were then 
used in a dot blot hybridization assay as described above. 
Results 
As expected, the probe FP2 detected the TGEV and PRCV mRNAs present in the 
total RNA isolated from the PRCV- and TGEV-infected ST cells (Figure 2). The probe 
FPl detected only TGEV mRNA present in the total RNA isolated from the TGEV-
infected ST cells. The FPl and FP2 probes were shown to be specific as the probes 
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showed no reactivity to the rotavirus, enterovirus, or parvovirus nucleic acids (data not 
shown). Using RNA from virus-containing cell culture lysates showed that at least 10^ 
pfu could of TGEV be detected (data not shown). The FPl and FP2 probes did not 
hybridize to the RNA isolated from the uninfected ST cell culture. All of the PRCV 
isolates replicated and produced CPE in the ST cell line on the first passage, and this 
appears to be a typical characteristic of PRCV isolates. 
Discussion 
The probe FP2 described in this study was specific for TGEV and PRCV RNA in 
a immunochemiluminescent dot blot hybridization assay. Additionally, the probe FPl 
was able to differentiate between PRCV and TGEV isolates in a 
immunochemiluminescent dot blot hybridization assay. This nucleic acid hybridization 
procedure takes advantage of the characteristic deletion in the 5' end of the S gene found 
in PRCV isolates. All PRCV isolates studied thus far have had large deletions in the 5' 
end of the S gene ranging from 621- to 678-nucleotides in length (3, 8, 13, 19,22). The 
probe FPl is a 0.58 kb probe that is within the 621-nucleotide deletion site found in the 
PRCV isolate AR310 (19). 
The source of TGEV or PRCV RNA to be used in the above described 
immunochemiluminescent dot blot hybridization assay can be isolated in one of two 
ways. First, TGEV or PRCV RNA can be obtained from virus-containing lysates from 
infected cell cultures, or total RNA can be obtained from infected ST cell cultures that are 
displaying TGEV or PRCV CPE. When using RNA from virus-containing cell culture 
lysates, my colleagues and I found that at least 10^ pfu of TGEV could be detected. 
Shockley et al. (17) calculated that 2x10^ virions of TGEV is equivalent to 25 pg of 
TGEV genomic RNA. Thus, the 10^ pfu detected in this study would indicate that the 
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immunochemiluminescent dot blot hybridization assay described here is able to detect the 
equivalent of 1.25 pg of TGEV genomic RNA. Other researchers have reported that 
TGEV specific cDNA probes labeled with 32p can detect from 25 to 200 pg of genomic 
TGEV RNA. This indicates that the immunochemiluminescent dot blot hybridization 
assay described here using digoxigenin-labeled cDNA probes is 20 to 160 times more 
sensitive than previous reports utilizing ^^P-labeled cDNA probes. 
The probes used in this study were found to be specific. Also, my colleagues 
and I have found that when using the immunochemiluminescent dot blot hybridization 
assay procedure to detect TGEV or PRCV RNA in virus-containing cell lysates, a rather 
high background level was present. The high background generally was evident on 
exposure of the X-ray film to the nylon membranes for periods longer than one hour. 
Thus, it appears that isolating total RNA from infected ST cells that are showing CPE of 
PRCV or TGEV will give the best results in this procedure. 
My colleagues and I have found that enterovirus contamination is a common 
occurrence in ST cell cultures when using nasal swabs to isolate PRCV from swine. 
Even though enterovirus causes a different CPE in ST cells than that produced by PRCV, 
enterovirus contamination should not be a problem in this assay as the cDNA probes 
used in this study were shown not to react to three different groups of enteroviruses 
(group 1,2, and 8c). As reported by other researchers, it would be expected that the 
probe FP2 would detect nucleic acid from antigenically related coronaviruses, such as 
FIPV and CCV(1,2,21). 
Though PRCV continues to be isolated from swine herds in the United States, the 
prevalence of PRCV is not known. As more researchers attempt to obtain PRCV isolates 
for field studies on the prevalence of PRCV or to further study the molecular 
characteristics of new PRCV isolates, the immunochemiluminescent dot blot 
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hybridization assay should be beneficial. The immunochemiluminescent dot blot 
hybridization assay described in this study provides a rapid, specific, and nonradioactive 
detection system to differentiate PRCV from TGEV. 
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Area of S gene 
deleted in PRCV 
SCENE 
cDNA Probe FP2 
cDNA Probe FPl 
Schematic diagram of the S gene of TGEV with the characteristic 
deletion of PRCV shown, a) Probe FP2 used to detect the S gene of 
both TGEV and PRCV in a dot blot hybridization assay. FP2 was 
amplified by the primers 101004 and 060704 using a template of FP2 
cloned in pKS+. b) Probe FPl used to detect the S gene of TGEV in a 
dot blot hybridization assay. FPl was amplified by the primers 101004 
and 100907 using a template of FPl cloned in pKS+, Dashed line 
represents the area that is deleted in PRCV. 
Figure 2. Dot blot hybridization assay using the digoxigenin-labeled FPl 
and FP2 cDNA probes and immunochemiluminescent detection of 
specific hybridization. A) The cDNA probe FP2 was labeled with 
digoxigenin-labeled dUTP and was hybridized with the total RNA from 
ST cell cultures that were infected with Miller TGEV (1), uninfected (2), 
or infected with ISU-1 (3), AR310 (4), IA1894 (5), LEPP (6), PON (7), 
IA725 (8), and IA588 (9). Note that the cDNA probe FP2 hybridized 
with total RNA from both TGEV- and PRCV-infected ST cell cultures. 
B) The cDNA probe FPl was labeled with digoxigenin-labeled dUTP and 
was hybridized with the total RNA from ST cell cultures that were 
infected with Miller TGEV (1), uninfected (2), or infected with ISU-1 
(3), AR310 (4), IA1894 (5), LEPP (6), PON (7), IA725 (8), and IA588 
(9). Note that the cDNA probe FPl hybridized only with total RNA from 
TGEV-infected ST cell cultures; the total RNA from PRCV-infected ST 
cell cultures was not detected with the cDNA probe FPl. 
1 2 3  4  5 6 7 8 9  
B 
1 2 3 4 5 6 7 8 9  
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GENERAL CONCLUSIONS 
In the first study, my colleagues and I isolated and partially characterized three 
new isolates of PRCV, designated AR310, LEPP, and IA1894. These PRCV isolates 
showed a selective tropism for respiratory tissue and were antigenically related to TGEV. 
Polymerase chain reaction (PCR) amplification of the 5'-half of the S genes of the three 
PRCV isolates indicated that a large deletion, characteristic of PRCV, was present. 
Using cDNA probes specific for the TGEV S gene, the PCR products were shown to be 
specific in a Southern blot. The three new PRCV isolates were shown to vary in S gene 
deletion size and pathogenicity. These new PRCV isolates should serve as important 
tools in gaining a better understanding of the pathogenesis of coronavirus infections. 
The PRCV isolate AR310 has been shown to cause interstitial pneumonia in 
gnotobiotic pigs (Halbur et al, 1993), Using five-week-old SPF pigs, PRCV isolates 
AR310, LEPP, and IA1894 were shown to exhibit a tropism for respiratory tissue with 
no detectable replication in intestinal tissue (Halbur et al., 1994). Also, the pathogenicity 
of the PRCV isolates AR310, LEPP, and IA1894 was shown to vary. The PRCV 
isolates AR310 and LEPP induced moderate bronchointerstitial pneumonia in five-week-
old SPF pigs, whereas the PRCV isolate IA1894 induced very mild bronchointerstitial 
pneumonia (Halbur et al., 1994). 
Porcine respiratory coronavirus is believed to have originated fi'om TGEV. 
Although the mechanism of the deletion occurring in the S gene of PRCV is not known, 
RNA recombination with polymerase jumping is a possible mechanism (Laude et al., 
1993; Sanchez et al., 1992). Whether immune pressure plays a role in the deletion of the 
S gene in PRCV is not known. The PRCV isolate AR310 is the first PRCV strain to be 
isolated from intestinal tissue. The herd in which AR310 was isolated had been 
vaccinated with a commercial TGEV vaccine and immune pressure may have played a 
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role in the development of the S gene deletion of AR310. However, it should be noted 
that TGEV was also isolated from other pigs in the same herd from which AR310 was 
isolated. Whether the original AR310 intestinal homogenate contained a mixture of 
TGEV variants, or the S gene deletion of AR310 occurred during cell culture adaptation 
is under study at this time. Porcine respiratory coronavirus can cause a viremia (Cox et 
al., 1990a) and a possible explanation for the isolation of PRCV AR310 from intestinal 
tissue homogenates may have been due to a PRCV viremia at the time of tissue 
collection. 
From information gained from the first study, my colleagues and I developed two 
cDNA probes from the S gene of TGEV that can be used to differentiate between PRCV 
and TGEV isolates. The probe FP2 hybridizes with RNA from both PRCV and TGEV, 
whereas the probe FPl hybridizes only with RNA from TGEV. Both FPl and FP2 were 
amplified by PCR and labeled with digoxigenin-labeled dUTP. The digoxigenin-labeled 
FPl and FP2 probes were used in a dot blot hybridization assay to differentiate between 
PRCV and TGEV isolates grown in cell culture, and specific hybridization was detected 
using a immunochemiluminescent detection method. The probes FPl and FP2 were 
found to be specific for TGEV and/or PRCV RNA as they did not react with nucleic acid 
from two group A rotaviruses (OSU and Gottfried), porcine parvovirus, or three 
enteroviruses (groups 1, 2, 8c). My colleagues and I found that TGEV or PRCV RNA 
can be obtained from virus-containing lysates from infected cell cultures, or total RNA 
could be obtained from infected ST cell cultures that are displaying TGEV or PRCV 
CPE. However, the best results were obtained by using total RNA from infected ST 
cells. When using TGEV genomic RNA from virus-containing cell culture lysates, my 
colleagues and I found that at least 10^ pfu of TGEV could be detected. The 
immunochemiluminescent dot blot hybridization assay described here should be useful in 
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laboratories that are attempting to isolate PRCV and need a rapid, specific, and 
nonradioactive detection system to differentiate PRCV from TGEV. 
In the second study, the nucleotide sequence from the S genes, the 3/3a genes, 
and the 3- l/3b genes of four PRCV isolates was determined and compared to other 
PRCV and TGEV isolates. Two of the PRCV isolates, AR310 and LEPP, were shown 
to be more pathogenic than another PRCV isolate IA1894 in a five-week-old specific 
pathogen free pig model (Halbur et al., 1994). All four of the PRCV isolates had a large 
inframe deletion in the 5' end of the S gene. The PRCV isolates AR310 and LEPP both 
had identical S gene deletions of 621-nucleotides starting 47 nucleotides after the S gene 
start site. The PRCV isolates, AR310 and LEPP, have the smallest deletions found thus 
far in the 5' end of the S gene (621-nucleotides). Until now, the size of the S gene 
deletions for other PRCV isolates from Europe and the United States has ranged from 
672- to 681-nucleotides (Britton et al., 1990; Jackwood et al., 1992; Rasschaert et al., 
1990; Wesley et al., 1991b). The PRCV isolate IA1894 had a 678-nucleotide deletion 44 
nucleotides after the S gene start site, whereas the PRCV isolate ISU-1 had a 681-
nucleotide deletion 62 nucleotides after the S gene start site. Even though the deletions in 
the 5' end of the S gene of PRCV AR310 and PRCV LEPP are smaller than that of other 
PRCV isolates, the area deleted encompasses the S protein amino acid residues of 92, 
94,218, and 219 that were predicted by Sanchez et al. (1992) to be important in 
predicting tissue tropism of PRCV and TGEV isolates. 
Analysis of the 3/3a genes of the four PRCV nucleotides isolates showed a high 
degree of variability. The 3 gene of the PRCV isolates AR310 and LEPP was preceded 
by a CTAAAC leader RNA binding site and the 3 gene was predicted to yield a protein of 
72 amino acids, the same size as that of the virulent Miller strain of TGEV. The 3a gene 
of the PRCV isolate IA1894 was preceded by a CTAAAC leader RNA binding site and 
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the 3a gene was predicted to yield a truncated protein of 53 amino acids due to a 23-
nucleotide deletion in the 3a gene. The CTAAAC leader RNA binding site and ATG start 
codon of the 3 gene of the PRCV isolate lSU-1 was removed due to a 168-nucleotide 
deletion. Analysis of the 3-l/3b genes of the four PRCV nucleotides isolates also 
showed a rather high degree of variability. The 3-1 gene of the PRCV isolates AR310 
and LEPP was preceded by a CTAAAC leader RNA binding site but was found to have 
an one-nucleotide deletion that was predicted yield a truncated (63 amino acids versus 
244 amino acids) 3-1 protein. The last two nucleotides of the CTAAAC leader RNA 
binding site preceding 3-1 gene of the PRCV isolate IA1894 were removed by a five-
nucleotide deletion but the 3-1 gene was predicted to encode for a protein of 244 amino 
acids. The 3-1 gene of the PRCV isolate ISU-1 was preceded by a CTAAAC leader 
RNA binding site but was found to have a 117-nucleotide inframe deletion that was 
predicted to yield a smaller (205 amino acids versus 244 amino acids) 3-1 protein. The 
fact that the PRCV isolates AR310 and LEPP were more pathogenic than the PRCV 
isolate IA1894 indicates that the presence of an intact 3 gene may be important in 
determining the pathogenicity of PRCV isolates. 
Of significance, the PRCV isolates AR310 and LEPP are the first to have been 
found to have an intact and functional 3 gene. Surprisingly, the 3-1 gene coding region 
of the PRCV isolates AR310 and LEPP contained a one-nucleotide deletion is predicted 
to cause a frameshift in the ORE resulting in a truncated 3-1 protein of 64 amino acids. 
Whether this truncated 3-1 protein would still be functional is not known, but it may be 
possible that this truncated 3-1 protein may still have the necessary domains to be 
functional. The sequence information from all other PRCV isolates previously 
sequenced have shown that the 3 gene has deletions or alterations that render the 3 gene 
nonfunctional. However, the 3-1 gene of all other PRCV isolates shows that the 3-1 
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gene is preceded by a CTAAAC leader RNA-binding site and the following ORF was 
intact. Thus, the PRCV isolates previously reported on have displayed two certain 
characteristics typical of PRCV. First, previously described PRCV isolates displayed the 
characteristic of a large deletion in the 5' end of the S gene ranging from 672- to 681-
nucleotides (Britton et al., 1990; Jackwood et al., 1992; Rasschaert et al., 1990; Wesley 
et al., 1991b). Second, these previously described PRCV isolates all have altered or 
partially deleted CTAAAC leader RNA-binding sites that result in the 3 gene being 
nonfunctional (Page et al., 1991; Rasschaert et al., 1990; Wesley et al., 1991b). 
Additionally, previously studied PRCV isolates, with the exception of Ind/89, all have 
deletions ranging from 22- to 36-nucleotides present in the putative 3 gene (Page et al., 
1991; Rasschaert et al., 1990). The PRCV isolates AR310 and LEPP can thus be 
described as "uncharacteristic" PRCV isolates in that they have a smaller S gene deletion 
(621-nucleotides) and the 3 gene is predicted to be intact and functional and yet these 
isolates exhibit a tropism for respiratory tissue. 
As the sequence information from the PRCV isolate IA1894 indicates, this 
particular isolate is more in keeping with the previously described PRCV isolates, in that 
PRCV lAl 894 had a larger S gene deletion (678-nucleotides) and had a 23-nucleotide 
deletion in the 3a gene that would result in a truncated 3a protein. However, the 3b gene 
of the PRCV isolate LA 1894 was preceded by an altered CTAAAC leader RNA binding 
site but the ORF was found to be intact and nearly identical to that of TGEV. This would 
mean, with the exception of the 23-nucleotide deletion present in 3a gene, that the PRCV 
IA1894 mRNA 3 is like that of Purdue and FS772/70 strains of TGEV in which the 
mRNA 3 is thought to code for both 3a and 3b proteins (Britton et al., 1990; Kapke et 
al., 1988). 
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The PRCV isolate ISU-1 also fits into the category of previously described 
PRCV isolates since PRCV ISU-1 had a larger S gene deletion (681-nucleotides) and had 
its 3 gene altered to a psuedogene due to a 168-nucleotide deletion in the 3 gene that 
removed both the CTAAAC leader RNA-binding site and the ATG start site of the 3 
gene. Additionally, the 3-1 gene of PRCV ISU-1 was found to have a 117-nucleotide 
inframe deletion at amino acid residue 32, that would effectively remove 39 amino acid 
residues out of a possible 244 amino acid residues found in the intact 3-1 protein. 
Whether this 117-nucleotide inframe deletion in the 3-1 gene of PRCV ISU-1 would still 
yield a functional protein is not known. Since both the genes 3 and 3-1 of the PRCV 
isolate ISU-1 are altered, it exhibits the same genetic characteristics as the SP mutant of 
TGEV which is lacking the entire 3 gene and part of the 3-1 gene (previously described 
as regions A and B, respectively) due to a 462-nucleotide deletion (Wesley et al., 1990a). 
Using SI nuclease analysis, Wesley et al. (1990a) demonstrated that the SP TGEV S 
gene was similar to that of virulent TGEV and contained no large deletions in the SP S 
gene characteristic of PRCV. The SP TGEV was not able to replicate in the villus 
epithelium of the gut of neonatal pigs and thus did not cause enteric disease. However, 
using IFA the SP TGEV was shown to replicate in the cells of the lamina propria of 
neonatal pigs infected with SP TGEV. It is not known if the SP TGEV was able to 
replicate in the lungs and other respiratory tissue of SP TGEV infected pigs. The SP 
TGEV was able to replicate in ST cells, but exhibited a SP morphology. The lack of 
intact 3 and 3-1 genes in PRCV ISU-1 does not affect its ability to replicate in ST cells or 
its plaque morphology, as PRCV ISU-1 can reach titers exceeding 10^ pfu/ml and the 
plaque size is approximately 5 mm (data not shown). The lack of an intact 3a gene does 
not affect the ability of PRCV lA 1894 to replicate in ST cells as it can reach titers 
exceeding 10^ pfu/ml and the plaque size is approximately 5 mm (data not shown). In a 
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similar manner, the same can be said for the PRCV isolates AR310 and LEPP as these 
isolates readily grow to titers exceeding 10^ pfu/ml and the plaque size is approximately 5 
mm (data not shown). Wesley et al. (1990a) proposed that one of the functions of the 3 
and 3-1 genes was determination of plaque size in cell culture. Since the PRCV isolate 
ISU-1 is missing the 3 gene just like all other PRCV isolates (except AR310 and LEPP), 
but has a smaller 3-1 protein and can still form large plaques in cell culture, the ability of 
the PRCV isolate ISU-1 to form large plaques may indicate that its smaller 3-1 protein is 
still functional. The 3-1 gene may be responsible for determining plaque size in cell 
culture as the SP TGEV mutant was lacking this region, and was not able to produce 
large plaques in cell culture. 
Studies in our laboratory (Halbur et al., 1994), have shown that the PRCV 
isolates AR310 and LEPP are more virulent in five-week-old SPF pig model than the 
PRCV isolate IA1894. Wesley et al. (1990a) have hypothesized that the role of the 3 and 
3-1 genes of TGEV are involved in pathogenesis and virulence. This hypothesis can be 
extended to PRCV. The fact that the PRCV isolates AR310 and LEPP both have an 
intact 3 gene, and the fact that these two isolates have been shown to cause more 
extensive lung lesion development and are more pathogenic than the typical PRCV isolate 
lA 1894, supports the hypothesis that the 3 gene is important in the virulence of both 
TGEV and PRCV. 
It is believed that PRCV evolved from TGEV. The PRCV isolates AR310 and 
LEPP will be useful in understanding the origins of PRCV as they may represent 
intermediate isolates in the evolution of PRCV from TGEV. 
In this study, my colleagues and 1 describe unique PRCV isolates that have 
varying locations and sizes of S gene deletions. The 3 gene was shown to be intact for 
the PRCV isolates AR310 and LEPP, but the 3-1 gene was predicted to code for a 
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truncated 3-1 protein due to a frameshift caused by a one-nucleotide deletion. The PRCV 
isolates AR310 and LEPP were shown to be more pathogenic in five-week-old SPF pigs 
than the PRCV isolate IA1894. 
The PRCV isolate IA1894, except for a 23-nucleotide deletion in the coding 
region of 3a gene, had a mRNA 3 that was revealed to be very similar to that to that of 
the virulent TGEV isolates FS772/70 and Purdue, These two TGEV isolates have the 3a 
gene and the 3b gene present on single mRNA species and the 3b protein is assumed to 
be expressed from the functionally bicistronic mRNA 3 (Britton et al., 1990; Kapke et 
al., 1988; Laude et al., 1993). Since the PRCV isolate IA1894 has been determined to 
be less pathogenic than the PRCV isolates AR310 and LEPP, and yet the mRNA 3 of 
PRCV LA 1894 is very similar (with the exception of the 23-nucleotide deletion) to that of 
two virulent TGEV isolates, this suggests that the 3 gene is important in determining the 
virulence of PRCV and TGEV isolates. Specifically, the region of the 3/3a protein that is 
deleted from IA1894 and yet is still conserved in the PRCV isolates AR310 and LEPP 
and the virulent TGEV isolates CHV, PP3, FS772/70, and Purdue is a region of the four 
amino acid residues KLGL. These four amino acid residues may comprise an important 
motif or domain in the 3/3a protein that is essential for virulence in the animal host. The 
function of the 3/3a protein and its role in virulence needs to be clarified with further 
study. 
Future studies to clarify the role of the 3/3a gene in virulence of PRCV and 
TGEV isolates would best be addressed by the correction of 3/3a gene defects by RNA 
recombination. Also, the use of RNA recombination to introduce a TGEV-like S gene to 
repair the deleted S gene regions of PRCV isolates would also be useful to further clarify 
the role of the S gene and its smaller S protein product in the change of tissue tropism of 
PRCV from the enteropathogenic TGEV. The PRCV isolates AR310, LEPP, and 
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IA1894 would be excellent candidates for future experiments to correct 3/3a, 3-l/3b, and 
S gene deletions. For example, if the S gene deletion of AR310 or LEPP was corrected 
to a TGEV-like S gene, would the S gene-corrected AR310 or LEPP become 
enteropathogenic? Additionally, if the PRCV isolate LA 1894 had the 23-nucleotide 
deletion present in the 3a coding region corrected, would the 3a gene-corrected IA1894 
cause just as severe lung lesions as AR310 or LEPP in the five-week-old pig model? 
Furthermore, if the S gene deletion of the 3a gene-corrected L\1894 was corrected by 
RNA recombination would the S gene-corrected-3a gene-corrected L\1894 become an 
enteropathogenic TGEV isolate? 
From the present study, my colleagues and I can confirm, as have others, that the 
3/3a gene of both TGEV and PRCV isolates is highly variable. In addition, the 3- l/3b 
genes of at least some PRCV isolates appears to be variable also. The extent of deletions 
present in the PRCV isolates AR310, LEPP, IA1894, ISU-1 allows for some intriguing 
speculation as to the relationship of the S, 3/3a, and 3-l/3b genes in PRCV isolates. All 
previously analyzed PRCV isolates have been found to have large deletion in the 5' end 
of the S gene accompanied by an altered or deleted 3/3a gene, while the 3-l/3b gene has 
remained intact. In this study, my colleagues and I have reported on additional PRCV 
isolates that do have large S gene deletions. However, the genes 3/3a and 3-l/3b were 
more variable in that two of the PRCV isolates (AR310 and LEPP) are predicted to have 
intact 3 proteins combined with truncated 3-1 proteins of 64 amino acid residues; another 
PRCV isolate (IA1894) is predicted to have a truncated 3a protein of 55 amino acid 
residues combined with an intact 3-1 protein; and the PRCV isolate (ISU-1) has the entire 
3 gene missing combined with a smaller 3-1 protein of 205 amino acid residues. It has 
been suggested by Laude et al. (1993) that there is a possibility of a functional link 
between the 3/3a and S gene alterations of PRCV isolates that may be complementing 
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each other. With the information presented here, the complementation of an altered 3-
l/3b gene with an altered S gene may also be necessary. This may mean that in order to 
be a PRCV isolate, there must be a deletion in the S gene (to alter tissue tropism), 
accompanied by an altered 3/3a gene, an altered 3-l/3b gene, or both the 3/3a and 3-l/3b 
genes altered. In order to exhibit the characteristic tropism of PRCV, it may be that a 
large S gene deletion has to be accompanied by alterations in the 3/3a gene, the 3-l/3b 
gene, or both. A large deletion in the S gene may not be compatible without these 
alterations. Until the polymerase region of the coronavirus genome from virulent and 
avirulent coronaviruses can be studied in depth, the area of the genome most likely to be 
involved in determining pathogenicity will be genes 3 and 3-1. No function has been 
assigned to these proteins as of yet. 
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APPENDIX: 
EXPRESSION OF THE S GLYCOPROTEIN OF TRANSMISSIBLE 
GASTROENTERITIS VIRUS IN INSECT CELLS 
Eric M. Vaughn and Prem S. Paul 
Introduction 
Transmissible gastroenteritis (TGE) is a common and economically important 
disease of neonatal swine (Saif and Bohl, 1986). Transmissible gastroenteritis is 
characterized by severe diarrhea, dehydration, and high mortality in piglets under two 
weeks of age (Saif and Bohl, 1986). The transmissible gastroenteritis virus (TGEV), 
belongs to the Coronaviridae family of viruses. The transmissible gastroenteritis virus 
has three structural viral proteins, these being M, S, and N (Saif and Bohl, 1986; 
Garwes et al., 1976). The M protein is glycosylated with an apparent molecular mass 
(Mr) of 25 to 30 kDa and is associated with the viral envelope. The spike protein,S, has 
an apparent Mr of 200 kDa and is also glycosylated (Garwes et al., 1976). The N 
protein is not glycosylated, has an apparent Mr of 45 to 50 kDa, and is also associated 
with the binding of viral RNA and serves as a nucleocapsid (Britton et al., 1988a). The 
S protein is the viral protein that induces neutralizing antibodies (Garwes et al., 
1978/79). In this paper, my colleagues and I report on the expression of the recombinant 
TGEV S protein for eventual functional and immunological studies. 
The insect baculovirus Autographa californica (AcNPV) has been widely used as 
a helper-independent expression vector for high level foreign gene expression (Luckow 
and Summers, 1989; O'Reilly et al., 1992). Recombinant proteins expressed in the 
AcNPV system appear to undergo proper post-translational modification and transport in 
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insect cells (Luckow and Summers, 1989; O'Reilly et al., 1992). In this paper, my 
colleagues and I report on the construction of the S gene and expression of the entire S 
gene sequence in insect cells, and demonstration of that at least one of the major 
neutralizing epitopes is maintained. 
Materials and Methods 
Genomic RNA isolation 
The gut-passaged virulent Miller strain of TGEV (National Veterinary Services 
Laboratory, Ames, lA) also referred to as CHV TGEV, was the TGEV strain used in this 
study. The swine testicular (ST) cell line was used to isolate and propagate the viruses in 
this study and was maintained as previously described (Zhu et al., 1990). Four-day-old 
ST cells in 75 cm^ flasks (Costar, Cambridge, MA) were infected with a multiplicity of 
infection of approximately 0.1 pfu of CHV TGEV. The infected ST cell cultures were 
incubated at 37°C for 48 hours. After 48 hours, when extensive CPE had developed, the 
cultures were frozen and thawed three times and clarified by centrifugation at 1000 x g 
for 10 minutes. The virus containing supernatant was then mixed with NaCl and PEG-
8000 to give a final concentration of 2.3% and 7% respectively and stirred overnight at 
4°C. The virus was then pelleted by centrifugation at 100,000 x g for 30 minutes at 4°C. 
The virus pellet was resuspended in 10 ml of MEM and was then placed on top of a 
discontinuous sucrose gradient (10%-25%-40%) and centrifuged at 100,000x g for 90 
minutes. The virus-containing band at the 25%-40% sucrose interface was collected. 
The virus was then pelleted at 100,(X)0 x g for 30 minutes in MEM. The partially 
purified virus pellet was than resuspended in 500 |il of TNE (pH 9.0) with 1% SDS and 
20 |Lig proteinase K, and incubated at 37°C for 30 minutes. The genomic RNA was then 
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extracted with phenol :chloroform and ethanol precipitated. The RNA was washed with 
70% ethanol and stored in water at -70°C. 
cDNA synthesis and PGR amplification 
First strand cDNA was made from the genomic RNA from infected ST cells by 
avian myeloblastosis virus reverse transcriptase using random oligonucleotide primers 
(Invitrogen, San Diego, GA). The cDNA-RNA hybrids were amplified by PGR using 
Taq DNA polymerase (Boehringer Mannheim, Indianapolis, IN) using the following 
primers and cycles. 
The 5'-half of the S gene (2.3 kb) of TGEV was amplified using the primers 
010708 and 060704 under the following parameters: 1 cycle of 1 minute at 94°G, 1 
minute at 48°G, and 5 minutes at 72°G; 30 cycles of 1 minute at 94°G, 1 minute at 48°G, 
and 3 minutes at 72°G; followed by 1 cycle of 1 minute at 94°G, 1 minute at 48°G, and 5 
minutes at 72°G in a DNA thermal cycler (Goy Gorporation, Grass Lake, MI). The 3'-
half of the S gene (2.2 kb) of TGEV was amplified using the primers 060703 and 
021208 under the conditions described above. 
Construction the TGEV S gene 
A schematic diagram of the construction of TGEV S gene is shown in Figure 1. 
After PGR amplification, the 5'-half of the S gene (2.3 kb) and the 3-half of the S gene 
(2.2 kb) of TGEV were digested with EcoRI and BamHl and were separated on a 2% 
NuSieve GTG (FMG Bioproducts, Rockland, ME) agarose gel and then purified from 
the agarose gel by the Magic PGR prep method (Promega, Madison, WI). The gel-
purified PGR products were then cloned in the phagemid vector pKS+. The 5' and 3' 
termini of the two clones, designated GHV l-2a (5' half of the S gene) and GHV 2-1 (3' 
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half of the S gene) were sequenced with universal and reverse primers for verification of 
the clones. The inserts from CHV l-2a and CHV 2-1 were removed by digestion with 
£coRI and BanMl and were gel-purified as described above. Both inserts from CHV 1-
2a and CHV 2-1 were digested with Kpnl and again gel-purified. The 
Eco^BamWlJKpnl digested inserts were then ligated into pKS+ that had been digested 
with EcoRl and BamHl and dephosphorylated. One clone with a 4.3 kb insert was 
selected and the 5' and 3' termini of the clone, designated CHV S exp, were sequenced 
with universal and reverse primers for verification of the insert. 
Generation of recombinant baculoviruses containing the S gene 
The clone CHV S exp was digested with EmRI and BamHl and was gel-purified 
as described above and ligated into the EcoRl and BamHl sites of the baculovirus 
expression vector pVL1392. A clone, designated pVL1392-S exp was selected and was 
purified by using the Qiagen column purification system. One hundred ng of the clone 
pVL1392-S exp was mixed with 50 ng of linearized and deleted AcNPV DNA in 25 |Ltl of 
TE buffer and 25 |xl of Lipofectin (Gibco BRL), mixed briefly, and incubated at room 
temperature for 30 minutes. The entire Lipofectin/DNA mixture was then added to Sf9 
cells in a 6-well plate and incubated at room temperature for one hour. After one hour the 
Lipofectin/DNA mixture was removed and the Sf9 cells were then refed with Grace's 
insect medium with 10% FBS and antibiotics. The Sf9 cells were then incubated at 28°C 
for 5 days. After the 5 day incubation the cell supernatant containing recombinant S-
baculoviruses was collected and stored at -70°C, and the Sf9 cells were fixed with 
methanol and screened by indirect immunofluorescence assay (IFA) to verify that 
recombination had occurred and that the S protein was being expressed. Once 
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recombination and S protein expression were confirmed, the recombinant S-
baculoviruses were plaque purified three times. 
Indirect immunofluorescence assay 
Sf9 cells were grown in 6-well plates (Costar, Cambridge, MA) and infected with 
the recombinant S-baculovirus virus suspended in Grace's insect medium (Gibco BRL) 
with 10 % fetal bovine serum (FBS) and antibiotics, and incubated at 28°C. At 48 hours 
p.i., the medium was removed and the cells were fixed with methanol for 10 minutes. 
After removal of the methanol, the fixed cells were allowed to dry completely. The anti-
TGEV S glycoprotein monoclonal antibody (MAb) 3H11 (Zhu et al., 1990) was 
incubated with the fixed cells for one hour at 37 C. The fixed cells were then washed 
and then stained with fluorescein-conjugated goat anti-mouse IgG (heavy and light chain) 
conjugate (Cappel Laboratories, Malvern, PA) for one hour at 37 C. The unbound 
conjugated antibodies were washed away with PBS, and glycerol:PBS (1:1) was added 
to each well. The plates were then examined for immunofluorescence. Uninfected Sf9 
cells were processed in the same manner as above and served as negative controls. 
Radioimmunoprecipitation assav 
A RIP was utilized to determine the size and level of expression of the 
recombinant S glycoprotein in Sf9 cells. Sf9 cells in 6-well plates were infected at a 
m.o.i. of 0.1 pfu/cell with the recombinant S-baculovirus and incubated at 28°C. 
Uninfected Sf9 cells were used as a mock-infected control. At 24,48,72, and 96 hours 
p.i., the medium was replaced with methionine-free Grace's insect medium and the cells 
were incubated at 28 °C for one hour. The methionine-free Grace's insect medium was 
replaced with fresh methionine-free MEM with 250 |iCi/ml 35s-methionine-cysteine 
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added. Two hours after the addition of the 35s-methionine-cysteine, the cell monolayers 
scraped from the plastic flask and pelleted by centrifugation at 200 x g for 10 minutes. 
The cellular pellets containing labeled viral proteins and were then disrupted with I ml of 
lysis buffer (50 mM NaCl, 50 mM tris, 5mM EDTA, 1% Triton X-100, and ImM 
phenylmethylsulfonyl fluoride). The lysis buffer and cellular pellet mixtures were mixed 
vigorously for one minute, and placed on ice for 3 minutes. The remaining cellular 
residues were removed by centrifugation. The lysates were stored at -20 C until needed. 
One hundred and fifty (Xl of the appropriate lysate was mixed with 4 |li1 of ascitic fluid 
containing the MAb 3H11 and incubated overnight at 4°C. Immune complexes were then 
collected by the addition of sepharose beads coated with protein A (Sigma, St, Louis, 
MO.), and incubated for one hour at room temperature. The antigen-antibody 
complexes/protein A sepharose beads mixtures were then washed three times with lysis 
buffer and then three times with deionized distilled water, resuspended in 50 |il sample 
buffer, and run on a SDS-polyacrylamide gel. Twenty-five |Xl of the appropriately 
labeled virus- or mock-infected interface were mixed with 25 |Lil of sample buffer 
(0.125M tris-HCl, pH 6.8,4% sodium dodecyl sulfate (SDS), 20% glycerol, 10% 2-
mercaptoethanol) and placed in a boiling water bath for 5 minutes. The samples were 
electrophoresed at 15 inA constant current through a discontinuous 10% SDS-
polyacrylamide gel. The ionic strength of the acrylamide gel and running buffer were 
0.375M tris-HCl (pH 8.8) and 0.025M tris-HCl (pH 8.3), respectively. High and low 
molecular mass proteins were used as reference standards for determination of the 
molecular mass of viral proteins. The acrylamide gels were placed in fixation solution 
for one hour, then placed in autoradiography enhancer (NEN Research Products, 
Boston, MA) for 30 minutes, and then rehydrated in distilled water for 30 minutes. Then 
the acrylamide gels were dried and film (X-OMAT, Eastman Kodak Co., Rochester, 
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NY) exposed to the gels at -70 C for the production of autoradiographs. The molecular 
mass of the TGEV proteins were determined by running ^^C-labeled molecular mass 
markers on the same gel. 
Results 
An indirect immunofluorescence assay with the MAb 3H11 showed cytoplasmic 
fluorescence indicating that the recombinant S protein of TGEV was being expressed in 
the Sf9 cells (Figure 2). To verify that the recombinant S protein being expressed was of 
the correct molecular mass and to determine at which time maximum levels of the 
recombinant S protein were being expressed, a RIP was performed. The RIP showed 
that the MAb 3H11 had precipitated two protein bands (Figure 3). The S protein bands 
were determined to have a Mr of 180,000 and 160,000. The 180,000 protein is close to 
the expected size for the glycosylated S protein of 175,000 found intracellularly 
(Rasschaert and Laude, 1987). The 160,000 protein has the same Mr of the 
unglycosylated S protein (Rasschaert and Laude, 1987). The optimal level of S protein 
expression appeared to be at 48 hours p.i. 
Discussion 
Godet et al (1991) have previously expressed the S protein from the Purdue strain 
of TGEV insect cells and found that the predominate form of the recombinant S protein 
had a Mr of 175,000 which is similar in size to the 180,000 species my colleague and I 
identified. Godet et al. (1991) found a relatively low production (1 % of the total protein 
content) of the TGEV S protein in insect cells and attributed this to the fact that insect 
cells are inefficient at expressing proteins of large size (200,000) and/or a high sugar 
content (28%). However, Godet et al. (1991) found that the recombinant S protein had 
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undergone trimerization like that found in the native S protein and many of the major 
neutralization epitopes were maintained. The discrepancy in size between the 
recombinant S protein and the native TGEV S protein (180,000 versus 200,000) could 
be attributed to the absence of terminal glycosylation in insect cells (Godet et al., 1991; 
Kuroda et al., 1990). Another possible reason for the size difference may be retarded 
processing due to the lack of efficient oligomerization in insect cells (Godet et al., 1991 ; 
Kuroda et al., 1991). 
In conclusion, the ability of the MAb 3H11 to recognize the recombinant S 
glycoprotein in an IFA and a RIP indicates that at least one of the major neutralizing 
epitopes on the native TGEV S protein is present on the recombinant S protein. This 
indicates that if pigs were immunized with the recombinant S protein, some of the 
antibodies produced should be able to neutralize TGEV. Thus, the recombinant S protein 
expressed in insect cells should be useful in future studies of the functional and 
immunological role of the TGEV S protein. 
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Figure 1. Construction of the S gene for expression in the baculovirus vector pVL1392. The 5'-half 
of the S gene was amplified by PGR with the primers 010708 and 060704, cloned, and 
designated CHV l-2a. The 3'-half of the S gene was amplified by PCR with the primers 
060703 and 021208, cloned, and designated CHV 2-1. The clones CHV l-2a and CHV 
2-1 were then digested with Kpnl and ligated into pKS+ to form the clone CHV S exp. 
Figure 2. Immunofluorescent staining of recombinant S protein with the anti-
TGEV S glycoprotein MAb MHl 1 in methanol fixed Sf9 cells infected 
with recombinant S-baculovirus (A), or uninfected (B). 

Figure 3. Radioimmunoprecipitation of the recombinant S protein with the anti-
TGEV S glycoprotein MAb MHl 1 from uninfected Sf9 cells (lane 1) and 
Sf9 cells infected with recombinant S-baculovirus for 24 (lane 2), 48 
(lane 3), 72 (lane 4), 96 (lane 5) hours post infection. 
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